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Already hundred years ago, Paul Ehrlich envisioned the use of antibodies for the spe-
cific targeting of cancer cells without causing harm to healthy tissue. With the invention
of the hybridoma technique, Ehrlich’s magic bullit concept seemed to come within
practical reach. This technique, as described by Kohler and Milstein in 1975, enabled the
production of antibodies of defined specificity in sufficient quantities for clinical thera-
py. As a consequence, a number of clinical trials were initiated, using various mono-
clonal antibodies (MoAbs) to target diffuse and solid tumors and varying immune dis-
eases.
OKT3 was the first therapeutic MoAb to be approved for marketing by the US Food and
Drug Administration (FDA) in 1986. This murine MoAb demonstrated activity in revers-
ing acute organ transplant rejection. MoAb 17-1A, registered in 1994 in Germany, was
the first MoAb for the treatment of cancer to win approval in any country. This murine
MoAb significantly reduced post-operative mortality in colon cancer patients when
applied as adjuvant therapy. Unfortunately, these two cases appeared to be exceptions
rather than the forebode of a new class of broadly effective therapeutics. In general,
responses to MoAb therapy were poor, if any, and their administration resulted fre-
quently in allergic type reactions. Excuses were found in the immunogenicity of the
xenogenic MoAbs, the heterogenic expression or modulation of antigen, insufficient
accessibility of target cells, the presence of MoAb-capturing circulating free antigen,
and limited interaction of the (mostly murine) MoAbs with the host immune effector
mechanisms.
Though far from satisfying, these initial experiences formed the base for the develop-
ment of improved antibody strategies. These include the (partial) substitution of the
constant regions of the murine MoAbs with their human counterparts to render them
less immunogenic and to improve their interaction with the host immune system.
More recently, different techniques have become available which enable the production
of fully human MoAbs or fragments thereof. Another strategy forms the generation of
bispecific antibodies with affinity for both the target cell and an immune effector cell.
By bridging these cells, bispecific antibodies aim at the maximal exploitation of the
patient’s immune system. As an alternative, MoAbs have been conjugated to effector
molecules, like radioisotopes or plant/bacterial derived toxins, in an attempt to improve
on their intrinsic, host independent, cytotoxicity.
The implication of these technological and conceptual advances strongly boosted the
scientific as well as pharmaceutical interest. In line with this MoAb-revival, the FDA
approved its first therapeutic antibody for treatment of cancer in 1997. This humanized
CD20 MoAb (Rituximab) demonstrated efficacy in the treatment of certain forms of B-
cell Non-Hodgkin’s lymphoma. Since then, an additional five (partly) humanized
MoAbs have been approved by the FDA for the treatment of certain forms of cancer and
immune disorders. Moreover, with about 60 MoAb-based agents currently being test-
ed in the clinic, MoAb represent the second largest category of biotechnology products
in clinical trials.1
The present thesis focuses on the approach of antibody-toxin conjugates, the so called
immunotoxins (IT). More specifically, the potential pitfalls, as well as the drawbacks
and therapeutic advantages of these agents when applied in the field of hematology will
be highlighted.
R E F E R E N C E
1. Walsh G: Biopharmaceutical benchmarks. Nat Biotechnol 18:831-833, 2000
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1 . 1 G E N E R A L  P R I N C I P L E
Conventional ITs consist of MoAbs conjugated to a potent toxin, mostly of bacterial or
plant origin. Their mechanism of action is depicted in Figure 1. The MoAb-moiety first
binds specifically to its antigen expressed on target cells, following which the entire anti-
gen-IT complex is internalized. Once inside the cell, the bond between the MoAb and
toxin is broken, thereby releasing free toxin into the cytoplasm. The toxin then irre-
versibly inhibits protein synthesis by means of a catalytic reaction culminating in cell
death. Because the toxin-moiety is unable to enter the cell autonomously, and is inac-
tive outside the cell, ITs are only hazardous to cells capable of binding and internaliz-
ing the MoAb.
Instead of MoAbs, or fragments thereof, cells can also be targeted by cytokines which
receptor is (over)expressed on the target cell. As an alternative to chemical linkage,
MoAb-fragments or cytokines can also be genetically spliced to a toxin, generating a
recombinant IT.
1 . 2 M O N O C L O N A L  A N T I B O D Y  P A R T  
Antibody structure
Antibodies can be considered as bifunctional molecules, compromising a highly vari-
able antigen-binding domain (V domain) on one site and a constant effector domain
(C domain) on the other site (Figure 2). Based on their physical properties, antibodies
can be divided in IgM, IgG, IgA, IgE, an IgD classes, each having its own function in the
host defense system. IgG is the antibody class most widely exploited for clinical use.
The IgG molecule compromises two heavy chains of the structure VH-CH1-CH2-CH3
and two light chains of the structure VL-CL. The heavy and light chain are linked to each
other by a disulphide bond between CH1 and CL. Additional disulphide bonds formed
in the so called hinge region of the two heavy chains result in the formation of homod-
imers, containing two identical antigen binding-sites. The actual antigen-recognition
site is provided by the complementarity-determining regions (CDR), formed by three
hypervariable loops of each the VH and VL domain (CDRH1-3 and CDRL1-3, respec-
tively). This antigen-combining region is immunologically defined as the antibody’s
idiotype. The IgG effector functions are located in the Fc-part in the form of an C1q com-
plement-binding site and Fc-receptor binding site.
When considering MoAbs solely as a toxin transporter, it makes sense to use only those
fragments containing the binding function of the CDR’s, such as the 110 kDa bivalent
F(ab’)2 fragment, or the monovalent Fab’ or Fab fragments (Figure 2). The even small-
er recombinant single-chain Fv fragments (sFv) contain only the VL and VH domain
connected to each other through a short flexible peptide spacer. In disulfide stabilized
Fv fragments (dsFv), the peptide linker is replaced by a more stable disulfide bond
introduced by genetically engineering cysteine residues in VL and VH at positions allow-
ing post-translational disulfide bond formation. The Fv-fragments are only 26 kDa in
size, less than 20% of the 155 kDa IgG.
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Figure 1 Mechanism of action
Of note, in particular cases, the MoAb Fc-part can be used as the targeting moiety. An
example forms the treatment of allergic disorders by the elimination of high-affinity Fc-
epsilon-receptor I (FcγRI) expressing mast cells and basophils by toxin-conjugated IgE
Fc-fragments.1-3
Specificity and distibution of antigen
The MoAb’s binding specificity is the major property determining its suitability as a
toxin transporter. Ideally, the MoAb binds an antigen that is expressed solely on those
cells that are to be eliminated. The Ig-idiotype expressed by malignant B cells and
myeloma cells, for instance, represents a tumor-clone specific marker.4-9 A more gen-
eral tumor specific marker is formed by the mutant epidermal growth factor receptor
(EGFRvIII), expressed in glioblastoma, and carcinomas of breast and lung. EGFRvIII
contains an in-frame deletion resulting in the surface expression of a tumor-specific
extracellular sequence. ITs directed against this tumor-specific target demonstrated
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Figure 2 Whole IgG and IgG-derived fragments used in Immunotoxins
Removing the Fc portion of a 155 kDa IgG molecule results in F(ab’)2 fragments of 110 kDa. These can be con-
verted to Fab’ fragments by reduction, proteolytic treatment or by recombinant means. Single-chain Fv (scFv)
fragments consists of the variable domain of a MoAb joined by a linker(26 kDa). In a dsFV the linker is
replaced by a more stable disulfide bond.
clear cytotoxicity to EGFRvIII transfected cells, while showing little or no efficay towards
cells expressing high levels of normal EGFR.10,11
In practice, however, tumor restricted antigens are rare and differences in expression
relative to non-target tissue are generally quantitative rather than qualitative (e.g. tissue-
associated rather than tumor specific). About 25-30% of patients with breast and ovar-
ian cancer shows a 10 to 100-fold overexpression of the human epidermal growth fac-
tor receptor 2 (HER-2, ebrB2). This phenotype, caused by a mutation in the HER-2/neu
gene, is associated with a rapid disease progression and a poor prognosis.12 Treatment
of this particular patient group with anti-HER-2 MoAb resulted in objective responses.13
Several groups are now working on anti-HER-2 ITs in an attempt to further improve on
the clinical efficacy.14-20 Other tumor-associated markers which have been clinically
exploited as target for ITs include lewisy (Ley) expressed on a variety of solid tumors21,
high-molecular-weight melanoma associated antigen (HMW-MAA) expressed on
melanoma22-26, CD56 (neural cell adhesion molecule, NCAM) associated with small
cell lung cancer27-29, and carcinoembryonic antigen (CEA) overexpressed on adenocar-
cinomas30. The clinical use of ITs directed against Ley clearly illustrated the potential
limitations of targeting tumor-associated antigens.21 The Ley-expression on normal vas-
cular endothelial cells resulted in serious vascular leak syndrome (VLS) preventing the
administration of sufficient IT to achieve therapeutic blood levels.31 Similarly, the HER-
2 expression on normal liver cells caused hepatotoxicity in all six patients treated with
an anti-HER-2 IT.20 Generally, though, it has been demonstrated that ITs can be deliv-
ered safely to tumor-associated antigens without severe irreversible toxicities occurring.
Moreover, target-antigen expression on healthy bystander tissue is less critical in case
of strongly regenerative tissue. An illustrative example form the hematopoietic lineage
markers.32 Though an effective therapy is expected to affect healthy lineage cells as well,
early progenitor cells will rapidly restore the hematopoietic compartment. At current,
hematological disorders represent the group most effectively targeted with immuntox-
ins (see also Chapter 2).
The opposite concern of cross-reactivity is the occurrence of antigen negative (or non-
overexpressing) target cells. This can be at the population level, e.g. less than 30% of
patients with breast/ovarian cancer over-expresses HER-2, but may also be at the
patient level, due to heterogeneous antigen expression within the tumor.33-35 In practice,
an arbitrary threshold is often set defining the minimal percentage of antigen-positive
cells required for therapy. In certain cases, co-administration of cytokines may increase
the expression of tumor-associated antigens. An example forms the IFN-γ induced
upregulation of the tumor-associated antigen 72 (TAG-72) and CEA on colon carcino-
ma.36-39 Moreover, the use of an appropriate combination of immunotoxins may cir-
cumvent the heterogeneity observed in the expression of individual antigens.40-44 Addi-
tional obstacles preventing an optimal targeting are a concentration of natural ligand,
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competing with the MoAb for binding, or a high amount of circulating free antigen or
antigen expressing normal cells, which may both act as an antigen sink.45,46
As an attractive alternative to direct tumor-targeting, Burrow et al. introduced the con-
cept of targeting the tumor-nursing vascular bed.47-49 This approach affords several
important advantages: (1) the pivotal problem of poor tumor penetration is circum-
vented, (2) even incomplete destruction of the vascular bed results in massive tumor
destruction, and (3) a single immunotoxin can be used for the treatment of a variety of
tumors of different origin. The proof of principle was generated in nude mice grafted
with IFN-γ transfected tumor cells. These cells induced an artificial expression of major
histocompatibility complex (MHC) Class II antigens on the surrounding tumor vascu-
lar endothelium. The subsequent administration of anti-Class II directed IT caused
extensive thrombosis of the tumor vasculature, inducing permanent complete remis-
sions in over half of the animals. In later trials, comparable results could be obtained
using ITs reactive with endoglin, a natural proliferation-associated antigen of endothe-
lial cells.50-52. More recently, ‘clotting initiating human tissue factor’ proved in this set-
ting to be a useful alternative for the conventional plant or bacterial derived (immuno-
genic) toxin-moiety.53-55
Internalization of MoAb-antigen complex
Following antigen-binding, the toxin-conjugated MoAbs needs to be internalized to
deliver the toxin to the cytoplasm. Preijers et al. demonstrated for several anti-T-cell ITs
that the absolute amount of internalized molecules rather than the antigen surface
expression determines the efficacy.56 The amount and kinetics of internalization itself
are determined by the combination of antigen, MoAb and target cell.56-67
Surface antigens differ widely regarding their intrinsic internalization capacity. Some
appear to be good internalizers, like T-cell antigens CD3 and CD7 and B-cell antigen
CD22, while others hardly internalize, like T-cell antigen CD8 or B-cell antigen
CD20.56,68-71 The use of MoAb-fragments instead of whole IgG generally reduces the
efficacy of the respective IT, either due to a decrease in antigen-binding or in the sub-
sequent internalization.66,72-75 Anti-CD5 ITs form an exception and are more effective
with F(ab’)2 or Fab’-fragments than with whole IgG.65,67,76 For CD19-ITs it has been
demonstrated that the MoAb isotype may affect the internalization and, thereby, the
efficacy of the IT. This phenomenon could be attributed to an interaction of the Fc-part
of murine IgG1 MoAb (and not IgG2a MoAb) to the Fc-gamma-receptor IIa (FcγRIIa).
Analogous to the mechanism as described by Kurlander, this facilitated the internaliza-
tion of antigen-bound IT.77
Once internalized, the intracellular routing determines the ultimate efficacy of the
immunotoxin.59,69,78,79 The IT needs to be transported to an appropriate subcellular
compartment to facilitate the translocation of the toxin-moiety to the cytoplasm. As a
result, ITs with comparable internalization rates may differ greatly in efficacy. Anti-CD19
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ITs, for example, are generally less effective than anti-CD22 ITs, despite similar or high-
er internalization rates.80-82 For T-cell antigen CD2, and the B-cell antigen surface-IgD,
it has been demonstrated that MoAb binding epitopes closer to the cell surface make
superior ITs. This was also attributed to a favorable intracellular handling.59,62
The above picture becomes even more complex considering that plant and bacterial
toxins prefer different routes of internalization for optimal efficacy (see Paragraph
1.3).58,83 Therefore, an indirect sandwich cytotoxicity assay has been developed which
facilitates the in vitro screening of particular MoAb-toxin conjugates.84 In this assay,
dilutions of MoAbs are incubated with the target cells, followed by the binding of a sec-
ond (isotype-specific) antibody-fragment conjugated to a toxin of choice. This tech-
nique allows the quick screening of a panel of MoAbs in combination with different tox-
ins.84-87 The only concern is that the indirect approach might influence the
internalization and/or intracellular handling of the particular toxin. Using this assay, we
dramatically underscored the potential of a CD7 MoAb that proved highly effective
when conjugated directly to the toxin applied (WT1-dgA, unpublished observations).
1 . 3 T O X I N S
The toxins most commonly applied for the construction of ITs are derived from either
bacteria or plants and have in common that they catalytically and irreversibly disrupt
protein synthesis, typically at picomolar concentration (Figure 3). The bacterial toxins
most extensively studied so far are Pseudomonas exotoxin (PE) and diphtheria toxin
C H A P T E R  1
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Figure 3 Schematic representation of toxin molecular structure.
PE, Pseudomonas exotoxin: Ia,Ib - binding domain, II - translocation domain, III - catalytic domain. DT,
diptheria toxin: A, catalytic fragment, B, binding fragment. The shaded segments mark the position of the pro-
tease-sensitive loop region. Ricin: A, active chain, B, binding chain.
Figure adapted from E.J.Wawrzynczak.277
(DT). The plant toxins, also referred to as ribosome inhibitory proteins (RIP), can be
divided into holotoxins (type II RIP), including abrin, mistletoe lectin, modeccin, and
ricin, and hemitoxins (type I RIP), such as gelonin, pokeweed antiviral protein (PAP),
and saporin.
Pseudomonas exotoxin
PE contains three functional domains, responsible for binding (domain Ia), transloca-
tion (domain II), and protein synthesis inhibition (domain III). Domain Ib, of yet
unknown function, joins domain II and the C-terminal domain III.88-90 Native PE is
excreted by the bacterium as a 66 kDa single-chain protein. The N-terminal domain Ia
binds the α2-macroglobulin receptor present on the surface of all eukaryotic cell types.
Following endocytosis, domain II is proteolytically cleaved at a low pH by cellular pro-
tease furine, resulting in two disulfide-bonded fragments of 28 and 37 kDa.91,92 The 37
kDa fragment contains part of the translocation domain II and the active enzyme
domain III. The latter contains a REDLK sequence which facilitates the transport of the
37 kDa fragment from the transreticular Golgi apparatus to the endoplasmatic reticu-
lum (ER).93 There, the remaining domain II fragment mediates the translocation of
domain III to the cytoplasm. In the cytoplasm, domain III inactivates elongation factor
2 (EF-2) by its ADP ribosylating activity resulting in the cell’s death. Current PE-based
IT use truncated forms of PE, in which the entire Ia domain (PE40)94-97 and frequently
also part of the Ib domain (PE38, PE35)98-105 have been deleted. Cell targeting ligands
are chemically or genetically linked to the N-terminus. In some cases, the C-terminal
REDLK sequence is altered to a KDEL sequence.106-109 This sequence has a higher affin-
ity for the ER KDEL receptor and, therefore, results in an increased efficacy of the
respective IT. 
Diptheria toxin
DT compromises an A and B-domain, which are responsible for cell binding and inhi-
bition of proteins synthesis, respectively.88 The crystal structure reveals a third domain,
the translocation domain (T), located within the B-domain in the center of the mole-
cule.110 Native DT is released in the bacterial medium as a single polypeptide chain of
535 amino acids of approximately 62 kDa. Outside the cell, DT is proteolytically cleaved
between the C-terminal A (24 kDa) and N-terminal B-domain (38 kDa), resulting in a
disulfide bonded two-chain form. The C-terminal B-domain binds to a complex of
heparin-binding EGF-like growth factor precursor and CD9. After endocytosis, the disul-
fide bond is broken and the low endosomal pH promotes a conformational change of
the T domain resulting in the formation of a transmembrane channel through which
the enzymatic A domain can enter the cytoplasm.111,112 In the cytosol, the A domain dis-
rupts cellular protein synthesis by ADP ribosylation of EF-2. For the construction of IT,
the C-terminus of either a binding site mutant (a.o. CRM107, CRM9)113,114 or C-termi-
nal truncation mutant (DT388, DT390, DAB486, DAB389)115-118 is linked to a cell bind-
ing ligand. Because most people are vaccinated against DT, C-terminal truncation
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mutants are to be preferred as pre-existing anti-DT antibodies may primarily be direct-
ed against the cell binding B-domain.118
Plant holotoxins toxins
Plant holotoxins compromise two disulfide-bonded chains: a protein synthesis inhibit-
ing A-chain, and a cell binding and translocation facilitating B-chain.119 Ricin, a natural
product derived from the castor bean (Ricinus Communis), is the plant holotoxin most
extensively tested in vivo. Native ricin is synthesized as a 64 kDa single chain pro-
enzyme containing a 12 residue linking peptide joining the 32 kDa A- and B-chain. Fol-
lowing post-translational proteolytic cleavage, an interchain disulfide bond links the two
chains. Cellular intoxication starts by binding of cell surface galactose residues by the
three lectin domains within the B-chain.120 After endocytosis, a considerable portion of
the internalized ricin is transported and degraded in the lysosomes.121 A fraction of the
internalized toxin is delivered to the trans-Golgi network. The further routing appears to
be dependent on receptors recycling between the terminal compartments of the Golgi
stack and the ER.122-124 The B chain dissociates from the A chain somewhere during the
transport to the ER. In the ER, the A chain is translocated to the cytoplasm and inhibits
protein synthesis through N-glycosidase activity removing the base of A4324 in 28s rRNA,
thus preventing the association of EF-1 and EF-2.125
For clinical use, the binding capacity of the B-chain has to be eliminated either by addi-
tion of excess galactose or lactose126 (only for ex vivo applications), chemical blocking
of the lectin-sites e.g. with galactose-based affinity labels (blocked ricin)127-131, or omit-
ting the entire B-chain132. An additional concern forms the high mannose and fucose
carbohydrate groups present on A and B-chain, which are bound by receptors on liver
Kupfer cells leading to rapid clearance and hepatoxicity.133 Using either chemically
deglycosylated ricin A (dgA) or non-glycosylated recombinant ricin A (rA) has success-
fully circumvented this problem.134-137 Notably, deglycosylation is not an option for
blocked ricin due to the galactose-based blocking of lectin activity.
The cytotoxicity of ricin A-based ITs is substantially lower than that of blocked ricin-
based ITs.128,138 This can largely be ascribed to the membrane translocation enhancing
capability of the B-chain.129,131,139 Moreover, the B-chain seems to protect the A-chain
from intracellular degradation.140 Whereas PE and DT are dependent on proteolytic
cleavage for enzymatic activity, the ricin A chain is largely inactivated by endosomal or
lysosomal proteases. Compounds that neutralize the low pH of intracellular compart-
ments, or interfere with the routing to the lysosomes, may strongly enhance the cyto-
toxicity of ricin A-based IT.141-143 Most commonly used are lysosomotropic agents, like
NH4Cl and chloroquine, and carboxylic ionophores, like monensin and nigericin.68,144-
150 Though biologically active concentrations are usually not achievable in vivo, these
agents have proven to be useful for ex vivo applications like the purging of hemato-
poietic stem cell grafts.151-153
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Plant Hemitoxins
Plant RIP I Hemitoxins, like saporin, gelonin, and pokeweek antiviral protein (PAP),
contain no cell binding domain and resemble the A-chain of RIP II in size and in func-
tion.119 For the construction of ITs, RIP I are typically conjugated directly to a cell tar-
geting ligand without further modifications.154-158
Alternative toxins
Li and Ramakrishnan constructed a recombinant hybrid plant-bacterial toxin by fusing
the coding region of ricin A-chain to the A-domain of DT. The rationale is that since bac-
terial and plant toxin act at different steps in protein translocation, a combination of
their activities could be more effective. In fact, ITs containing these chimeric toxins were
in vitro 100-1000 fold more effective than ITs prepared with either toxin alone.159
Though extremely potent, the major drawback of the bacterial and plant derived toxins
is their proven immunogenicity. Especially now human targeting ligands (antibodies
and cytokines) are readily available, it makes sense to search for human toxin equiva-
lents as well. So far, several human Rnases, Dnases, and human TNFα have been used
to construct fully human ITs.160-172 Though not as toxic as their plant/bacterial coun-
terparts, the initial in vitro results appear to be encouraging. The major benefit of
human ITs is to be expected in the treatment of diseases which ask for successive
administrations (e.g. autoimmune disorders). Since they have not been clinically test-
ed yet, it remains an open question whether the junction of human toxin and cell tar-
geting ligand does not form a new antigenic determinant.
As an alternative to the large catalytic toxins (typically ≥30 kDa), several synthetic
chemotherapeutic molecules have also been coupled to MoAbs. These include vin-
blastine, doxorubicin, daunomycin, methotrexate, adriamycin, maytansinoids and
calicheamicin.173-182 Due to their smaller size (<1 kDa), these agents may improve
tumor tissue distribution and will probably be less immunogenic. As compared to their
unconjugated forms, these agents proved more effective, and cause less side effects,
following conjugation to the MoAb. Their intracellular mechanism of action, however,
is identical. As such, they lack the advantage of plant or bacterial derived toxins which,
by there alternative mode of cytoxicity, may overcome acquired drug resistance to con-
ventional therapy.183-189
1 . 4 L I N K I N G  M O N O C L O N A L  A N T I B O D Y  A N D  T O X I N
Chemical conjugates
Conventional ITs are prepared by linking a toxin fragment and cell binding ligand using
a chemical crosslinker. Early studies demonstrated that plant toxin-based ITs should be
conjugated by a disulfide-bond containing linker to enable the essential intracellular dis-
sociation of ligand and toxin.126,190-192 For maximal stability outside the cell, crosslink-
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ers have been developed that contain a benzene ring and methyl group around the
disulfide bond to protect it from reduction by thiols in the blood and tissues.193,194
When using blocked ricin, a nonreducible thioether bond is prefered as the natural
occurring interchain disulfide bond is already present. The same holds true for trun-
cated bacterial toxins, still containing their native protease-sensitive sequence and
interchain disulfide bond.
The chemical conjugation procedure has some potential disadvantages. The ligand
conjugation is based on the derivatization of lysine residues, some of which may be
located within the antigen binding domain. The same holds true for derivatization of
the toxin, which may interfere with its catalytic activity.195 In general, chemically con-
structed ITs form a heterogeneous mixture with respect to derivatization sites and the
number of toxins per IT molecule. Recently, production methods have been developed
resulting in an increased product uniformity.196 There is no clear consensus, though,
regarding the optimal number of conjugated toxins per ligand.81,197-200 ITs should be
individually tested to determine whether the addition of two versus one toxin improves
the in vivo cytotoxicity. If a ligand-toxin combination forms an effective conjugate, the
conventional chemical production method has proven to be straightforward with good
production yields, especially for whole IgG ITs. Moreover, the chemical linkage allows a
great range of available toxins to choose from.
Recombinant fusion toxins
Recombinant fusion toxins are prepared by genetically splicing a toxin encoding DNA
to a gene encoding for a MoAb-fragment or other cell binding ligand, and expressing
the resulting construct as a single chain fusion protein. This approach is especially suit-
ed for the truncated bacterial toxins, which contain a native protease-sensitive sequence
required for intracellular dissociation. Plant toxin-based ITs, in contrast, require post-
translational removal of the interchain peptide sequence to facilitate intracellular ligand
dissociation. Ricin A-based fusion toxins compromising an artificial protease sensitive
linker, have thus far demonstrated only modest cytotoxicity.201
MoAb-based recombinant immunotoxins typically contain monovalent scFv or dsFv
fragments (see Figure 2). This is not only for technical reasons (bacterial expression
systems not allowing expression of whole IgG), but also since the small size is consid-
ered an important advantage for the penetration of solid tumors.202,203 Some potential
disadvantages should be noted as well. The absence of IgG Fc-parts prevents poten-
tially beneficial interactions with the patient’s immune system (see Paragraph 1.5).
Moreover, the smaller size results in an accelerated clearance that, together with the
monovalent binding, may negatively affect tumor saturation. The limited choice of tox-
ins may also be a disadvantage, as the intracellular routing can be suboptimal for the
available toxins. Another concern is that the reduced size may result in an increased
renal excretion associated with profound renal toxicity.204
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The ongoing developments in genetic engineering are likely to solve most of these
problems. An example forms the fusion, by various techniques, of Fv fragments into di-
or multivalent molecules.205 Depending on the Fv fragments applied, these can be
mono, bi or multi-specific. The resulting molecules often demonstrate improved phar-
macokinetics and have affinities equalizing or surpassing that of whole IgG. The addi-
tional incorporation of constant parts of the IgG heavy chain results in so called mini-
bodies possessing natural IgG effector functions. The phage display technology is
another recent development having a major impact on the production of recombinant
ITs. The expression of scFv or Fab’ fragments on the surface of filamentous phage
enables the isolation of specific MoAb fragments from huge phage-display libraries,
thus circumventing the conventional immunization and hybridoma technology.
Libraries derived from human donor tissue (e.g. PBLs, spleen, tonsil or bone marrow)
provide fully human antibody fragments of the desired specificity. These fragments can
readily be engineered into the preferred form and spliced to an appropriate toxin-encod-
ing gene. Considering the rapid developments within this area, recombinant produc-
tion of ITs will undoubtedly become the future standard, surpassing conventional bio-
chemical techniques in rapidly generating homogeneous batches with great flexibility
regarding the form of ligand and toxin. Moreover, the greatest promise is still to be ful-
filled, the generation of entirely human constructs compromising a human ligand fused
to a human enzyme equalizing the conventional toxins in efficacy.
1 . 5 N O N - T O X I N - B A S E D  E F F E C T O R  M E C H A N I S M S
Apart from its role as toxin transporter, the MoAb moiety contains intrinsic effector
mechanisms that may significantly contribute to the overall therapeutic efficacy. These
include the following:
The MoAb Fc-part
The MoAb Fc-part may fix complement C1q or bind to Fc receptors expressed on vari-
ous immune cells.206 Triggering the complement cascade results in direct comple-
ment-dependent cytotoxicity (CDC), as well as in the activation of several immune
effector cells. Binding of Fc receptors initiates a diversity of biological responses as well,
including antibody dependent cellular cytotoxicity (ADCC), phagocytosis, endocytosis,
release of inflammatory mediators, and enhancement of antigen presentation.
Though the potential anti-tumor effect of these mechanisms has been clearly demon-
strated in xenografted tumor mouse models, the full clinical relevance has to be deter-
mined yet.207-209 Several studies report of complement deposition or mononuclear
infiltrates in post-treatment biopsies of cancer patients treated with unconjugated
(murine) MoAbs.210,211 In a comparative clinical trial of two CAMPATH (CDw52) rat iso-
type-switch variants, the most effective target cell depletion was observed with the
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ADCC-inducing IgG2b MoAb.212 Moreover, CDC and ADCC are both considered in vivo
effector mechanisms of chimeric anti-CD20 MoAbs in the treatment of B cell malig-
nancies.213-218
Interference with cellular functions
The binding of the MoAb itself may interfere with cellular functions. The MoAb may
block or mimic the binding of natural ligand. This may directly induce growth arrest or
apoptosis, or the cell may be deprived of a critical survival/proliferation signal.
Members of the type I growth factor receptor family, including epidermal growth factor
(EFG) receptor (EGFR, erbB1) and HER-2 (erbB2), have been implicated in the cellular
transformation of several human malignancies.219-223 The antiproliferative effect of
EGFR and HER-2 blocking MoAbs has been demonstrated in several preclinical stud-
ies, including xenografted mouse tumor models.224-228 Moreover, a humanized version
of a HER-2 blocking MoAb induced objective clinical responses in patients with breast
cancer.13 Currently, combinations of anti-EGFR and anti-HER-2 MoAbs with other ther-
apeutic agents are clinically evaluated as accumulating data suggest these MoAbs
enhance the response to certain chemo- and hormone therapies.229-231
Humanized anti-CD20 MoAb Rituximab forms an example of a therapeutic MoAb
which clinical efficacy might partly be mediated by apoptosis induction. CD20 is a sig-
naling protein involved in the regulation of B-cell proliferation, and is expressed on
nearly all normal and malignant mature B cells. Ligation of CD20 by several MoAbs
induces cell death by apoptosis.232-236 In addition to ADCC and CDC, this may con-
tribute to the impressive responses observed in the treatment of CD20-positive neo-
plasms with unconjugated CD20 MoAbs.237-240
Anti-idiotype responses
The MoAb’s immunogenicity is a major obstacle potentially preventing multiple cycles
of therapy. The reverse side is that the humoral responses mounted by the patient may
elicit host anti-target cell antibodies as well. According to the ‘idiotypic-network’, the
administered MoAb (Ab1) may induce host anti-idiotype antibodies (Ab2), which in
turn may provoke host anti-anti-idiotype antibodies (Ab3), which in part bind the anti-
gen of the Ab1 MoAb.241 Indirect support for this concept was provided by the treat-
ment of colon carcinoma with murine MoAb 17-1A. The presence of Ab3 antibodies
appeared to be a positive prognostic factor for prolonged survival.242-248 Other studies
have been entirely based on exploiting the anti-idiotype strategy. In these studies,
patients were administered Ab2 antibodies, mounted in animals immunized with a
tumor-specific Ab1 MoAb (e.g. CO17-1A, HMW-MAA, CEA). Together with the forma-
tion of Ab3, several clinical responses could be observed, providing the proof of
principle.249-254
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Relevance of MoAb-based effector mechanisms for IT efficacy
There are several reports which confirm that the above effector mechanisms may con-
tribute to the IT efficacy as well.
Hertler et al., for instance, observed that an anti-CD5 IT (T101-ricin A) induced a rapid
but transient fall in white blood cells of patients with chronic lymphocytic leukemia.255
This response was attributed to an interaction of the MoAb-moiety with the reticuloen-
dothelial system.143,255 Yokota et al. demonstrated in a mouse tumor-xenograft model
that the interaction with macrophages enhanced the anti-tumor efficacy of an IT-com-
bination.42,256 More recently, Flavell et al demonstrated in a mouse model that part of
the anti-leukemia effect of a CD7-saporin IT was delivered by ADCC through recruit-
ment of NK cells.257 Vitteta et al. provided an example of the MoAb-binding contribut-
ing to the IT efficacy. They demonstrated that the cytotoxicity of an anti-CD19 IT was
partly based on the growth inhibitory signal induced by binding of the CD19 anti-
gen.258,259 This binding also impaires the activity of the drug efflux pump P-glycoprotein
(P-gp), leaving target cells more susceptible for chemotherapy.260 For anti-CD3 ITs, it
has been demonstrated that binding of the CD3/T cell receptor complex (CD3/TCR)
attributes to the IT efficacy by inducing activation induced cell death (AICD).261-263
Moreover, when treating immune disorder, the binding of the CD3/TCR may block anti-
gen stimulation.263 Similarly, targeting activated T-cells with anti-CD25 ITs may decrease
ongoing activation by blocking the IL-2 signaling.
1 . 6 L E S S O N S  F R O M  C L I N I C A L  T R I A L S
A variety of ITs has been tested in the clinic for diverse indications. Both recombinant
and chemical conjugated ITs have been tested, administered by bolus as well as con-
tinuous infusion schedules. Most of these studies have been Phase I/II trials, designed
to determine the dose limiting toxicity, maximal tolerable dose, and to gather informa-
tion regarding biological and clinical efficacy. Due to the nature of these studies, it is
too early to draw definite conclusions regarding the administration schedule or type of
IT which are eventually to be preferred for in vivo use. Nevertheless, some interesting
trends have been observed allowing the following general conclusions.
The observed toxicities can roughly be divided in ‘general toxicities’ directly mediated
by the toxin moiety, and ‘specific toxicities’ due to binding of the cell targeting ligand to
bystander tissue. An example of a general toxicity is vascular leak syndrome (VLS), char-
acterized by hypoalbuminaemia, weight gain, peripheral oedema, pleural effusion and,
occasionally, life threatening pulmonary oedema. Though observed with all applied bac-
terial and plant toxins, dose limiting severe VLS appears to be predominantly associa-
ted with ricin (A)-based ITs. Generally, VLS is transient and ceases shortly after discon-
tinuation of IT administration. The second dose limiting toxicity reported for dgA-based
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ITs is myalgia, rarely associated with rhabdomyolysis. Reversible elevations of serum
liver enzymes have frequently been reported for ITs constructed with DT, PE, type I RIP,
and blocked ricin.264-266 Hepatotoxicity has not been associated with dgA-ITs.
An example of specific toxicity has been reported by Pai et al. They observed an unex-
pected and severe central nervous system toxicity when clinically evaluating an IT
(OVB3-PE) reactive with human ovarian cancer. The underlying cross-reactivity with
normal human brain tissue was not detected during preclinical screening. Similarly, an
IT reactive with breast cancer (260F9-RTA) caused severe sensorimotor neuropathy
due to unexpected reactivity with Schwann cells. To predict and to anticipate on specif-
ic toxicities, ITs are to be extensively screened pre-clinically using a broad panel of
human tissues from multiple donors. Nevertheless, MoAb-antigen interactions might
be missed due to tissue fixation altering the antigenicity or destroying certain epitopes.
The same holds true for the opposite, epitopes may be exposed that are hidden, or only
marginally accessible, under normal physical conditions (e.g. intracellular antigens or
antigens protected by the blood-brain barrier). Cross-reactivity observed in vitro should,
therefore, not automatically eliminate a MoAb from consideration.27,267 In general,
cross-reactivity observed during preclinical screening asks for additional studies in rel-
evant test animals.
A common finding among IT trials is the occurrence of humoral responses to either the
cell targeting ligand or the toxin component. For patients with hematological disorders
the incidence of humoral anti-IT responses is typically in the order of 20-30%.99,263,268-
273 The immunogenicity rate seen in ITs trials against solid tumors, in contrast, is often
90 to 100%.21,29 Many of these responses can be detected within 10 days of the first
administration. Though hypersensitivity reactions are rare, repeated dosages may be
less effective due to accelerated plasma clearance or the formation of inactive immune-
complexes. Notably, extensive clinical responses have been seen even in the face of
anti-IT antibodies.25,274,275
The accessibility of target cells is a major factor determining the IT-efficacy. So far, solid
tumors are treated with only limited success. This may not only be due to heteroge-
neous blood supply, but also to tight junctions between tumor cells and a high inter-
stitial pressure. Though tumor penetration of small recombinant toxins is more effec-
tive, this appears to be counterbalanced by their rapid clearance by the kidney. The T1/2
of the recombinant conjugates is often less than 1 hour, as compared to 6 or more
hours for whole IgG-containing ITs. The treatment of diffuse hematological and
immunological disorders has proved more successful, with overall clinical response
rates ranging from 12-75%.276 Though many of these responses were partial and often
transient, this is not such a bad score considering the early nature of most studies
(mostly Phase I or II trials). So far, one immunotoxin has actually passed the registra-
tion process. The FDA approved recombinant toxin DAB389IL2 (Ontak) for the treat-
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ment of patients with advanced or recurrent cutaneous T-cell lymphoma.
Though responses have been obtained at safe dose levels, some important issues have
to be addressed in order for ITs to become broadly effective therapeutics. Major chal-
lenges include the prevention of severe toxin-induced vascular leakage, the reduction of
immunogenicity, and improving on the penetration of solid tumors. The optimal clini-
cal benefit is likely to be obtained in an adjuvant setting, following conventional ‘target-
cell-debulking’ therapy. Simultaneous application of multiple ITs may be necessary to
solve the problem of heterogeneous antigen expression.
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C H A P T E R  2
IMMUNOTOXINS IN HEMATOLOGY
C O N T E N T S
2.1 Hematopoietic stem cell transplantation
2.2 Ex vivo purging of stem cell grafts
2.3 Treatment of GVHD and graft rejection
2.4 Treatment of leukemias and lymphomas
2.5 Starting point of thesis
2 . 1 H E M A T O P O I E T I C  S T E M  C E L L  T R A N S P L A N T A T I O N :
The transplantation of hematopoietic stem cells (SCT) forms a world-wide accepted
method for the reconstitution of normal hematopoiesis in patients treated for a hema-
tological malignancy or otherwise suffering from a defective hematopoietic or immuno-
logic system. The stem cells can be derived from the patient himself (autologous trans-
plantation) or, from a suitable donor (allogeneic transplantation). Major obstacles for
successful outcome of SCT form recurrence of the malignancy and, in case of allo-
geneic SCT, graft-rejection and graft-versus-host disease (GVHD). ITs have been used
in an attempt to improve on the outcome of transplantation by specifically removing
undesirable cell types from either the stem cells graft or the patient. These can be
malignant cells as well as over-reactive or misdirected immunocompetent cells
(schematically depicted in Figure 1). Paragraph 2.2 and 2.3 review the current status of
the SCT-related clinical applications of ITs described so far.
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2 . 2 E X  V I V O  P U R G I N G  O F  S T E M  C E L L  G R A F T S
Allogeneic stem cell grafts
Immunocompetent T cells in the graft play a key role in allogeneic SCT. Their (minimal)
presence is required for a successful engraftment. Besides, they may contribute to the
so-called graft-versus-leukemia effect (GVL), which involves the elimination of residual
malignant cells. Unfortunately, they may also initiate graft-versus-host disease (GVHD),
a major cause of morbidity and mortality after allogeneic STC. The partial depletion of
T cells from allogeneic marrow grafts has been the first reported clinical use of ITs. The
initial studies used ricin A-chain or ricin holotoxin conjugated to MoAbs against CD5,
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Figure 1 Schematic representation of the stem cell transplantation (STC) procedure
A patient suffering from a hematological malignancy is treated with extensive radio and/or chemotherapy for
the elimination of malignant cells. In order to restore the affected hematopoiesis the patient is then transplant-
ed with hematopoietic stem cells previously collected during clinical remission (autologous STC), or derived
from a suitable donor (allogeneic STC). Adverse events negatively affecting the outcome of SCT are recurrence
of the malignancy, and, in case of allogeneic STC, rejection of the stem cell graft and graft-versus-host disease
(GVHD). With their specific toxicity, ITs can be used for the ex vivo or in vivo elimination of over-reactive or
misdirected immunocompetent cells (either of donor or recipient origin: indicated as ID and IR, respectively),
or residual malignant cells (indicated as M).
CD3 or a mixture of CD3, CD5 and CD11a.1-4 The ex vivo application allowed the addi-
tion of cytotoxicity enhancer NH4Cl (ricin A-chain) or an excess of lactose to prevent
aspecific binding (ricin holotoxin). The T-cell depletion ranged from 1-3 logs for the indi-
vidual ITs, to up to 4 logs for the combination. All studies noted a significant decrease
in the incidence of severe GVHD. Unfortunately, the removal of T cells appeared to be
a double-edged sword, associated with poor engraftment and an increased incidence
of relapse of the underlying disease. The same holds true for other immunological or
physical methods used for (partial) T cell depletion or positive selection of CD34 posi-
tive cells.5-7 Even though some of these methods enable the exact control of the num-
ber of T cells in the final graft, SCT remains a complicated procedure, often balancing
between graft-failure and leukemic relapse on one side and life-threatening GVHD at
the other. Ideally, future purging techniques should deplete only those T cells destined
to participate in the anti-host reaction, while conserving those with anti-leukemia reac-
tivity. A step in that direction is the ongoing identification of dominant GVHD-associ-
ated CTL epitopes.8 In combination with the tetrameric HLA-peptide complexes tech-
nology (‘tetramers’), this might bring back a role for ITs. Conjugating toxins to
TCR-specific tetramers, may create highly selective ITs capable of killing CTL with unde-
sired specificities.9,10 Alteratively, T-cell antigens might directly be fused to a toxin, as
has been demonstrated for myelin basic protein.11 The final success of these strategies
is dependent on the degree to which GVHD and GVL can be separated.
Autologous stem cell grafts
Autologous SCT forms an alternative when no suitable donor is available. In this case,
the stem cell graft is collected during remission and prior to the destruction of bone
marrow by chemo- and/or radiotherapy. This scenario introduces the risk of persistent
malignant cells within the graft contributing to a relapse upon re-infusion. ITs has been
used for the purging of malignant cells from autologous grafts of patients with T-lin-
eage acute lymphoblastic leukemia or T cell lymphoma. Though these studies demon-
strated no adverse effect on engraftment, a clear clinical benefit regarding relapse free
survival was hard to prove.4,12,13 A conclusive statistical evaluation will require large ran-
domized clinical trials. Nevertheless, genetic marking studies clearly have demonstrat-
ed the contribution of ‘graft-originating’ malignant cells to the relapse following autol-
ogous SCT for neuroblastoma and CML.14,15 These results still argue for maximal tumor
reduction of autologous grafts, e.g. by the IT-based purging of positively selected CD34-
positive hematopoietic progenitor cells.16,17
2 . 3 T R E A T M E N T  O F  G V H D  A N D  S T E M  C E L L  R E J E C T I O N
Acute GVHD (aGVHD) and accompanying immunosuppression continues to be the
major cause of morbidity and mortality in patients receiving allogeneic SCT.18 With the
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standard prophylaxis (typically cyclosporine, often combined with methothrexate)
GVHD occurs in 30-70% of HLA-matched recipients and contributes to death in 20-
40% of those affected. Even if a patient survives severe GVHD, this generally results in
long-lasting disability and morbidity leading to repeated admission to hospital.
The etiology of aGVHD is considered a multi-step process, already initiated by the
preparative treatment of the host with chemo- and/or radiotherapy (Figure 2).19,20 The
inevitable damage to the gastrointestinal tract, liver, and blood vessels induces an
inflammatory reaction associated with the release of IL-1 and TNF-α and the over-
expression of cytoadhesion molecules and MHC class II antigens. These events lead to
an enhanced interaction of allo-reactive donor-T cells with major or minor HLA anti-
gens on the affected tissues. Activation of these cells results in the production of
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Figure 2 Schematic representation of the immunopathophysiology of GVHD
GVHD is considered a multi-step process. The pretransplant conditioning regimen induces damage of host
tissues resulting in the secretion of inflammatory cytokines (TNF-α and IL-1) and the subsequent upregula-
tion of MHC antigens. These conditions favor the interaction with allo-reactive donor T cells, which upon
activation secrete IL-2, INF-γ. These cytokines induce further T-cell expansion and activate monocytes,
macrophages and NK-cells to produce IL-1, TNF-α and IL-6. Altogether, this cascade may cause serious
direct and indirect cytotoxicity to epithelial cells of skin, liver and gut.
Figure reprinted from Ref. 92 by courtesy of Marcel Dekker, Inc.
cytokines (IL-2 and INF-γ) which in turn activate additional effector cells, like mono-
cytes, macrophages and NK-cells, to produce inflammatory proteins (IL-1, TNF-α and
IL-6). Altogether, this may result in serious direct and indirect cytotoxicity to epithelial
cells of skin, liver and gut. 
When prophylaxis has failed, severe aGVHD is usually treated with low dose corticos-
teroids. If the reaction progresses, the dose may be increased or, alternatively, poly-
clonal antithymocyte/antilymphocyte globulin (ATG/ALG) or experimental immunosu-
pressive agents may be applied. Most of the experimental therapies are focussed on the
removal of T cells or interference with their IL-2 signaling. Based on their capacity of
eliminating specific cell populations, IT may also be suited for this type of therapy.
H65-RTA, a ricin A-based anti-CD5 IT, is the first IT clinically used for the in vivo treat-
ment of aGVHD. In the initial studies, the use of H65-RTA resulted in extensive
responses in about half of the patients with steroid-resistant aGVHD (~25% complete
responses).21-23 Compared to historical ATG-treated controls, the overall responses
rates obtained with H65-RTA were higher (52 vs. 31%) and the median survival was
longer (148 vs. 80 days).23 Unfortenately, in later comparative trials H65-RTA was not
more effective than high-dose corticosteroids or ATG.24,25 Additionally, the use of H65-
RTA for the prophylaxis of aGVHD or stem cell rejection revealed no clear advantage
over current cyclosporin-based regimens.26-30
Several animal studies now suggest that CD3-directed ITs may be more suitable for the
control of GVHD or graft-rejection than their anti-CD5 counterparts. The group of
Vallera and Blazer studied the therapeutic potential of a hamster derived anti-murine-
CD3 MoAb in an aggressive murine model of established GVHD. Conjugated to ricin
A, the CD3 MoAb appeared to be far more effective than a similar ITs directed against
the murine CD5-equivalent (Lyt-1), despite both ITs having similar clearance and biodis-
tribution.31 Its efficacy could partly be explained by the CD3 MoAb inducing modulation
of the T-cell receptor and T cell depletion.32 Moreover, conjugation to ricin A dramati-
cally improved the depletion efficacy of both the IgG and F(ab’)2-fragments.31,33 Vallera
et al. are now trying to identify the most appropriate form of anti-CD3 ITs for clinical
use. Their latest report addressed the evaluation of a single chain fusion toxin, com-
prising the Fv fragment of the anti-murine-CD3 MoAb genetically linked to truncated
diphteria toxin.34-36 Due to its relatively small size (68 kDA), this fusion toxins was read-
ily filtrated into kidney, causing severe and irreversible renal damage. This problem
appears now to be solved by the introduction of a cysteine residue at the c-terminus of
the sFv part, resulting in the formation of disulfide bonded bivalent IT with an expand-
ed therapeutic window.36
Neville et al. studied the T-cell depletion efficacy of an anti-rhesus-CD3 murine IgG1
MoAb conjugated to a diphteria toxin binding mutant (FN18-CRM9).37 This construct
was able of depleting >99% of T cells from both the blood and lymph node compart-
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ments of healthy rhesus monkeys. Restoration of the T-cell compartment took 12 to 30
days and appeared to be thymus dependent. Depletion activity of native FN18 was lim-
ited to the blood compartment and lasted only for a day.37 Additional primate studies
focussed on the use of FN18-CRM9 in protocols aiming at tolerance induction. Encour-
aging results were obtained, including the induction of long-term tolerance in kidney
and pancreatic islet transplant recipients.38-44 As an extension to these primate studies,
an anti-porcine CD3-IT has been generated (pCD3-CRM9) for evaluation in a non-
myeloblative stem cell transplantation model established in miniature swine.45 When
pCD3-CRM9 was added to a mild preparative regimen, infusion of blood stem cells
from leucocyte antigen-matched animals resulted in stable mixed chimerism without
aGVHD occuring.46 Moreover, this protocol provided donor-specific tolerance as indi-
cated by long-term acceptance of donor skin and consistent rejection of third party skin.
2 . 4 T R E A T M E N T  O F  L E U K E M I A S  A N D  L Y M P H O M A S
Their diffuse nature, and the relative abundance of tissue-specific antigens, make
hematological malignancies an attractive target for IT therapy. Table 1 summarizes the
outcome of the major studies reported so far. Most of them are directed at B cell
derived malignancies, mainly due to their high incidence as compared to T-cell neo-
plasms (ratio of about 5:1). 
Vitetta and colleagues performed a series of studies in which they evaluated RFB4-dgA
(anti-CD22) and HD37-dgA (anti-CD19) for the treatment of relapsed Non-Hodgkin’s
Lymphoma (NHL). Initial studies with RFB4-dgA demonstrated no particular advan-
tages of Fab’-ITs over whole IgG-ITs with regard to clinical responses, toxicities or
immunogenicity. Subsequent studies were performed with the more cost-effective
whole-IgG ITs. Both RFB4-dgA and HD37-dgA were administered as bolus and contin-
uous infusions, revealing no obvious advantage of one schedule above the other, and
resulting in a comparable maximal tolerable dose (MTD: ~16-20 mg/m2/8 days for both
ITs). The most prominent toxicities were VLS, myalgia, rhabdomyolysis and aphasia.
Overall response rates of RFB4-dgA were higher than those obtained with HD37-dgA
(~25% and 10%, respectively). Based on the synergistic effect observed in preclinical
studies47, the combination of HD37-dgA and RFB4-dgA (Combotox) is now being clin-
ically evaluated.48 The first study appears to be hampered by unpredictable clinical
courses, attributable to batch-dependent multimerization of HD37-dgA. Especially
patients lacking circulating tumor cells were vulnerable for severe VLS and hemolytic
uremic syndrome (HUS). Three deaths were noted, of which two were probably IT-relat-
ed. Further studies are planned using non-aggregate-forming formulations of HD37-
dgA. 
Another comprehensive series of clinical studies is performed with B4-bR, an anti-CD19
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Antigen Diseasea Administration #Patients
T101-RTA CD5 B-CLL b.i. twice wkly x 4 wk 9
H65-RTA CD5 CTCL b.i. daily x 10 d 14
Anti-CD7-dgA (DA7) CD7 T-NHL, T-LGL b.i. daily x 5 d 11
HD37-dgA CD19 B-NHL b.i. every 48h x 4 23
c.i. for 8 d 10
b.i. every 4h x 4 8
B43-PAP CD19 B-ALL c.i. for 5 d, 1 or 3 cycles 17
RFB4-dgA (Fab’) CD22 B-NHL b.i. every 48h x 2-6 15
RFB4-dgA (IgG) CD22 B-NHL b.i. every 48h x 2-12 26
c.i. for 8 d 18
RFB4-dgA (IgG) & CD19/CD22 B-NHL c.i. for 8 d 22
HD37-dgA
B4-bR CD22 B-cell neoplasms b.i. daily x 5 d 25
B-cell neoplasms c.i. for 7 d 34
B-NHL, postABMT, Ph I c.i. for 7 d 12
B-NHL, postABMT, Ph II c.i. for 7 d, every 14 d 49
B-NHL, postABMT, Ph III c.i. for 7 d, every 7 d 157
AIDS-NHL, relapsed c.i. for 28 d 9
AIDS-NHL, untreated c.i. for 7 d 28
RFT5-dgA CD25 HD b.i. every 48h x 4, 1-4 cycles 25
Anti-Tac(Fv)-PE38 (LMB-2) CD25 B & T lymph/leukemia, HD b.i. every 48h x 3 35
BerH2-SAP CD30 Hodgkin’s b.i. on day 1 ± 7 12
DAB486IL-2 IL-2R NHL, Hodgkin’s, CLL b.i. on day 1, 3-5, 14-20 18
NHL, Hodgkin’s, CLL b.i. daily x 5 d 15
NHL b.i. daily x 5 d 23
CTCL & Sezary b.i. dly x 5 d, every 21 d 14
DAB389IL-2 IL-2R Mycosis fungoides b.i. dly x 5 d every 21 d 71
Table 1 Major clinical trials of IT for the treatment of hematological malignancies
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MTD Toxicitiesb Human anti-IT Ab Responsesc Ref.
24-112 mg/m2 total Fever, nausea, rash 1/9 Rapid transient fall in WBC 68,69
0.33 mg/kg/d VLS, fever, chills, nausea, fatigue 10/14 4 PR 70
0.2 mg/kg/d VLS, aphasia 1/11 0 CR, 2 PR 71
16 mg/m2/8 d VLS, rhabdomyolysis 5/15 1 CR, 1 PR 72
19.2 mg/m2/8 d VLS, acrocyanosis 2/8 1 PR 72
8 mg/m2 VLS, hypotension, rhabdomyolysis 2/7 1 PR 73
1.25 mg/kg VLS, myalgia 0 4 CR, 1 PR 74
75 mg/m2 VLS, myalgias, aphasia, rhabdomyolysis 4/14 5 PR 75
26-40 mg/m2 total VLS, myalgias, aphasia, rhabdomyolysis 9/24 1 CR, 5 PR 76
19.2 mg/m2/8 d VLS, aphasia, hypotension 6/14 4 PR 77
≤10 mg - 30 mg/m2 VLS, HUS 6/22 2 PR 48
250 µg/kg total AST, ALT, PLTs, VLS, fatigue 9/25 1 CR, 2 PR 78
350 µg/kg total AST, ALT, PLTs, VLS, myalgia, edema 24/34 2 CR, 3 PR 79
280 µg/kg total AST, ALT, PLTs, VLS, fever 7/12 7 relapse free, MFU 4 years 80
210 µg/kg total AST, ALT, PLTs, VLS 23/49 27 relapse free, MFU 38 months 50
210 µg/kg total PLTs, VLS, fatigue, dyspnea NA Comparable with control 81
560 µg/kg total AST, ALT 3/9 1 CR, 1 PR 82
140 µg/kg total AST, ALT, fever, myalgia, fatigue 8/28 14 CR, 12 PR 83
15 mg/m2/cycle VLS, myalgias, hypersensitivity 7/15 2 PR 84,85
120 µg/kg total AST, ALT, cardiomyopathy, diarrhea, fever 11/35 1 CR, 7 PR 86
0.4 mg/kg/d AST, ALT, PLTs, VLS, fever, fatigue 12/12 8 PR 87,88
0.1 mg/kg/d AST, ALT, fever, dyspnea, rash 7/18 1CR, 2 PR 51
0.2 mg/kg/d AST, ALT, hypoalbuminemia, hypersensitivity 6/14 1 CR 89
0.3 mg/kg/d PLTs, r]enal insufficiency, hemolysis 15/20 2 PR 52
0.2 mg/kg/d AST, ALT 8/14 1 PR 55
9 or 18 µg/kg/d AST, ALT, VLS, hypersensitivity 70/71 3 CR, 18 PR 90,91
aB-CLL, B-cell chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; T-NHL, T-cell non-
Hodgkin’s lymphoma; T-LGL, T-cell large granular lymphocyte leukemia; B-NHL, B-cell non-Hodgkin’s lym-
phoma; B-ALL, B-cell acute lymphoblastic leukemia; postABMT, post autologous bone marrow transplanta-
tion; AIDS-NHL, AIDS-related non-Hodgkin’s lymphoma; HD, Hodgkin’s disease; AML, acute myeloid
leukemia.
bVLS, vascular leak syndrome; HUS, hemolytic uremic syndrome; AST, aspartate amino transferase; ALT,
amino alanine transferase; PLTs, thrombocytopenia
cWBC, white blood cell counts; PR, partial response; CR, complete response; MFU, median follow up.
MoAb conjugated to blocked ricin (B4-bR). Following the evaluation of various dosing
protocols and different clinical settings, B4-bR was the first IT to be tested in the mini-
mal disease setting. B4-bR has been administered to patients with NHL brought in
complete remission with high-dose chemotherapy and stem cell transplantation.
Regrettably, no beneficial effects on disease free survival could be demonstrated in a
randomized Phase III trial.49,50 The hepatotoxicity of bR was and important factor lim-
iting therapeutic success by reducing the therapeutic window.
Of note is the good performance of IL-2 receptor (IL-2R) targeted recombinant ITs in
certain hematological diseases. Truncated diphtheria toxin spliced to IL-2 (DAB486IL-2
and the improved version DAB389IL-2) showed impressive efficacy in treating CD25-
positive refractory cutaneous T-cell lyphoma (CTCL), with overall response rates of
approximately 30%.51-58 DAB389IL-2 (Ontak) has been approved by the FDA (May 1999)
for the treatment of patients with persistent or recurrent CD25-positive CTCL.
The group of Pastan created an alternative anti-IL-2R IT by genetically linking an anti-
CD25 MoAb Fv-fragment to truncated Pseudomonas exotoxin (LMB-2).59-61 This IT dif-
fers from DAB389IL-2 in that it binds CD25 (IL-2R α-chain) with high affinity also in the
absence of the IL-2R β and γ chain. This may be an advantage for malignancies solely
expressing the IL-2R α-chain, like the Reed Sternberg cells in Hodgkin’s disease. LMB-2
has been adminstered to patients with various CD25-postive hematological malignan-
cies. Remarkably, all four patients with hairy cell leukemia (HCL) responded to therapy,
with one complete responder of more than 20 months of duration. Additionally, four
partial responses were observed in CTCL (n = 1), CLL (n = 8), HD (n = 11), and adult T-
cell leukemia (n = 2). Additional in vitro studies with freshly derived patient cells con-
firmed the particular vulnerability of HCL cells as compared to B-CLL cells expressing
equal or higher numbers of CD25 per cell.62
The above examples represent a proof of principal that IT-based therapy of hematolog-
ical malignancies can be clinically useful. Several clinical responses could be noted in
refractory patients with bulky disease. The ongoing and coming clinical trials will be cru-
cial in determining the future role of ITs. Not only will they teach us which particular
hematological diseases are vulnerable for what type of IT, they also should identify the
optimal clinical setting for maximal therapeutic benefit.
2 . 5 S T A R T I N G  P O I N T  O F  T H E S I S
The UMC St Radboud was among the first to introduce the IT research in the Nether-
lands, in 1983. This research was initially focused on identifying the factors influencing
the activity of IT, like the nature and density of target-antigens, the internalization rate,
the use of toxicity enhancers, and the activation state of the target cells.63-66 These stud-
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ies resulted in the first institutional clinical application, the ex vivo purging of autolo-
gous marrow grafts of patients suffering from T cell leukemia or lymphoma.12 Aim of
this treatment was to reduce the incidence of a malignant relapse caused by residual
malignant cells in the autologous graft. The more or less routinely ex vivo purging of
bone marrow can be regarded as the starting point of this theses. As such, this appli-
cation initiated additional research focussing at ways to improve the purging efficacy
and to reliably monitor its efficacy in a heterogeneous population such as bone marrow
grafts. At the mean time, the international excitement regarding the therapeutic possi-
bilities of the ‘magic-bullit concept’ more or less drove the IT from the laboratory to the
clinic. Several institutes, mostly US academic centers, initiated phase I/II studies based
on the IT-targeting of diffuse and solid tumors and varying immune diseases. Encour-
aged by the outcome of these early studies, especially regarding the treatment of dif-
fuse disorders, and motivated by the urgent clinical need, the Department of Hematol-
ogy decided to develop an IT-based therapy for lifethreatening aGVHD. Additionally,
another research line was started studying the anti-tumor activity of an anti-B cell IT in
a mouse xenografted tumor model. The next part of this thesis forms a selection of the
institutional IT-research during the last decade. It covers part of the early in vitro work
(Chapter 3 to 5), and the set up and preliminary results of a clinical pilot study for the
treatment of aGVHD (Chapters 6 and 7). Notably, the complementary work, address-
ing the IT-based treatment of B cell malignancies, is described in the thesis of Van
Horssen.67
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A B S T R A C T
The cytotoxicity of WT32 (CD3)-ricin A immunotoxin (IT) to the acute lymphoblastic
leukemia T-cell line Jurkat was compared with the rate of internalization and intracellu-
lar degradation of WT32 and WT32-ricin A during continuous exposure. Moreover the
influence of NH4Cl and monensin on these processes was studied.
Based on protein synthesis inhibition ([3H]leucine incorporation), it appeared that cyto-
toxicity was not fully expressed directly after exposure to IT due to delay either in the
internalization of membrane-bound IT or the action of intracellular ricin A. Varying the
duration of incubation and postponing [3H]leucine addition up to 24 h after initiation
showed that cytotoxicity occurred in two phases, rapid internalization of initially bound
IT followed by a continuous but slower uptake possibly due to reexpression of the CD3
antigen.
No differences were found in the rate of internalization and degradation of 125I-labeled
WT32 and WT32-ricin A. Internalization started rapidly after binding at 37°C, was fastest
during the first 12 h (~360,000 molecules/cell) and continued for at least 24 h
(~420,000 molecules/cell). Exocytosis of intracellularly degraded molecules became
measurable after 1 to 2 h of incubation  at 37°C and increased up to approximately
400,000 molecules/cell in 24 h. After 4 h of incubation at 37°C the amount of internal-
ized molecules exceeded the amount of WT32 that could maximally bind to the cell
membrane (~150,000 molecules/cell) confirming reexpression of antigen.
Addition of NH4Cl and monensin enhanced the cytotoxicity of WT32-ricin A, probably
due to an increased intracellular amount of IT. These agents appeared to reduce strong-
ly the degradation of internalized WT32, resulting in an accumulation of intracellular
molecules. NH4Cl was most effective during the first 12 h of incubation, whereas mon-
ensin increased the amount of intracellular WT32 molecules after 2 to 24 h. 
Our observations suggest that incubation conditions for the optimal cytotoxicity of IT
treatment can be predicted by studying the internalization and degradation of the IT or
respective monoclonal antibody. 
I N T R O D U C T I O N
Monoclonal antibodies (MoAbs) coupled to toxins such as the A-chain of the phy-
tolectin ricin appear to be highly specific ITs for the ex-vivo elimination of both malig-
nant and normal T-cells which occur in autologous and allogeneic bone marrow (BM)
grafts, respectively.1-5 The efficacy of ricin A ITs depends on the number of molecules
internalized by target cells and their intracellular routing and processing.6-11 Ricin A-
chain catalytically and irreversibly inhibits protein synthesis by cleaving the N-glycosidic
bond of a single adenosine residue of 28S rRNA.12 Theoretically, a cell can be killed by
a single molecule that enters the cytosol13 but since the bulk of IT is usually transport-
ed into cellular compartments where ricin A is either proteolytically cleaved or inacti-
vated by low pH7,14-16, a sufficient number of molecules must be endocytosed to guar-
antee cytotoxicity.
Cells with a low density of antigen may survive treatment when the number of inter-
nalized IT molecules remains below the required threshold. This problem may be part-
ly overcome by adding lysosomotropic amines (e.g., ammonium chloride, chloroquine)
or carboxylic ionophores (e.g., monensin, nigericin) which enhance cytotoxicity by influ-
encing different intracellular processes such as routing and metabolism.17-21 Alterna-
tively, when the IT is continuously internalized as a result of reexpression of the target
antigen, cytotoxic efficacy can be improved by prolonging incubation. However, this
may be harmful to normal BM cells, and therefore it is important to determine the opti-
mal period for individual ITs in purging BM grafts.
CD3-ricin A-chain ITs appear good candidates for the selective elimination of malignant
and normal T lymphocytes.2,4,22,23 However, optimal incubation conditions remain to
be determined. We therefore studied the kinetics of cytotoxicity of WT32-ricin A in the
presence or absence of the enhancers ammonium chloride or monensin, and compared
these with the intracellular uptake and processing of 125I-WT32 and 125I-WT32-ricin A.
M A T E R I A L S  A N D  M E T H O D S
Cell line
The human acute lymphoblastic leukemia T-cell line Jurkat was cultured in RPMI 1640
(Flow Labs, Irvine, Scotland) supplemented with 10% heat-inactivated fetal calf serum
(FCS) (Gibco, Paisley, Scotland), glutamine (2mM), penicillin (100 U/ml) and strepto-
mycin (100 µg/ml) in a humidified incubator with 5% CO2 in air at 37°C. Cells were
maintained in the log phase.
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Monoclonal antibody and immunotoxin preparation
Murine anti-human T-cell MoAb WT32 (IgG2a, CD3)24 was purified from ascitic fluid by
ammonium sulfate precipitation and affinity chromatography with staphyloccocal pro-
tein A-sepharose (Pharmacia, Uppsala, Sweden). WT32 was conjugated on a 1 to 1.1
ratio to ricin A using N-succinimydyl-3-(2-pyridyldithio)propionate (SPDP) (Pharmacia)
and assayed as described elsewhere.9 Antibody-binding activity was confirmed by flow
cytometry (FCM) and enzyme-linked immunosorbent assay.9 Nonspecific cytotoxicity
was tested on cell lines which did not express the CD3-antigen.9 Ricin A was kindly pro-
vided by Dr. F.K. Jansen (Centre de Recherches Clin Midy, Montpellier, France).
Radioiodination
WT32 and WT32-ricin A were labeled with 125I (Amersham International, UK) using the
Chloramine-T method (Hunter, 1973), and then purified by chromatography on a
Sephadex G25 column (PD-10; Pharmacia). Eluted fractions containing 125I-WT32 and
125I-WT32-ricin A were pooled, and molecules smaller than Mr 30,000 were removed by
means of a centriprep-30 concentrator (Grace B.V., Amicon Division, Rotterdam, Hol-
land). Thereafter radioactivity due to free 125I and fragments smaller than Mr 30,000
was less than 0.3% of the total radioactivity. The concentration of the labeled antibody
and its ricin A conjugate was determined by radioimmunoassay, while immunoreactiv-
ity was assayed by means of binding limiting quantities of labeled WT32 and WT32-ricin
A. Conjugation of ricin A to the antibody was confirmed by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) of 125I-labeled IT, followed by autoradiogra-
phy and scanning densitometry (data not shown).
Cytotoxicity of WT32-ricin A
Culture medium containing 106 cells/ml was incubated at 37°C with WT32 ricin A (10-8
M) with and without either 6 mM NH4Cl or freshly prepared 100 nM monensin (Sigma,
St. Louis, MO). After 1, 2, 4, 8, 16, and 24 h of incubation, cells were washed with RPMI
1640 containing 1% FCS and then resuspended in fresh medium. They were distributed
in triplicate into 96-well microtiter plates (Costar, Cambridge, MA) at a concentration
of 105 cells/well. Subsequently, cells were immediately incubated with 1 µCi [3H]leucine
(Amersham) at 37°C for 1 h, following which they were harvested. The radioactivity was
determined, and protein synthesis was expressed as the percentage [3H]leucine incor-
poration of untreated cells after correcting for non-specific incorporation in the pres-
ence of 1 mM cycloheximide.
Cytotoxicity caused by continuous internalization of WT32-ricin A
The increase of cytotoxicity after prolonging incubation might be explained by delayed
internalization of IT already bound soon after exposure or slow onset of cytotoxicity. To
eliminate differences in cytotoxicity caused by these phenomena rather than by contin-
uous internalization of IT, the assay was modified by introducing an IT-free incubation
after cells were washed up to 24 h after the initiation of the experiment (23, 22, 20, 16,
8, and 0 h, respectively), and then proceeding with [3H]leucine incorporation.
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Intracellular and surface bound 125I -WT32 and 125I -WT32-ricin A
Following continuous incubation of Jurkat cells with 125I-labeled antibody or its ricin A
conjugate, the number of intracellular molecules was determined using a modification
of the procedure previously described.9 Briefly, a suspension of 5x105 target cells was
incubated with 10-8 M 125I-WT32 or 125I-WT32-ricin A for various times at either 37°C or
4°C at a final volume of 100 µl. Thereafter cells were washed and counted to determine
the total amount of associated radioactivity. Subsequently, cells were incubated with
isotonic glycine buffer (pH 2) at 4°C for 30 min, to remove surface-bound molecules
and then washed, after which radioactivity was again determined. The absolute number
of intracellular molecules was calculated from the glycine buffer-treated cells initially
incubated at 37°C after correcting for the cells treated with the same buffer at 4°C.
The number of molecules bound to the cell surface was determined by subtracting the
amount of intracellular radioactivity from total radioactivity after incubation at 37°C. The
maximal number of binding sites was determined by incubation with increasing
amounts of 125I-WT32 at 4°C for 1 h.
Degradation of 125I -WT32 and 125I -WT32-ricin A
The degraded and subsequently exocytosed amount of internalized molecules was
determined by measuring radioactivity of the trichloroacetic acid (TCA)-soluble fraction
of culture supernatant. After incubation with 125I-WT32 or 125I-WT32-ricin A at 37°C or
4°C, cells were pelleted by centrifugation. Seventyfive µl of supernatant was treated with
1 ml of 25% TCA and 75 µl 1% bovine serum albumin (BSA) at 4°C for 15 min and then
centrifuged at 1500 G for 15 min. The radioactivity of the soluble fraction from cells incu-
bated at 4°C was substracted from that obtained at 37°C to remove any background
radioactivity.
Extracellular degradation was excluded since there was negligible radioactivity found in
the TCA-soluble fraction of B-cell line Daudi, which does not express CD3, and of puri-
fied surface membranes from disrupted Jurkat cells after incubation with 125I-WT32 or
125I-WT32-ricin A as described by Press et al.19,25 Similar results were obtained after
incubating Jurkat with a 125I-labeled control antibody (CD19, IgG2a) or its ricin A con-
jugate  (data not shown), suggesting that no extracellular degradation occurred during
incubation.
Internalization 125I -WT32 and 125I -WT32-ricin A
Internalization was defined by the total number of molecules transported across the
cell membrane during incubation. The degree of internalization was calculated by
adding the fraction which was intracellularly degraded and subsequently exocytosed to
the amount of intracellular molecules.
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Kinetics of cytotoxicity of WT32-ricin A directly after IT treatment
Prolonging IT treatment led to a reduction in [3H]leucine incorporation from 85% after 1 h
to 9% after 24 h Figure 1. This might be explained by continuous binding and internal-
ization of IT. Alternatively it might be the result of slow internalization of IT bound to cells
in the first phase of incubation or of a delay in the toxicity of intracellular ricin A molecules.
Cytotoxicity caused by continuous internalization
Introduction of an IT-free incubation up to 24 h after the initiation of the experiment
resulted in an additional decrease of protein synthesis which became less pronounced
after prolonged treatment (Fig. 1). The kinetics of protein synthesis measured after the
post-IT-treatment period showed a biphasic pattern: a considerable decrease of protein
synthesis during the first 2 h of IT treatment (60%), followed by a slower decrease for
up to 24 h (89% after 24 h). In this setting the reduction of protein synthesis could only
be the result of continuous internalization of IT.
Influence of enhancers of cytotoxicity
The presence of NH4Cl as well as of monensin resulted in significantly greater decrease
of protein synthesis after 1 h (Figure 2), although monensin appeared to be slightly
more effective than NH4Cl (83%, 74% and 47% reduction with monensin, NH4Cl and
without enhancers, respectively). Similar concentrations of NH4Cl or monensin in the
absence of IT were non toxic since [3H]leucine incorporation was unaffected (data not
shown). Enhancement of cytotoxicity became less pronounced after prolonging incu-
bation in the presence of IT.
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Figure 1
Kinetics of cytotoxicity of WT32-ricin A
Jurkat cells were incubated at 37°C with 10-8 M
WT32-ricin A for various periods. After IT treat-
ment cells were washed, and directly after ()
or 24 h after () initiation of the experiment
they were incubated with [ 3H]leucine for 1 h.
Protein synthesis is expressed as a percentage of
[ 3H]leucine incorporation of untreated cells.
Untreated cells incorporated ~20,000 cpm;
background incorporation was ~100 cpm.
Assays were performed in triplicate; SDs were
less than 10%.
Kinetics of internalization and intracellular degradation of 125I-WT32 and 125I-WT32-ricin A
To confirm the possibility of continuous internalization due to reexpression of antigen
as suggested by the pattern of protein synthesis inhibition, the kinetics of internaliza-
tion and intracellular degradation were studied by means of 125I-labeled WT32 and its
ricin A conjugate. The maximal number of binding sites was determined with increas-
ing concentrations of 125I-WT32 at 4°C and was achieved with 4 µg/ml 125I-WT32
(~150,000 molecules) (Figure 3).
Both 125I-WT32 and 125I-WT32-ricin A were internalized at the same rate (Figure 4). At
37°C 125I-labeled antibody and its ricin A conjugate were rapidly internalized during the
first 12 h (~360,000 molecules); thereafter internalization continued at a slower rate for
up to at least 24 h (between 420,000 and 440,000 molecules). After 4 h the number
of internalized molecules surpassed the amount of 125I-WT32 that could maximally bind
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Figure 2
Influence of cytotoxicity enhancers
Jurkat cells were incubated at 37°C with 10-8 M
WT32-ricin A for various periods in the absence
() or presence () of 6 mM NH4Cl or 100
nM monensin (). After IT treatment cells
were washed, followed by an incubation in the
absence of IT and enhancers up to 24 h after ini-
tiation of the experiment, and then by a 1-h
uptake of [ 3H]leucine. Protein synthesis is
expressed as percentage [ 3H]leucine incorpora-
tion of untreated cells. Untreated cells incorpo-
rated ~20,000 cpm; background incorporation
was ~100 cpm. Assays were performed in tripli-
cate; SDs were less than 10%.
Figure 3
Binding of 125I-WT32 to Jurkat cells at 4°C
Jurkat cells were incubated with 1, 2, 4, 6 and 8
µg/ml 125I-WT32 at 4°C for 1 h. After incubation
unbound 125I-WT32 was washed out, and the
number of cell-associated 125I-WT32 molecules
was determined (). Assays were perfomed in
triplicate; SDs were less than 10%.
to the cell membrane (~150,000), confirming the continuous reexpression of antigen.
The amount of membrane-bound molecules at 37°C (~60,000 after 2 h) decreased
slightly during the 24-h period. Binding of 125I-WT32 and 125I-WT32-ricin A at the con-
centration used was optimal after 2 h at 4°C and remained unchanged up to 24 h (data
not shown).
The number of intracellular molecules reached a maximum after a 2-h incubation at
37°C (~80,000 molecules) and declined to about 18.000 molecules after 24 h.
Breakdown and exocytosis of internalized molecules were measurable after 1 h and
increased to about 330,000 molecules in 12 h. Thereafter the exocytosis rate was
reduced but still continued up to about 400,000 molecules after 24 h.
Influence of cytotoxicity enhancers on the internalization and intracellular degradation
To determine the influence of the cytotoxicity enhancers on the uptake and intracellular
degradation of 125I-labeled WT32 and its ricin A conjugate at 37°C, the above-described
experiments were repeated with 125I-WT32 in the presence of NH4Cl (Figure 5A) or
monensin (Figure 5B).
The addition of NH4Cl resulted in a considerable increase in the amount of intracellu-
lar 125I-WT32, with a maximum of at least 140,000 molecules between 4 and 8 h. There-
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Figure 4 Internalization and intracellular degradation of WT32 and WT32-ricin A
Jurkat was incubated at 37°C or 4°C with 125I-labeled WT32 (A) or WT32-ricin A (B) for various periods.
Results of cells incubated at 37°C corrected for cells treated at 4°C, as described in “Material and Methods”, are
depicted. The number of internalized and subsequently degraded and exocytosed molecules was measured by
counting TCA-soluble radioactivity of the supernatant of incubation medium (). The number of surface
bound molecules was measured by counting cell bound radioactivity that was removable by glycine buffer pH2
(). The intracellular number of molecules was measured by counting cell associated radioactivity  not-remov-
able by the glycine buffer (). Absolute amount of internalized molecules was determined as the sum of intra-
cellular molecules and intracellular broken down and subsequently exocytosed molecules (). One of three (A)
and one of five (B) concordant experiments are shown.
after this increase diminished, almost disappearing after 24 h of incubation (Figures 4
and 5A).
Monensin also resulted in an increase of intracellular 125I-WT32, but this was less pro-
nounced during the first 8 h. After 4 h the amount of intracellular 125I-WT32 reached a
peak of approximately 100,000 molecules, which gradually declined to 80,000 mole-
cules after 24 h of incubation. However this was larger than the yield either with NH4Cl
or without enhancer after 24 h. 
The absolute number of internalized molecules in the presence of NH4Cl was slightly
decreased in comparison to the conditions without enhancers, suggesting that NH4Cl
did not influence the internalization of 125I-WT32 (~380,000 and 410,000 molecules
after 24 h, with and without NH4Cl, respectively). The addition of monensin resulted in
a larger reduction in the number of molecules entering the cell (~330,000 molecules
after 24 h).
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Figure 5 Internalization and intracellular degradation of WT32
Jurkat was incubated at 37°C or 4°C with 125I-WT32 for various periods in the presence of 6mM NH4Cl (A) or
100 nM monensin (B). Results from cells incubated at 37°C corrected for cells treated at 4°C, as described in
“Material and Methods”, are depicted. Exocytosis of degraded WT32 (), surface-bound WT32 (), intracel-
lular WT32 () and internalized WT32 () were determined. For additional legends see Fig. 4. One of four
(A) and one of three (B) concordant experiments are shown.
D I S C U S S I O N
The cytotoxicity of WT32-ricin A was not fully expressed directly due to a delay in either
the internalization of initially bound IT or the action of intracellular ricin A. This has also
been reported by Ravel et al.20 and Sung et al.26, using T101-ricin A (CD5) and 454-ricin
A (CD71), respectively. They observed that cytotoxicity increased when measuring pro-
tein synthesis was postponed. This phenomenon can strongly influence the outcome
of kinetics studies for the determination of the optimal incubation time. To determine
the efficacy of prolonging IT-treatment, it is therefore important to standardize the peri-
od between initiation of IT incubation and the moment of [3H]leucine exposure. This
was assessed by introducing an IT-free incubation up to 24 h after the initiation of the
experiment. The reduction of protein synthesis in the current setting showed a bipha-
sic pattern of strong inhibition during the first period followed by a slower inhibition
during the second period. This suggests a rapid internalization of initially bound WT32-
ricin A during the first period of IT treatment, followed by a more slowly continuous
uptake of WT32-ricin A, possibly due to reexpression of CD3 antigen.
In order to confirm the continuous uptake of IT due to reexpression of CD3 antigen,
binding, internalization and degradation of WT32 as well as WT32-ricin A were exam-
ined after continuous exposure of Jurkat cells to 125I-labeled ligands. Free MoAb and the
respective IT were both studied because conjugation of ricin A to the MoAb may affect
the internalization or intracellular routing of the complex, depending on the target anti-
gen. It has been reported that conjugation of RFT11 (CD2) to ricin A decreases the intra-
cellular degradation of ligand.10 In this study we show that there is neither difference in
internalization nor in intracellular degradation between WT32 and WT32-ricin A. This
has also been described for other MoAbs and ricin A ITs.6,9,11,27
Press et al.19 and Geissler et al.18 studied the internalization and degradation of CD3-
MoAb 125I-64.1 in T-cells and the T-cell line HPB-ALL after initial pulse labeling of the
cell surface with 125I-64.1 at 4°C for 1 h. Washing out unbound ligand prior to incuba-
tion at 37°C, however, would reduce the amount that can be maximally internalized due
to: (a) disturbing the equilibrium between free and bound ligand, resulting in the dis-
sociation of membrane-bound ligand; and (b) preventing the binding and internaliza-
tion of ligand induced by reexpression of the antigen. We therefore performed internal-
ization studies in the continuous presence of an excess of free MoAb or IT in the
medium. We were able to demonstrate the reexpression of CD3 antigen or the expres-
sion of newly synthesized CD3 antigen by the observation that the amount of internal-
ized ligands exceeded 2.5 times the maximal number of antigen binding sites under sat-
urating conditions in 24 h. This is in accordance with observations of Krangel28, who
demonstrated a recycling of the CD3/TCR complex to the cell membrane following
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endocytosis in the presence of CD3 MoAb. The capacity of the CD3 antigen to induce
the internalization of potential cytotoxic ITs for up to 24 h resembles the observation
that prolongation of treatment with WT32-ricin A up to 24 h increases cytotoxicity.
Cytotoxicity of WT32-ricin A to T-cells and T-cell lines is enhanced by NH4Cl9,22,23 and
monensin. Although the mechanism of potentiating is not fully understood, different
intracellular compartments and transport mechanisms might be influenced (reviewed
in Ref. 29). Previous studies have shown that NH4Cl and monensin considerably
decreased the degradation of 64.1(CD3) by T cells and the T-cell line HPB-ALL.18,19,24
We demonstrated that NH4Cl and monensin reduced the degradation of intracellular
125I-WT32 by Jurkat but found differences in their action. Intracellular degradation was
decreased during different periods of the continuous incubation, resulting in a tempo-
rary accumulation of MoAb. NH4Cl was most effective during the first 12 h of incuba-
tion, whereas monensin decreased the degradation of intracellular 125I-WT32 after 2 h
to at least 24 h of incubation. Moreover, NH4Cl resulted in a higher intracellular accu-
mulation of ligand. As was published before, NH4Cl did not influence the total amount
of internalization.9,27 Monensin, however, reduced the number of internalized mole-
cules in contrast to observations of Ravel et al.27, who found that monensin had no
influence on internalization. Though these results seem to be in favor of NH4Cl as an
enhancing agent, monensin may act more effectively on intracellular handling of ricin
A than NH4Cl, which was confirmed in the cytotoxicity kinetics, since monensin was at
least as effective as NH4Cl.
The efficacy of WT32-ricin A might be extended to cells with low antigen density when
treatment is prolonged and either NH4Cl or monensin is added due to continuous
uptake and intracellular accumulation of ITs. Since exposure to ricin A-ITs for 24 h is not
harmful to either bone marrow (BM) progenitor cells or stem cells23, it may now be
possible to improve considerably the purging of BM intended for autologous trans-
plantation and therefore the success of this form of therapy.
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A B S T R A C T
We analyzed the effect of isotype variation on effectiveness of B-cell CD19 immunotox-
ins (ITs) by using class switch variants (CLB-B4-IgG1 and CLB-B4-IgG2a) conjugated to
ricin A. Notably, IgG1-IT appeared to be ~100-fold more potent than IgG2a-IT toward B-
cell lines Daudi and KM3. Binding and internalization studies with 125I-labelled mono-
clonal antibodies (MoAbs) revealed a higher cellular uptake of IgG1 compared to IgG2a,
despite similar binding affinities. Following removal of the Fc-part, both MoAb inter-
nalized at the same rate as IgG2a, indicating that the Fc part of IgG1 is involved in
enhanced cellular uptake. The involvement of FcγRII(CD32) in this process was demon-
strated by a decreased cytotoxicity of IgG1-IT (and not IgG2a-IT) in the presence of
FcγRII-blocking MoAbs AT10 or IV .3. To identify the isoform responsible for this phe-
nomenon, internalization of IgG1 and IgG2a in 11 B-cell lines, and malignant B-cells of
8 patients was compared with expression of FcγRII subclasses. In addition to four cell
lines (Daudi, KM3, Nalm6, and Raji), the malignant B-cells of two patients showed
enhanced uptake of IgG1 relative to IgG2a. Only the FcγRIIa transcript was found in all
B-cells. Furthermore, enhanced uptake of IgG1 correlated with rosetting of erythrocytes
sensitized with anti-glycophorin A MoAb of IgG1 isotype rather than with FcγRIIa mem-
brane expression levels. These data support the idea that functional FcγRIIa is involved
in the enhanced IgG1 uptake observed in a subset of B-cells. Our study, therefore,
points to an important role for the Fc region of IT in delivery of cytotoxic effects.
I N T R O D U C T I O N
During the past decade, a large number of MoAbs have been conjugated to the highly
toxic A chain of the phytolectin ricin in an effort to create tumor-toxic agents. These may
be of use for treatment of bone marrow in vitro or may be useful in vivo for patients
suffering from hematological malignancies (reviewed in Refs. 1-3). The killing potencies
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of such ricin A-chain ITs appeared to vary widely. Firstly, the cytotoxic efficacy of IT
depends upon the number of IT molecules internalized by target cells, as well as the
intracellular route followed upon internalization.4-6 Both factors are influenced by the
nature of the target cell, type of antigen7,8, target antigen density6,9, MoAb binding affin-
ity9,10, and the IT epitope11-13. Furthermore, the biological effects of ITs have been
observed to vary depending upon the use of F(ab’)2, F(ab’), or intact IgG.14-16 The effect
of variation in isotype on the cytotoxic effectiveness of ITs remained unaddressed.
We constructed two anti-CD19 ITs, which differ in isotype only, by conjugating the
murine anti-CD19 MoAb CLB-B4-IgG1 and its isotype-switch variant CLB-B4-IgG2a17 to
ricin A. These ITs differed only in their Fc-parts and expressed identical binding affini-
ties. Interestingly, however, a profound difference in their cytotoxic efficacy was
observed using B-cell lines such as Daudi and KM3 as targets. We analyzed the mech-
anisms underlying the difference in effectiveness between these two IT. Our data point
to a role of significant role for the IIa subclass of FcγRII (CD32) molecules expressed
on B cells.
M A T E R I A L S  A N D  M E T H O D S
Malignant B-cells and cell lines
Malignant B-cells were obtained from bone marrow or blood of B-cell acute lymphocytic
leukemia patients after informed consent. B-cell acute lymphocytic leukemia cells were
enriched by Ficoll (1.077 g/ml) density gradient centrifugation. The isolated cell popu-
lations consisted of more than 90% of CD19-positive cells as determined by flow cyto-
metric analysis (FCM)(Coulter Epics Elite, Hialeah, FL). The cells were suspended in
culture medium and were either used directly or cryopreserved (with 10% DMSO) with-
out loss of functional potential.18
The human B-cell lines CRL, Daudi, DOHH2, Fravel, KM3, Nalm6, Raji, Ramos, Ros-1,
RPMI, and the T-cell line Jurkat were cultured in a culture medium consising of RPMI
1640 medium (Flow, Irvine, Scotland) supplemented with 10% heat-inactivated fetal
calf serum (FCS) (Gibco, Paisley, Scotland), glutamine (2mM), penicillin (100 units/ml)
and streptomycin (100 µg/ml) in a humidified incubator with 5% CO2 in air at 37°C. 3T6
fibroblasts expressing human FcγRIIa, FcγRIIb1, or FcγRIIb2 molecules were grown in
culture medium supplemented with geneticin (0.8 mg/ml; GIBCO BRL, Grand Island,
NY).
Monoclonal antibodies
Murine anti-CD19 MoAb CLB-B4-IgG1, and isotype switch-variant CLB-B4-IgG2a17 were
kindly provided by Dr I. Slaper (CLB, Amsterdam, The Netherlands). Hybridoma cells
secreting TS2.18 (CD2 and IgG1)19 and 35.1 (CD2 and IgG2a)20 were purchased from
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American Type Culture Collection (Rockville, MD). The CD2-MoAbs were used as iso-
type-matched controls. MoAbs were purified from ascites fluid by ammonium sulfate
precipitation and affinity chromatography with staphylococcal protein A-sepharose
(Pharmacia, Uppsala, Sweden).
MoAb 197 (IgG2a)21 was used to block FcγRI (CD64), and was obtained from Medarex
(Clinton, NJ). IgG and F(ab’)2 fragments of MoAb AT10 (IgG1)22, generously provided
by Dr M. Glennie (Tenovus Research Laboratory, SouthHampton, United Kingdom),
and IV .3 (IgG2b)23 from Medarex served to inhibit binding to FcγRII (CD32).
Preparation of F(ab’)2 fragments
F(ab’)2 fragments of CLB-B4-IgG1 and CLB-B4-IgG2a were prepared using a F(ab’)2
preparation kit (Pierce, Rockford, IL) according to the manufacturer’s protocol. Briefly,
CLB-B4-IgG1 and CLB-B4-IgG2a were incubated with immobilized pepsin at pH 4.2 (20
mM sodium acetate buffer) for 4 and 16 h, respectively. Undigested IgG molecules and
Fc-fragments were removed by affinity chromatography with protein A-Sepharose.
Remaining fragments smaller than Mr 30,000 were removed by means of a Centriprep
30 concentrator (Amicon, Beverly, MA). The purity of F(ab’)2 fragments was determined
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), which
revealed less then 1% contamination with either intact IgG or Fc fragments (data not
shown)
IT preparation
CLB-B4-IgG1, CLB-B4-IgG2a, TS2.18, and 35.1 were conjugated to ricin A (kindly provid-
ed by Dr. F. K. Jansen, Centre de Recherches Clin Midy, Montpellier, France) using N-
succinimydyl 3-(2-pyridyldithio)propionate (SPDP)(Pharmacia), as described.6 The con-
jugation ratios of ricin A to MoAb were estimated by measurement of absorbance at
280 nm and radioimmunoasay (RIA) and were determined to be 0.9, 1.1, 0.9, and 0.8
for CLB-B4-IgG1, CLB-B4-IgG2a, TS2.18, and 35.1, respectively. Preservation of antibody-
binding activity following conjugation was assessed by FCM. 
Cytotoxic potential of IT
Cells in culture medium were distributed into 96-well microtiter plates (Costar, Cam-
bridge, MA) at a concentration of 105 cell/well and incubated in triplicate at 37°C with
varying concentrations of IT (10-8-10-13 M) in the presence or absence of 6 mM NH4Cl.
After 16 h of incubation, 0.5 µCi [3H]leucine (Amersham, Buckinghamshire, United
Kingdom) was added, and cells were further incubated at 37°C for another 24 h and har-
vested. The radioactivity was quantitated, and protein synthesis was expressed as the
percentage [3H]leucine incorporation of cells cultured at 37°C without IT.6
In some of the cytotoxicity assays, FcγRs were blocked by pre-incubation of target cells
with MoAb 197 (purified IgG, 2 µg/ml), AT10 (ascites fluid, diluted 1:500) or IV .3 (puri-
fied IgG, 2 µg/ml) for 45 min at 4°C. Cells were washed, and cytotoxicity was assayed
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as above. Effectiveness and specificity of blocking with these MoAbs was verified by
inhibition of EA-rosetting (Refs. 24 and 25; data not shown).
Radioiodination
MoAbs CLB-B4-IgG1 and CLB-B-4-IgG2a (intact IgG and F(ab’)2-fragments), TS2.18 and
35.1 were labelled with Na125I (Amersham) using the Chloramine-T method26, and puri-
fied by chromatography on Sephadex G25 (PD-10; Pharmacia). Eluted fractions con-
taining 125I-IgG and 125I-F(ab’)2-fragments, respectively, were pooled, and molecules
smaller than Mr 30,000 were removed by Centriprep 30 concentration. Radioactivity
due to free 125I and fragments smaller than Mr 30,000 were always less than 0.3% of
total radioactivity. The concentration of labelled IgG and F(ab’)2 fragments was deter-
mined by Mancini assays27, and specific binding activity was assessed by performing
binding studies with limiting amounts of labelled IgG and F(ab’)2 fragments.28
Scatchard analysis
Suspension of 5 x 105 Daudi cells were incubated with various concentrations of 125I-
labelled IgG or F(ab’)2 fragments for 2 h at 4°C (final volume, 100 µl). Thereafter, cells
were washed, and radioactivity was counted to determine the number of cell-associat-
ed molecules. Binding to Daudi cells not mediated by antigen was assessed in the
presence of a 100-fold excess of unlabelled antibody and was less then 5% of total cell-
associated radiolabel for both CD19 MoAbs. Nonspecific binding to incubation tubes
was assessed by performing the experiment in the absence of targets. The affinity con-
stant (Ka) and the number of bound molecules/cell under saturating conditions were
calculated according to Scatchard.29
Internalization of 125I-IgG and 125I-F(ab’)2
The cellular uptake and processing of 125I-labelled IgG, or F(ab’)2 fragments, were
determined as described.28 Briefly, a suspension of 5 x 105 cells was incubated with 10-8
M 125I-IgG or 125I-F(ab’)2 in culture medium at 37°C (final volume, 100 µl). Following dif-
ferent times, cells were pelleted, and the amount of (internalized, and subsequently)
degraded and exocytosed MoAb was estimated by measurement of TCA (25%)-soluble
radioactivity of the supernatant. Cells were then washed twice and assessed for total
cell-associated (surface-bound, and intracellular) radioactivity. Surface radioactivity was
subsequently released by incubation with isotonic glycine-HCl buffer (pH2; 4°C for 30
min); then cells were washed, and intracellular radioactivity was determined. Nonanti-
gen-mediated binding and internalization of 125I-ligand was assessed in the presence of
a 100-fold excess of unlabelled antibody and was typically less then 5% of total cell-asso-
ciated radiolabel. Experiments perfomed at 4°C were used to correct for surface
radioactivity not removable by glycine-HCl buffer (usually <5%) and background
radioactivity of the TCA-soluble fraction. Extracellular degradation at 37°C could be
excluded since negligible radioactivity was found in the TCA-soluble fraction of T-cell
line Jurkat, which does not express CD19, and in purified surface membranes from dis-
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rupted Daudi or KM3 cells following incubation with 125I-IgG or 125I-F(ab’)2.
Internalization was defined as the total number of molecules transported across the
cell membrane, and calculated by summation of TCA-soluble radioactivity to intracel-
lular radioactivity.
Detection of FcγRIIa, FcγRIIb1 and FcγRIIb2 transcripts in the panel of B-cell lines
The presence of FcγRIIa, FcγRIIb1 and FcγRIIb2 transcripts in the panel of B-cell lines
was assessed by RT-PCR as described before.30 Briefly, total cellular RNA was extracted
from 5 x 106 cells using the RNazol B isolation method31, concentrated by ethanol pre-
cipitation, resuspended in diethylpyrocarbonated water, and stored at -70°C. Total cel-
lular RNA (5 µg) was reverse transcribed and the presence of FcγRIIa and FcγRIIb cDNA
were amplified by PCR, using FcγRIIa- and FcγRIIb-specific primer pairs. PCR products
were analyzed by electrophoresis on 1.8% (w/v) agarose gels stained with ethidium bro-
mide, followed by Southern blotting to Zeta-probe nylon membranes (Bio-rad). To
detect FcγRIIa and FcγRIIb PCR products, blots were hybridized overnight with FcγRIIa-
and FcγRIIb-specific 32P-labelled oligonucleotide probes, which were then washed, and
analyzed using a 400A Phosphor-imager System (Molecular Dynamics, Sunnyvale,
CA). cDNA of FcγRIIa, FcγRIIb1, and FcγRIIb2 transfectants served as controls.
Membrane expression of FcγRII
Surface expression levels of FcγRII (CD32) were determined via indirect immunofluo-
rescence measured by FCM. Cells in phosphate-buffered saline (PBS) supplemented
with 0.1% (w/v) bovine serum albumine and 0.1% sodium azide were incubated with
MoAb IV .3 (2 µg/ml) for 45 min at 4°C and then washed and incubated with fluorescein
isothiocyanate-labeled F(ab’)2 fragments of goat-anti-mouse IgG (Nutacon, American
Qualex Division, Amsterdam, the Netherlands) for another 45 min at 4°C. Subse-
quently, cells were washed and the mean fluorescence intensity (MFI) of 10,000 cells
was evaluated by FCM and expressed in arbitrary units.
EA-IgG rosetting
Rosette formation between B-cells and E sensitized with anti-glycophorin A switch-vari-
ant MoAb of IgG1-isotype32 was performed as described before.30 Briefly, a 0.5% sus-
pension of human E in PBS was incubated for 30 min at 37°C with the anti-glycophorin
A MoAb and then washed and suspended in RPMI 1640-5% FCS. Fifty µl were then
added to 50 µl B-cells (4 x 105), centrifugated (4 min at 40 x g), and incubated for 1 h
at 4°C. Cells with at least three bound E were microscopically scored as EA-rosettes.
Statistical analysis
Statistical evaluation of results was performed using the Spearman correlation.
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R E S U L T S
Cytotoxicity of CLB-B4-ricin A isotype-switch variants
The efficacy of the class switch variant ITs was determined by protein synthesis inhibi-
tion assayed with B-cell lines Daudi and KM3, which show high and intermediate mem-
brane-expression levels of CD19, respectively. Both ITs demonstrated poor cytotoxicity
(ID50s of ≥ 10-8 M) in the absence of NH4Cl. In the presence of NH4Cl (6 mM) which
enhances IT cytotoxicity33, the IgG1-IT became about 100 times more potent than
IgG2a-IT (ID50s of ~10
-10 M, and I0-8 M, respectively). Neither IT, even in the presence
of NH4Cl, showed any cytotoxicity against T-cell line Jurkat, which lacks expression of
CD19 (Figure 1).
In order to confirm that the cytotoxic effect of the CLB-B4-IT is mediated through the
CD19 antigen, the blocking effect of free CD19 MoAb was examined. The addition of a
100-fold excess of CLB-B4-IgG2a completely blocked the cytotoxic action of the CLB-B4-
IT against Daudi cells (ID50 > 10
-8 M in the presence of NH4Cl for both the IgG1-IT and
IgG2a-IT; data not shown). Moreover, non-binding control IT TS2.18-ricin A (CD2 and
IgG1) and 35.1-ricin A (CD2 and IgG2a) demonstrated no cytotoxicity against Daudi
cells (data not shown).
Scatchard analysis of the CLB-B4 IgGs and F(ab’)2 fragments
In order to determine whether the observed differences in cytotoxicity were attributable
to differences in affinity, we performed binding studies with both MoAb (and their
F(ab’)2-fragments) on Daudi cells. Both affinity (~8 x 10
9 M-1), and number of cell-bound
molecules (~67,000) were found comparable for both MoAbs (and their F(ab’)2 frag-
ments; Table 1).
Table 1 Scatchard analysis of CLB-B4-IgG1 and CLB-B4-IgG2a binding to Daudi cellsa
CLB-B4-IgG1 CLB-B4-IgG2a
Molecules Molecules
Bound/cell Bound/cell
Antibody form Ka (x 10
-9 M) (x 10-4) Ka (x 10
-9 M) (x 10-4)
IgG 7.1 ± 1.0 6.7 ± 1.2 8.3 ± 2.1 6.4 ± 0.8
F(ab’)2 8.6 ± 1.4 6.9 ± 0.9 7.5 ± 1.8 6.9 ± 1.2
aCells were incubated with various concentrations of 125I-MoAb for 2 h at 4°C and then washed and assessed
for membrane-bound radioactivity to calculate the affinity constant (Ka); the number of bound molecules/cell
were counted under saturating conditions according to Scatchard (29). The mean ± SD of three independent
experiments is shown.
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Binding and internalization kinetics of CLB-B4-IgG1 and CLB-B4-IgG2a
Because the efficacy of IT strongly depends on numbers of internalized molecules6, we
studied binding and internalization kinetics of the switch variants. Following incubation
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Figure 1 Cytotoxicity mediated by CLB-B4-ricin A-IgG1 and CLB-B4-ricin A-IgG2a
Daudi (A and B), KM3 (C and D), or Jurkat (E and F) cells were incubated with various concentrations of
CLB-B4-ricin A-IgG1 (A, C, and E) or CLB-B4-ricin A-IgG2a (B, D, and F) in the absence (,) or pres-
ence (,) of 6 mM NH4Cl at 37°C. After 16 h, cells were washed and cultured with [
3H]leucine for another
24 h. Protein synthesis is expressed as the percentage [3H]leucine incorporation relative to cells cultured in medi-
um alone (control cells). Control Daudi and KM3 cells incorporated ~15,000 cpm, and Jurkat cells incorporat-
ed ~20,000 cpm. Background incorporation approximated 100 cpm. Assays were performed in triplicate (n =
3), and SD was <10%.
at 4°C with 10-8 M, equal amounts of IgG1 and IgG2a MoAbs were bound to the cell
membranes (Daudi and KM3 cells, ~40,000 and ~15,000 molecules, respectively; data
not shown). Incubation at 37°C, however, resulted in consistent internalization differ-
ences (Figure 2). Daudi cells internalized 3.5 times and KM3 cells 2.5 times more IgG1
MoAb than IgG2a MoAb (Daudi, 35,000 IgG1 molecules and 10,000 IgG2a molecules;
KM3, 10,000 IgG1 molecules and 4,000 IgG2a molecules) during a 12-h incubation.
The highest number of intracellularly present molecules was reached after 4 and 8 h for
Daudi (~25,000 IgG1 molecules and 7,500 IgG2a-molecules), and KM3 cells (~4,000
IgG1 molecules and 3000 IgG2a molecules), respectively. Thereafter the number of
intracellularly present molecules declined as a result of exocytosis (of intracellularly
degraded MoAb).
Because the switch-variants differ only in subclass, we next tested the effect of remov-
ing the CD19-Fc fragment on internalization. Daudi cells were incubated with 10-8 M of
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Figure 2 Cellular uptake and processing of CLB-B4-IgG1 and CLB-B4-IgG2a
Daudi (A and B) and KM3 (C and D) were incubated with 125I-labeled CLB-B4-IgG1 (A and C) or CLB-B4-
IgG2a (B and D) for various times at 37°C. Intracellularly degraded and subsequently exocytosed molecules
(TCA-soluble radioactivity of supernatants; ) and intracellular molecules (cell associated radioactivity not-
removable by glycine buffer; ) were assessed as described in “Material and Methods”. Internalized molecules
were determined as the sum of intracellular and intracellularly degraded and subsequently exocytosed molecules
(). Assays were performed in triplicate (n = 3), and SD was <10%. One of three concordant experiments is
shown.
intact IgG or F(ab’)2 fragments of CLB-B4 for 1 h at 37°C; then the amount internalized
molecules was determined (Figure 3). Both the IgG1- and the IgG2a-F(ab’)2-fragments
were internalized to a comparable extent as intact IgG2a MoAb, indicating that the Fc
part of the IgG1 MoAb was responsible for the observed increase in internalization. The
binding of CD19 antigen appeared to be a prerequisite because no cellular uptake could
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Figure 3 Effect of isotype on internalization
Daudi cells were incubated for 1 h at 37°C/4°C with 125I-labeled IgG or F(ab’)2-fragments of CLB-B4-IgG1 and
CLB-B4-IgG2a, or with isotype-matched MoAb TS2.18 (CD2 and IgG1) or 35.1 (CD2 and IgG2a). Data are
presented as molecules/cell incubated at 37°C (corrected for cells treated at 4°C) as described in “Material and
Methods”. Experiments were performed in triplicate, and SD was <10%. One of three experiments yielding sim-
ilar data is shown.
Figure 4 Effect of FcγR-blocking MoAb on IT-cytotoxicity
Daudi cells were incubated with various concentrations of the IgG1-IT (A) or IgG2a-IT (B) with NH4Cl, in
the absence () or presence () of FcγRI-blocking MoAb 197, or FcγRII-blocking MoAb AT10 (), or IV.3
() at 37°C. After 16 h, cells were washed and cultured with [ 3H]leucine for another 24 h. Protein synthesis is
expressed as the percentage [ 3H]leucine incorporation relative to cells cultured in medium lacking IT. Untreat-
ed Daudi cells incorporated ~15,000 cpm. Background incorporation was 100 cpm. Assays were performed in
triplicate, and SD was <10%. The experiment was repeated three times, yielding almost identical results.
be observed of isotype-matched irrelevant MoAb TS2.18 (CD2 and IgG1) or of 35.1 (CD2
and IgG2a).
Involvement of FcγRII in CLB-B4-ricin A cytotoxicity
Because the involvement of the IgG1-Fc fragment suggested an interaction with recep-
tors for the Fc domain of IgG, we performed cytotoxicity assays with Daudi cells in the
presence of FcγR-blocking MoAb. Addition of FcγRI-blocking MoAb 197 did not affect
cytotoxicity of the IgG1-IT or IgG2a-IT. Coincubation of cells with FcγRII-blocking MoAb
AT10 or IV .3 reduced the effectiveness of IgG1-IT without affecting IgG2a-IT cytotoxicity
(Figure 4). Addition of AT10 F(ab’)2 fragments (2 µg/ml) resulted in a similar blocking
to AT10 IgG (data not shown; n = 3), excluding the reduced cytotoxicity to be caused by
the Fc part of this FcγRII-blocking MoAb. These results indicated that FcγRII is involved
in the observed differences between the class switch ITs.
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Table 2 Relation between CLB-B4 internalization, FcγRIIa expression levels, and EA-rosette 
formation by B-cell lines and patient cells
Internalizationa (Molecules/cell)
Cells IgG1 IgG2a IgG1/IgG2ad FcγRIIa EA-rossettingc
expressionb (MFI) (%)
CRL 2,879 2,624 1.1 14.9 0
Daudi 9,540 3,085 3.1 18.8 96
DOHH2 11,245 11,063 1.0 1.1 0
Fravel 2,328 2,154 1.1 18.7 0
KM3 2,008 800 2.5 1.9 0
Nalm6 10,381 2,002 3.5 10.4 95
Raji 8,550 5,700 1.5 11.8 10
Ramos 11,251 11,941 1.0 0.4 0
REH 1,009 900 1.1 1.6 0
Ros1 4,532 4,498 1.0 22.0 0
RPMI1788 1,259 1,290 1.0 5.1 0
Patient 1 1,019 917 1.1 6.3 0
Patient 2 3,192 3,002 1.1 2.1 2
Patient 3 2,201 1,928 1.1 1.0 0
Patient 4 2,675 1,574 1.7 17.8 20
Patient 5 3,172 1,233 2.6 3.5 60
Patient 6 4,841 4,586 1.1 15.0 0
Patient 7 1,775 1,714 1.0 1.0 0
Patient 8 515 498 1.0 8.5 0
aCells were incubated for 1 h with 10-8 M 125I-labeled MoAb at 37°C; then the number of internalized mole-
cules/cell was determined as described in “Materials and Methods”. The mean of three independent experiments
is shown; SD < 10%. bFcγRII-expression levels were determined by indirect immunofluorescence. Cells were
incubated with MoAb IV.3 (predominantly interacting with FcγRIIa) for 45 min at 4°C, washed and cultured
for another 45 min with fluorescein isothiocyanate-labeled F(ab’)2 fraction of anti-mouse immunoglobulin
antiserum. Data shown represent the MFI of 10,000 cells. cEA-rosette formation was used to estimate func-
tional binding capacity of FcγRIIa. Cells were incubated with EA sensitized with IgG1 for 1 h at 4°C and
washed and assessed for EA-rosettes. Data represent the percentage of cells with three or more bound EA-IgG.
The mean of three experiments is shown; SD < 10%. dRatio of internalized IgG1 and IgG2a molecules upon
incubation for 1h at 37°C.
Relation between internalization, FcγRII-isoform expression and EA-IgG rosette formation
To determine the FcγRII-isoform involved in the internalization of the IgG1 MoAb, we
studied the relation between enhancement of IgG1 uptake and expression of the differ-
ent isoforms. The enhancement of IgG1 uptake in 11 B-cell lines and malignant B-cells
derived from 8 patients (determined after 1 h at 37°C) was expressed as the ratio of
internalized IgG1 and IgG2a molecules (Table 2). As in some cases, the number of
internalized molecules was rather low; nonspecific endocytosis due to a fluid phase
uptake was examined with MoAbs TS2.18 (CD2 and IgG1) and 35.1 (CD2 and IgG2a).
No cellular uptake of these control antibodies could be observed (data not shown).
Besides Daudi, KM3, Nalm6 and Raji cells, malignant B-cells from two of the patients
(patients nos. 4 and 5) showed an enhanced internalization of CD19-IgG1 molecules.
The expression of various FcγRII transcripts in the panel of B-cell lines was analyzed by
performing an FcγRIIa- and FcγRIIb-specific PCR. Total cellular RNA was isolated and
reverse transcribed to cDNA; specific primer pairs were used to amplify FcγRIIa, FcγRI-
Ib1 and FcγRIIb2 transcripts (Figure 5). FcγRIIa was found to be present in all B-cell
lines tested. The FcγRIIb1 and FcγRIIb2 expression levels varied between the different
B-cell lines. Notably, FcγRIIa represented the sole FcγRII transcript present in Nalm6,
KM3, DOHH2 and REH cells, suggesting that: (a) the FcγRIIa isoform is involved in
enhancement of IgG1 uptake (Nalm6 and KM3 showing IgG1:IgG2a ratios of 3.5 and
2.5, respectively); and (b) FcγRIIa RNA expression as such is not indicative for
enhanced IgG1 uptake (DOHH2 and REH, IgG1:IgG2a ratios of ~1). 
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Figure 5 Expression of FcγRIIa, FcγRIIb1 and FcγRIIb2 transcripts in a panel
of B-cell lines assessed by reverse transcription-PCR
RNA was isolated and reverse transcribed, and FcγRIIa and FcγRIIb transcripts were selectively amplified
(described in “Material and Methods”). Products were run on a 1.8% agarose gel, blotted, and hybridized with
isoform-specific oligonucleotide probes. FcγRIIa, FcγRIIb1, and FcγRIIb2 transfectants served as controls
(Lanes 1-3). Blots were probed with either 32P-labelled FcγRIIa (A) or FcγRIIb (B) specific oligonucleotides.
Because the presence of RNA transcripts does not necessarily imply membrane expres-
sion of the receptor, we determined the membrane-expression levels of FcgRIIa using
MoAb IV .3, which predominantly interacts with FcγRIIa (34; Table 2). Cell lines DOHH2,
KM3, Ramos, REH, and B cells derived from patients 1,2,3,5, and 7 showed no or poor
expression. All other cells showed intermediate to high expression. The relation
between membrane expression levels and enhanced uptake of CD19-IgG1 is plotted in
Figure 6. No correlation could be found (r = 0.32; P < 0.185; Fig. 6A).
The relation between expression levels and enhanced CD19-IgG1 uptake may be com-
plicated by membrane-expression of “nonfunctional” FcγRIIa molecules. Therefore, we
assessed functional IgG binding capacity of the FcγRIIa molecules by determining EA-
rosette formation using IgG1-sensitized E (EA-IgG1; Table 2). A highly significant corre-
lation between enhanced IgG1 uptake and EA-rosette formation was found (r = 0.76; P
< 0.001; Fig. 6B). Remarkably, KM3 cells showed an enhanced uptake of IgG1 (ratio 2.5)
without forming rosettes. This may have been due to the exceptionally low FcγRII-
expression level on KM3 (MFI, 2.2). These results suggest that FcγRIIa molecules capa-
ble of IgG1 are involved in the enhancement of internalization observed upon inter-
action of cells with CD19-IgG1-IT.
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Figure 6 Relation between enhancement of IgG1 uptake, FcγRII expression levels,
and EA-rosette formation
To assay FcγRII expression levels (A), cells (as indicated in Table 2) were incubated with MoAb IV.3 for 45
min at 4°C, washed and cultured for another 45 min with fluorescein isothiocyanate-labeled anti-mouse serum.
Data represent the mean fluorescence intensities (MFI). EA-rosette formation (B) was determined after incu-
bation of cells with EA-IgG1 for 1 h at 37°C. Data represent the percentage of cells (indicated in Table 2) with
three or more bound EA-IgG indicator cells. Assays were performed in duplicate. The experiment was repeated
three times, yielding almost identical results.
D I S C U S S I O N
Several reports addressed the use of CD19 MoAb-toxin conjugates as potent and spe-
cific reagents for neoplastic B-cell elimination. These include MoAb HD37 conjugated
to ricin A10, to saporin35, as well as MoAb B4 conjugated to blocked ricin36 and MoAb
B43 conjugated to pokeweed antiviral protein (PAP)37, all of the mouse IgG1 isotype. In
the present study, we evaluated the cytotoxic potency of CD19 class switch variants
CLB-B4-IgG1 and CLB-B4-IgG2a upon conjugation to ricin A. The IgG1-IT required the
presence of the cytotoxicity enhancer NH4Cl to show similar cytotoxicity as reported for
HD37-ricin A against Daudi cells (ID50s of ~10-10 M; Fig. 1)38. This difference in poten-
cy is probably due to a variation in epitope specificifty and/or binding affinity. More sur-
prisingly, in view of both MoAbs sharing identical epitopes and binding characteristics,
the CLB-B4-IgG2a-IT appeared to be ~100-fold less cytotoxic than the CLB-B4-IgG1-IT
when assayed on Daudi and KM3 cells (ID50 of ~10-8 M).
Internalization studies with 125I-labelled MoAb and F(ab’)2 fragments revealed that the
higher efficacy of the IgG1-IT is attributable to the IgG1 Fc fragment, enhancing the cel-
lular uptake following membrane binding (Figs. 2 and 3). The enhancement of IgG1
uptake was observed in 4 of 11 B-cell lines and in B-cells of 2 of 8 patients examined,
suggesting the involvement of a heterogeneously expressed receptor on B-cells. A like-
ly candidate to be involved in the enhanced uptake of IgG1 may be FcγRII (CD32), which
is both present on B-cells and capable of interacting with IgG1.30,39 By interaction with
the Fc part of membrane-bound CD19-IgG1, FcγRII may be capable of supporting inter-
nalization of antigen-MoAb complexes, analogous to the mechanisms described by
Kurlander.40 This hypothesis was supported by the observation that incubation with
FcγRII-blocking MoAb strongly reduced the cytotoxicity of the IgG1-IT (and not IgG2a-
IT; Fig. 4). The increase in potency resulting in the interaction of the IgG1-Fc part with
FcγRII (~100-fold; Fig. 1) is tremendous, considering the relatively modest increase in
internalization (~2.5-3.5-fold; Fig. 2). Further studies are needed to address this dispro-
portional increase in cytotoxicity, but it is tempting to speculate that the interaction with
FcγRII alters the intracellular routing and/or handling of the antigen-IT complex in a
way more favorable for ricin A to exert its cytotoxic action.
Expression of the FcγRII-isoform involved in the internalization of IgG1-IT in B cells was
assayed by isoform-specific PCR experiments. Notably, FcγRIIa was the only isoform
expressed by cell lines KM3 and Nalm6, showing enhanced IgG1-uptake. The strong cor-
relation of enhancement of IgG1-uptake with EA-IgG1 rosetting, rather than with expres-
sion levels determined using MoAb IV.3 (predominantly interacting with FcγRIIa)34,
suggested that part of the expressed FcγRIIa molecules are incapable of IgG1-binding
(and, thereby, incompetent to promote cellular uptake). This is in accordance with
observations of Koenderman et al, who demonstrated that not all FcγRIIa molecules
expressed by eosinophils are able to bind EA-IgG.25 Remarkably, the cell line KM3 did
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not form rosettes with EA-IgG1 but does show enhanced IgG1-uptake. In our view, this
may be attributable to the exceptionally low FcγRIIa expression levels on KM3, which
might be sufficient for enhancing IgG1 uptake in a catalytic manner (Table 2), but too
low to support stable EA-IgG1 binding in EA-rosette experiments (Fig. 6B).
Several factors have been described to affect internalization and intracellular handling
and, thereby, the cytotoxicity of ricin A ITs. Among these are the nature of the target cell
and antigen7,8, antigen density6,9, binding affinity of the MoAb9,10, and the epitope to
which the IT is directed11-13. Our observation of class switch variant ITs displaying dif-
ferent levels of cytotoxicities suggests also that the MoAb isotype is important for the
efficacy of anti-B-cell ITs. Additional studies, however, are needed to address whether or
not this phenomenon is restricted to CD19-ITs.
From our study, we conclude that the Fc part of ITs may be a parameter of importance
for the efficacy of anti-B-cell ITs. Selection of the most effective isotype may improve the
killing potency of an IT and, therefore, the success of these reagents in human therapy.
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A B S T R A C T
Immuntoxins (ITs) represent an attractive drug targeting concept with therapeutic
potential for the treatment of a variety of malignancies and immunological disorders.
Prior to their clinical evaluation, the reactivity of IT towards target and non-target cells
has to be extensively evaluated. In this report, a method is described for the preclinical
evaluation of IT-induced target cell killing. This method is based on the flow cytometric
(FCM) identification of viable cells escaping IT treatment. The simultaneous use of two
viability markers, propidium iodine (PI) and calceine (Calc), minimizes the occurrence
of falsely postive/negative cells due to autofluorescence, or extensive DNA-disintegra-
tion preventing PI-incorporation. The admixture of a fixed concentration of inert beads
prior to analysis enables the precise quantification of surviving cells. Using this
method, it appeared that IT-induced cell kill is not immediately accompanied by the
physical disruption of the cell membrane. An IT-free lag period of four days proves
essential for full exposure of efficacy. With a 1:9 mixture of leukemic Ramos cells and
normal bone marrow cells, it was demonstrated that the method can also be used for
the evaluation of IT-based killing of non-clonogenic target cells in a heterogeneous cell
sample. With its capacity of monitoring target cell kill in freshly derived heterogeneous
patient samples, the flow cytometric assay forms a valuable addition to the conven-
tional clonogenic assays en protein synthesis inhibition assays.
I N T R O D U C T I O N
Immunotoxins (ITs) are hybrid molecules consisting of a cell-specific compound, most-
ly monoclonal antibodies (MoAbs), conjugated to a potent bacterial or plant derived
toxin, e.g. modified diphteria toxin or the A chain of plant toxin ricin. Several studies
demonstrated the potential of ITs to selectively kill target cells in a highly efficient man-
ner.1-3 Moreover, the past two decades, ITs have been tested both in animals and
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human studies for the treatment of life-threatening diseases, including various cancers
and immunological disorders.4-11
Prior to its clinical use, ITs have to be extensively screened for reactivity against target
and non-target cells. Their potency is regularly expressed as the dose resulting in 50%
inhibition of protein synthesis (ID50). In general, ITs having an ID50 of 10
-10 M or less are
considered suitable for clinical use, supposed they do not cross-react with life-sustain-
ing tissues.12 It should be realized, though, that the presence of a small fraction of IT-
resistant target cells might give rise to recurrence of the disease without having much
impact on the ID50. Therefore, in designing the optimal therapy, it is also important to
determine the number of cells escaping various treatment regimens. So far, clonogenic
assays have proven to be an useful tool for an accurate quantification of cells resistant
to IT-treatment, especially when using cell lines as target.13-15 Unfortunately, the in vitro
clonogenicity of patient derived target-cells is often too low to perform a reliable clono-
genic assay. Because of this limitation, a quantitative flowcytometric (FCM) method
was developed capable of determining IT-induced cell kill in freshly derived patient-
samples as well. This study determines the prerequisites for a reliable quantification of
surviving target-cells in a heterogeneous population such as human bone marrow.
M A T E R I A L S  A N D  M E T H O D S
Malignant B-cell lines and bone marrow cells
Human B-cell lines Daudi, KM3 and Ramos were obtained from the American Type Cul-
ture Collection (ATTC, Rockville, MD). Normal bone marrow cells were obtained from
patients undergoing cardiac surgery, after informed consent. Erythrocytes and mature
granulocytes were removed by Ficoll (1.077 g/ml) density gradient centrifugation.
Mononuclear cells were suspended in culture medium and were either used directly, or
cryopreserved (10% dimethyl sulfoxide) without loss of functional potential.16
Cells were cultured in medium consisting of RPMI 1640 (Flow, Irvine, Scotland) sup-
plemented with 10% heat-inactivated FCS (Gibco, Paisley, Scotland), glutamine (2mM),
penicillin (100 units/ml) and streptomycin (100 µg/ml) in a humidified incubator with
5% CO2 in air at 37°C.
Immunotoxins (IT)
MoAb CLB-B4 (anti-CD19, IgG1) and CLB-B-ly/1 (anti-CD22, IgG1) were obtained from
the Central Laboratory of the Red Cross Blood Bank (Amsterdam, the Netherlands).
Recombinant ricin A was generously provided by Zeneca Pharmaceuticals (Maccles-
field, UK). ITs were constructed by biochemical linkage of MoAb and ricin A using N-
succinimydyl-3-(2-pyridyldithio)propionate (SPDP) (Pierce, Rockford, IL), as previously
described.13 Following conjugation, preservation of MoAb-binding activity was assessed
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by FCM (Coulter Epics Elite, Hialeah, FL). Retention of ricin A activity was determined
in a rabbit reticulocyte lysate assay, as described by Press et al.17
IT-treatment
Cells in culture medium at a concentration of 106 cells/ml were incubated with IT in
triplicate at 37°C. IT concentrations were expressed in molar, ranging from 10-13-10-8 M.
In some experiments, cytotoxicity enhancers NH4Cl (6 mM) or nigericin (10 nM) were
added to the culture medium to enhance the cytotoxity of the ricin A-IT. After 16 h of IT-
treatment, cells were washed and assayed for the number of surviving cells by either
flow cytometry or a clonogenic assays.
Flow cytometric evaluation of surviving cells
Following IT-treatment, cells were cultured for varying days in IT-free culture medium
at 37°C. After this lag period, cells were incubated with 2 µg/ml propidium iodine (PI)
(Molecular Probes, Junction City, OR) for 30 minutes at room temperature to stain
death cells. In later experiments, also 2 µg/ml calcein AM (Calc) (Molecular Probes)
was added as an additional viability marker. Samples were then analyzed in triplicate on
a flow cytometer (Coulter Epics Elite, Hialeah, FL) using a minimum of 10,000 cells.
Viable cells were identified as being PI-negative and, if applicable, Calc-positive. Over-
lap of emission spectra of PI and Calc was adjusted by electronic compensation using
single-labeled samples. Prior to FCM analysis, a fixed amount of inert beads (DNA-
check or Flow-Count fluorospheres, Coulter) was added to each sample (e.g. 5x104
beads/ml) to enable the quantification of surviving cells. To prevent sedimentation of
the beads, the FCM analysis was performed under continuous gently shaking of the
sample.
Clonogenic assays
The clonogenic capacity of IT-treated cells was determined as described earlier.13,14
Briefly, IT-treated cells were resuspended in cloning medium consisting of RPMI 1640
supplemented with 1 mM α-ketoglutarate (Sigma, St. Louis, MO), 1 mM sodium
oxaloacetate (Sigma), 5% fetal calf serum, and 10% heat inactivated horse serum
(Hyclone, Logan, UT). Varying numbers of cells (102-106) were seeded in double layer
agarose (3%) and cultured for 15 days at 37°C. Absolute numbers of surviving cells were
calculated from the number of colonies, the number of plated cells and the cloning fre-
quency of untreated cells (12% for Daudi and 28% for KM3).
Detection of IT-efficacy in a heterogeneous sample
Ramos cells were stained with the green-fluorescent membrane intercalating dye D-275
(Molecular probes, Eugene, OR), according to the manufacturer’s protocol. Labeled
Ramos cells were mixed in a 1:9 ratio with normal bone marrow and subsequently treat-
ed with IT and analyzed by FCM as described above. Overlap of emission spectra of PI
and D-275 could be adjusted by electronic compensation using single-labeled samples. 
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Kinetics of IT-Induced Cell Kill as Determined by FCM
PI incorporates in the DNA of dead cells after passing through their compromised
membranes. For a reliable assessment of IT-induced cell kill it is essential to determine
the ‘lag-period’ between the irreversible inhibition of protein synthesis and the result-
ing physical disruption of the cell membranes.
Figure 1 illustrates the fate of Daudi cells treated with CLB-B4-ricine A (anti-CD19) in
the presence of NH4Cl as enhancer of cytotoxicity. Prolongation of the post-treatment
(IT-free) incubation period up to four days resulted in a progressive increase in the
number of dead or dying cells, characterized by a strongly reduced forward scatter. This
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Figure 1
PI Uptake of Daudi treated cells
with anti-CD19 IT (CLB-B4-ricin A)
Cells were treated with anti-CD19 IT for 24 h and washed.
After an IT-free incubation of various days, PI was added
and cells were evaluated by FCM for viability. Cells treated
accordingly without IT served as control. The percentage PI-
positive cells is indicated. One of three concordant experi-
ments in shown.
change in light-scatter signals was accompanied by a disturbance of the physical
integrity of the cell membranes, as reflected by the resulting PI+ phenotype. The maxi-
mal number of dead cells was observed four days after treatment with CLB-B4-ricin A
(95% PI+), and did not increase upon further prolongation of the post-treatment peri-
od. The control sample treated with unconjugated MoAb CLB-B4 and ricin A, contained
about 10% dead cells following the same incubation period. Similar patterns were
observed with different combinations of ITs and cell lines (data not shown, n = 5).
Quantification of surviving cells
Treatment with IT may result in the elimination of several logs of antigen-bearing target
cells, especially in the presence of cytotoxicity enhancers as NH4Cl, monensin or
nigericin.13,14,18 For an accurate FCM-based quantification of surviving cells, an internal
standard in the form of inert beads was added to the IT-treated samples prior to FCM-
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Figure 2
Quantification
of IT-induced cell kill
Ramos cells were incubated
with a suboptimal concen-
tration anti-CD22 IT (CLB-
B-Ly/1-ricin A, 5x10-11 M),
in the presence (C) or
absence (B) of nigericin (10
nM). Cells incubated with
culture medium served as
control (A). After 24 h, cells
were washed and incubated
without IT for an addition-
al 4 days. Subsequently,
cells were stained with PI
and Calc and analyzed by
FCM for viability (PI-
/Calc+) in the presence of a
fixed concentration of inert
beads (5x104/ml). Analysis
was stopped when 1,000
beads had passed the flow
cell. One of three concor-
dant experiments is shown.
analysis. The amount of beads that passes the flow cell during analysis, enables the pre-
cise calculation of the number of viable cells. Moreover, to decrease the number of false
positive/negative cells (e.g. due to auto-fluorescence or the extensive disintegration of
DNA preventing PI-incorporation) Calc was added as a second viability marker. Only
cells being PI-/Calc+ were considered viable cells.
Figure 2 shows a typical FCM-analysis of Ramos cells 4 days after treatment with a sub-
optimal concentration CLB-B-ly/1-ricin A (5x10-11 M) in the presence or absence of cyto-
toxicity enhancer nigericin. The inert beads (105/ml) could easily be distinguished from
viable as well as non-viable cells based on their relatively small forward scatter and large
right angle scatter. As an alternative, beads could be identified by their strong broad-
band fluorescence (data not shown). FCM-analyses were stopped when 1,000 beads
had passed the flow cell. Comparison of the viable fractions of the control and IT-treat-
ed samples revealed a 90-fold increase of efficacy upon addition of nigericin (~0.24 and
2.2 logs of kill with and without nigericin, respectively). Nigericin alone did only mar-
ginally effect the viability (<7% reduction of viable cells).
Comparison of FCM-evaluation and clonogenic assays
Conventional clonogenic assays have proven to be a valuable tool for estimation of cell
kill. Table 1 presents the reduction in viable cells after incubation different combinations
of target-cells and ITs, as determined with FCM-evaluation and clonogenic assays. Both
assays revealed comparable results, demonstrating the superiority of the anti-CD22 IT
as compared to its anti-CD19 counterpart. Unconjugated MoAbs and ricin A did not
influence the viability of any of the target-cells in neither assay (data not shown, n = 3).
Monitoring of cell kill in a heterogeneous sample
Fluorescent labeled Ramos cells were mixed in a 1 to 9 ratio with BM in order to mimic
residual leukemic blasts. This mixture was treated with CLB-B-ly/1-ricin A in the pres-
ence of NH4Cl, and assayed for dead and viable cells by FCM-evaluation Figure 3. Their
green fluorescence made Ramos cells easily distinguishable from BM cells, including
CD19-positive lymphocytes derived from blood admixture. Comparison of the viable
fractions of the IT-treated sample and control, demonstrated an approximately 3 logs
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Table 1 Comparison of FCM-evaluation and clonogenic assays.
Depletion of target cells (logs)
CD19-ricin A CD22-ricin A
clonogenic flow clonogenic flow
assay cytometry assay cytometry
Daudi 1.3 1.5 3.0 3.3
KM3 1.3 1.1 2.0 2.7
SDs were less than 10% (n = 3)
of depletion of fluorescent Ramos cells. Omission of cytotoxicity enhancer NH4Cl
reduced the depletion-efficacy to approximately 1 logs (n = 3, data not shown).
D I S C U S S I O N
Viability staining in combination with flow cytometric analysis has been used for diverse
applications like monitoring of lymphocyte mediated target-cell lysis and toxicity testing
of chemicals.19-24 The use of this method for evaluation of IT-induced cell kill appeared
to be somewhat more complicated. Reason for this is that the toxin-based inhibition of
protein synthesis is not accompanied immediately by physical disruption of the cell
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Figure 3 Monitoring of IT-induced cell kill in bone marrow
Green fluorescent (D-275) labeled Ramos cells were mixed in a 1:9 ratio with BM cells. The mixture was treat-
ed with or without 10-8 M anti-CD22 IT (CLB-B-Ly/1-ricin A) in the presence of NH4Cl (6 mM) at 37°C. Fol-
lowing 24 h, cells were washed and incubated in culture medium for four additional days. Subsequently, cells
were stained with PI and evaluated for viability by FCM. Before analysis, a fixed concentration of inert beads
(105/ml) was added to the samples. Analysis was stopped after 1,000 beads had passed the flow cell. One of three
concordant experiments is shown.
membrane. An IT-free incubation period of four days appeared to be necessary for full
exposure of IT-toxicity. Moreover, the high potency of ITs (killing up to several logs of
target cells) requires a sensitive and precise method for the quantification of residual
cells. Simply counting the number of flow cytometric events seems not very adequate,
as this parameter is influenced by dead cell particles and fluctuating sampling rates.
Therefore, inspired by others, we added a fixed amount of inert beads to the IT-treated
sample prior to FCM-analysis.25 This enabled an accurate quantification of viable cells,
which closely correlated with the outcome of conventional clonogenic assays. This is
somewhat in contrast with the results obtained by Laurant et al.25 Already in 1986, they
described the use of viability staining to evaluate the sensitivity of fresh leukemic cells
to ITs. Their assay appeared to be indicative rather than quantitative, though, only
roughly qualifying leukemic cells as modestly, intermediate or highly suspectible to IT-
treatment. This may be explained by the moment of analysis, directly following IT-treat-
ment, which is before maximal exposure of efficacy. 
When evaluating target cell kill in a heterogeneous population as blood or BM, the
death/alive analysis needs to be combined with the identification of target-cells (Fig. 3).
The use of fluorescent cell specific MoAbs is most convenient, enabling both the via-
bility staining and target-cell identification in one analysis. However, this requires the
presence of one or more ‘identification-antigens’ besides the ‘target-antigen’ already
used for therapy. The latter is inappropriate as it might be modulated or covered by the
therapeutic mAb. Moreover, residual malignant cells may be enriched for cells with low
expression of target-antigen. As an alternative, target cells may be identified by the PCR-
amplification of a cell specific DNA-sequence.26-28 In that case, viable cells should first
be presorted to prevent DNA from IT-eliminated cells contributing to the PCR signal.
Based on the specifications of current flow cytometers, a triple-sorted fraction should
contain less than one in a million erroneously sorted non-viable cells, equalizing the
detection limit of sensitive PCR-assay.
Protein synthesis inhibition is widely used to express the potency of an IT. Estimation
of the ID50 is relatively easy, fast and independent of in vitro clonogenic capacity. Its
major disadvantage, though, is that the ID50 is hardly influenced by the presence of a
minor population of therapy-resistant (potentially tumorogenic) target-cells. The poten-
tial relevance of this is demonstrated by observations of Flavel et al., who demonstrat-
ed that the combined use of an anti-CD19 and anti-CD38 IT did not reduce the ID50
towards Burkitt’s lymphoma cell line Ramos, as compared to either IT alone.29 The sur-
vival of Ramos-xenografted mice, in contrast, dramatically increased upon simultane-
ous administration of both ITs. Apparently, the IT-combination eliminated target-cells
with low antigen density which otherwise would escape single IT-treatment. The flow
cytometric method is more likely to identify such relatively small cell population, which
appears to be of no significance in terms of overall protein synthesis.
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From our study, we conclude that the FCM-evaluation of IT-induced cell kill forms a use-
ful addition to the conventional clonogenic assays and protein synthesis inhibition
assay. Several studies confirmed that this assay can be used for the monitoring of IT-
induced target-cell elimination in freshly derived heterogeneous patient samples.10,18 As
such, this assay may prove a valuable tool to help improve this form of therapy.
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A B S T R A C T
This report describes the preparation of an immunotoxin-combination, consisting of an
anti-CD3 and anti-CD7 monoclonal antibody (MoAb) both conjugated to the A-chain of
plant toxin ricin, for the experimental treatment of graft-versus-host disease. MoAbs
and toxin were conjugated by conventional biochemical and chromatographic tech-
niques. Raw materials, intermediate and final products were evaluated conform the rel-
evant ‘points to consider’ of the FDA. Yields, purity and sterility of the two final prod-
ucts were all satisfactory. Preservation of MoAb-affinity and toxin-activity were
confirmed in biological assays. The LD50, 25-45 mg immunotoxin-combination/kg
mouse, equaled that of similar immunotoxins already in clinical use. Because in vitro
cross-reactivity screening revealed an unexpected binding of the CD3-MoAb to the
esophagus epithelium, human doses immunotoxin-combination were administered to
two cynomolgus monkeys. Clinically relevant serum concentrations were obtained with-
out irreversible toxicities occurring. The T1/2 varied between ~6-9 hours, the Cmax
ranged from 1.8-3.9 µg/ml. The main side effect was a transient rise of serum creatine
kinase. Importantly, neither damage nor binding of the CD3-immunotoxin to the mon-
key esophagus epithelium could be demonstrated. It was concluded that sufficient
material of proper quality and with an acceptable toxicity profile was produced, war-
ranting the evaluation in a clinical pilot-study.
I N T R O D U C T I O N
Monoclonal antibodies (MoAbs) conjugated to bacterial or plant-derived toxins (e.g.
pseudomonas exotoxin or the deglycosylated A-chain of plant toxin ricin), so called
immunotoxins, form attractive agents for the selective elimination of disease causing
cells (reviewed in 1-3). Within the last two decades, various immunotoxins have been
tested in clinical studies for the treatment of life-threatening disorders, including solid
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and diffuse tumors and immunological disorders.4-9 Despite differences in specificity
and efficacy, their mechanism of action is basically comparable. The MoAb moiety
binds specifically to an antigen expressed on the surface of target cells, wherafter the
entire antigen-immunotoxin complex is internalized. Once inside the cell, the toxin-sub-
unit is translocated to the cytosol where it inhibits protein synthesis irreversibly by
means of a catalytic reaction culminating in the cell’s death. The potency of a given
immunotoxin depends in essence on the number of immunotoxin-molecules internal-
ized, and on the intracellular handling following internalization.10-14 Recently, we
demonstrated in laboratory experiments that a combination of two deglycosylated ricin
A-chain (dgA) based immunotoxins, directed against lymphocyte differentiation anti-
gens CD3 and CD7, acts synergistically in killing activated T cells.9 This makes this par-
ticular immunotoxin-combination potentially valuable to control certain immunological
disorders, like transplantation related rejection and several auto-immune diseases. To
explore its therapeutic potential, a clinical pilot study is set up for the treatment of
patients with severe graft-versus-host disease, a serious complication of hematological
stem cell transplantation initiated by donor-derived T cells.9 This document describes
the semi-large scale laboratory production and quality control of the clinical grade
immunotoxin-combination used for the pilot-study.
M A T E R I A L S  A N D  M E T H O D S
Processes, facilities and documentation
The manufacturing processes and the production facilities were designed to minimize
the risk of contamination of raw materials, intermediates and the two final products.
Prior to the production, the formulae, manufacturing method and specifications of all
(intermediate) products were established and documented. The documentation includ-
ed instructions for operation of equipment, the manufacturing, packaging and storage.
MoAb and dgA
Hybridoma cells producing murine MoAb SPV-T3a (αCD3, IgG2bκ)15 and WT1 (αCD7,
IgG2aλ)16 were kindly provided by Drs. H. Spits (NKI, Amsterdam, The Netherlands)
and W. Tax (UMC St Radboud, Nijmegen, The Netherlands), respectively. From both
hybridomas, a master cell bank (MCB) and manufactering working cell bank (MWCB)
were prepared. The production of MoAb WT1 was performed at the institutional Cen-
tral Hematology Laboratory. The production of MoAb SPV-T3a, as well as the protein A
purification of both MoAb, was performed by IQ Corporation (Groningen, The Nether-
lands).
For antibody production, hybridoma WT1 was grown in 162 cm2 culture flasks in
RPMI1640 medium (Flow, Irvine, Scotland) supplemented with 8% fetal calf serum
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(FCS) (Integro, Zaandam, The Netherlands), glutamine (2mM), penicillin (100 U/ml)
and streptomycin (100 µg/ml) in a humidified incubator with 5% CO2 in air at 37°C.
Hybridoma SPV-T3a was cultured under the same conditions in RPMI1640 supple-
mented with 8% FCS, D(+)-glucose (2.5 g/l), sodium hydrogencarbonate (2.0 g/l), L-
glutamine (0.4 g/l), gentamycine (0.04 g/l), and HybridoCult supplement (IQ Corpo-
ration). Cells were first expanded in log-phase and then cultured for another two weeks
without medium changes, resulting in a final viability of about 10%. Subsequently, cell
cultures were centrifuged, and the supernatants were filter sterilized (crude harvest)
and stored at -20°C (SPV-T3a) or 4°C (WT1). For MoAb purification, the crude harvest
was 1:1 diluted with ‘bindings-buffer’, containing 1.5 M glycine and 3.0 M NaCl (pH 8.9),
and applied to a protein A column. Affinity bound MoAbs were eluted with citrate buffer
(0.1 M citrate, pH 2.8-3.0) and directly neutralized with 0.1 volume 1M Tris-HCl. Sub-
sequently, purified MoAbs were dialyzed against 0.01 M phosphate buffered saline (pH
7.4) (PBS), filter sterilized and stored at a concentration of approximately 4 mg/ml at
4°C.
Clinical grade deglycosylated ricin A (dgA) was purchased from Inland Laboratories
(Austin, TX). The dgA contained the two naturally occurring A-chain forms, of 30 and
32 kDa, found in the seeds of Ricinus communis.17,18 The dgA was stored at a concen-
tration of 3.06 mg/ml in phosphate buffered saline (pH 7.2) containing 50% glycerol at
-20°C. 
MoAb-dgA conjugation
Preparation of MoAb-dgA conjugates was based on the method described by Ghetie et
al.19 Sterile and endotoxin-free solutions were prepared by the Department of Clinical
Pharmacy. The preparative chromatographic columns were set up as a closed system
except for the inlet and outlet which were positioned in a class 100 laminar flow cabi-
net. Chromatographic media and columns (all Amersham Pharmacia Biotech, Uppsala,
Sweden) were sanitized for every conjugation according to the supplier’s ‘product sup-
port files’. The conjugation procedure started with the derivatization of MoAb with an
8 to 12-fold molar excess of crosslinker 4-succinimidyloxycarbonyl-α-methyl-α-(2-
pyridyldithio)toluene (SMPT)18 (Pierce, Rockford, IL), and the reduction of dgA with 5
mM DTT. Both reactions were carried out at 37°C for 1 hour. Excess SMPT and DTT
were subsequently removed by gel filtration on Sephadex G-25 (XK100/50 column)
equilibrated with PBS containing 0.05% Tween-20 (PBST). Average MoAb-MPT loading
was determined spectrophotometrically, as described elsewhere.20 For the actual con-
jugation reaction, MoAb-MPT was then mixed with a 2.5-fold molar excess of freshly
reduced dgA-SH. Subsequently, 0.2 volume 85% glycerol was added and the conjuga-
tion mixture was gently stirred and the reaction was allowed to proceed at 20-25°C for
48 hours. The resulting crude conjugate was purified by affinity chromatography on
Blue-Sepharose (XK50/60 column) for removal of unconjugated MoAb (The
Sepharose-conjugated Cybacron Blue has a high affinity for dgA). In case of WT1-dgA,
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the Blue-Sepharose was equilibrated with PBST. For SPV-T3a-dgA, the Na+ concentra-
tion of the reaction mixture and loading buffer had to be adjusted to 300 mM in order
to prevent affinity-binding of unconjugated SPV-T3a. Affinity-bound dgA and MoAb-dgA
conjugates were eluted with PBST containing 1M NaCl. High molecular weight materi-
al and free dgA were subsequently removed by size exclusion chromatography on
Sephacryl S-300 HR (K100/100 column) equilibrated with PBST (formulation buffer).
The resulting immunotoxins were concentrated to approximately 1 mg/ml and stored
as infusion concentrates in sterile 5 ml glass vials at -20°C at the Department of Clini-
cal Pharmacy. The immunotoxin-combination is prepared directly for use by diluting
equal amounts (w/w) of SPV-T3a-dgA and WT1-dgA in formulation buffer. 
Immunotoxin composition and biological activity
The composition of purified MoAb-dgA conjugates was analyzed by nonreducing SDS-
PAGE using 4-15% gradient gels (PhastSystem, Amersham Pharmacia Biotech). The
ratio of different reaction products was determined by densitometric scanning of the
separated product bands of Coommassie blue stained gels. Samples containing a 1:1
mixture of unconjugated dgA and MoAb were used for compensation of variance in
dye-uptake between both proteins.
Binding capacity of the MoAb before and after conjugation to dgA was examined by a
standard flowcytometric titration assay using an antigen positive cell line and a fluo-
rescent labeled goat-anti-mouse antibody to detect cell bound MoAb. Preservation of
Ricin A toxicity was determined by measurement of protein synthesis inhibition in a cell
free reticulocyte assay.21
These analyses were periodically repeated and compared to baseline values to monitor
the chemical stability and biological activity of the infusion concentrates during storage.
Sterility, endotoxins and adventitious agents
The FCS added to the culture medium was derived from healthy calves housed in a
BSE-free environment, and tested negative for Bovine Diarrhoea virus, Infectious
Bovine Rhinotracheitis, Parainfluenza and Bovine Polyoma virus. The MWCB of SPV-
T3a and WT1 were tested for bacterial and fungal contamination and for mycoplasm.
An ‘extended S+L- focus assay’ and ‘extended XC-plaque assay’ was performed by
Inveresk Research (Tranent, Scotland) for detection of xenotropic and ecotropic retro-
viruses, respectively. Species specific viruses were tested by the institutional Depart-
ment of Virology using a mouse antibody production test (MAP-assay), detecting 16 dif-
ferent exogenous mouse viruses including sendai virus, reovirus type 3, Mouse
rotavirus (EDIM), hantaan virus, and lymphocytic choriomeningitis virus. The presence
of adventitious viruses was tested by the Department of Virology using 8 different indi-
cator cell lines (including 3 human) and by inoculation of embryonated chicken eggs.
Purified MoAb were tested for endotoxins, sterility and mycoplasma. The final immuno-
toxins were tested for the presence of hybridoma DNA by Inveresk Research. The leak-
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age of affinity chromatography media was assayed using commercial enzyme
immunoassays according to the manufacturer’s instructions: Protein A using a kit from
Cygnus Technologies (Wrentheam, MA, USA), Cybacron Blue with a kit from Affinity
Chromatography Ltd (Girton, Cambridge, UK). The stored infusion concentrates were
tested for endotoxins, sterility and mycoplasma.
Cross reactivity with human tissues
Potential cross-reactivity of MoAb SPV-T3a and WT1 was tested by immunostaining of
the following panel of quickly frozen human tissue sections derived from the tissue
bank at the Department of Pathology (# donors): heart (3), lymph node (3), spleen (3),
lung (3), esophagus (3), stomach (3), ileum (3), colon (3), liver (3), pancreas (3), testis
(3), prostate (3), bladder (3), pyelum (3), kidney (3), ovary (3), Fallopian tube (2), uterus
(3), breast (3), cerebrum (3), cerebellum (3), spinal cord (1), skin (3), striated muscle
(3), thyroid (3), parathyroid (2), adrenal gland (3), pituitary (2), eyeball (1). Reactivity
against hematopoietic cell lines and stem cells has been tested extensively during the
initial characterization of the MoAbs. Potential cross-reactivity against embryonic/fetal
tissues has not been determined yet since pregnant women are no candidates for allo-
geneic stem cell transplantation.
In vitro dissociation in human plasma
Dissociation of MoAb and dgA during incubation in human plasma at 37°C was moni-
tored using enzyme immunoassays which detect intact MoAb-dgA conjugates.9
LD50 mice
All animal experiments were performed by personnel of the Central University Animal
Laboratory in accordance with the ‘Principles of Laboratory Animal Care’ (NIH publica-
tion #85-23, revised 1985). The LD50 experiment was performed with male BALB/C mice
of eight weeks weighing ~17 g, as described by Weil.22 Four doses were administered:
96, 193, 385 and 770 µg immunotoxin-combination per mouse, in a final volume of 200
µl. Administration was intravenously through one of the tail veins. Upon administra-
tion, mice were weighed daily and followed for survival for two weeks. The control
group was injected with formulation buffer only.
Administration to cynomolgus monkeys
The monkeys received two doses of immunotoxin-combination, administered 48 hours
apart as 100 ml infusions over a period of 4 hours. Prior to infusion, the monkeys were
sedated (ketamine 10 mg/kg, atropine 0,5 mg) and subsequently anesthetized (ratio
oxygen and nitrous oxide 1:2, enflurane 1,5%). The immunotoxin-combination was
administered via a subclavian (first infusion) or femoral (second infusion) central
venous catheter. For detection of any esophagus toxicity, endoscopy was performed on
day -7, 4 and 9 (day 1 being the first infusion day). During endoscopy, biopsies were
taken for microscopic analysis of potential tissue damage. Moreover, biopsy derived tis-
sue was stained with a peroxidase-labeled anti-mouse-IgG2b antibody for detection of
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SPV-T3a-dgA. Tissue pre-incubated in vitro with saturating amounts of SPV-T3a-dgA
served as positive control. In addition, both monkeys underwent regular physical exam-
inations and blood chemistries, complete blood counts and leukocyte differentials were
obtained for general safety assessment. One of the monkeys (receiving 0.1 and 0.2
mg/kg immunotoxin-combination) suffered from diabetes mellitus, but showed no
physical disorders which were expected to influence the outcome of the experiment.
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Figure 1 Immunotoxin preparation
MoAb and dgA are derivatized with SMPT (m-fold, with m = 0, 1, 2, ...) and reduced with DTT, respectively.
The purified reaction mixtures (Sephadex G25) are mixed and incubated at room temperature for 48 hours.
The resulting crude conjugate, containing protein aggregates, MoAb conjugated to dgA (n-fold, with n ≤ m),
and non-conjugated molecules, are then separated by BlueSepharose-affinity chromatography and S300-size
exclusion chromatography.
R E S U L T S
Immunotoxin production
The crude harvest of SPV-T3a and WT1 contained approximately 50 µg/ml MoAb. The
recovery following Protein A purification was ~85%, about 1 g of purified SPV-T3a and
WT1 were produced. The subsequent conjugation process is schematically depicted in
figure 1. To reduce the risk of losing all material by a technical failure, MoAbs were divid-
ed in two fractions which were conjugated separately to dgA and subsequently partly
purified by BlueSepharose. The MoAb-dgA containing BlueSepharose eluates of each
MoAb were then pooled and applied as one fraction to the Sephacryl S-300 column.
The final MoAb-recovery following conjugation was 34% and 26% for SPV-T3a and
WT1, respectively. Figure 2 displays a representative non-reducing SDS-PAGE analysis
of an SPV-T3a-dgA conjugation.
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Figure 2 SDS-PAGE analysis of SPV-T3a-dgA conjugation
A: high molecular weight marker; B: SPV-T3a (IgG2a); C: reduced dgA; D: crude conjugate; E: run-through
fraction BlueSepharose; F: high-affinity eluate BlueSepharose; G: pooled fractions of Sephacryl S300HR eluate
containing SPV-T3a-dgA.
A B C D E F G
Table 1 summarizes the main characteristics of the final products, the left column dis-
playing the proposed release criteria. Ideally, the final product consists entirely of MoAb
conjugated to one or two dgA molecules. In practice, the final product contains some
unconjugated MoAb, and MoAb bound to three or more dgA molecules, as well. The
composition of WT1-dgA did not strictly meet the (arbitrary) release criteria as for its
relatively high amount of free MoAb (23% instead of <10%). However, the acceptance
of WT1-dgA in its present form was justified by the absence of ‘contamination’ with
MoAb conjugated to three or more dgA-molecules, as well as by the high preservation
of antigen-binding activity (90%) and effective in vitro killing capacity.9 Another point of
Table 1 Product specifications
Proposed SPV-T3a-dgA (CD3) WT1-dgA (CD7)
Release Criteria
MoAb-Isoform IgG2bκ/IgG2aλ IgG2bκ IgG2aλ
Composition:
MoAb(dgA)≥3 <10% 6% 0%
MoAb(dgA)1-2 >80% 88% 78%
MoAb <10% 6% 23%
dgA <3% <1% (detection limit) <1%
Sterility Sterile Sterile Sterile
Endotoxins < 20 < 0.8 < 0.7
(EU/mg protein)
DNA content < 5 < 11 < 9
(pg/mg protein)
Protein A < 10 1.1 ± 0.3 2.7 ± 0.8
(ng/mg protein)
Cybacron Blue (nM) < 10 (detection limit) < 10 < 10
A-chain activity > 75 84 91
(% native dgA)
Binding activity > 50 70 90
(% native MoAb)
Dissociation in vitro ~15 10 10
(% in 24h)
In vitro Absent. If not, relevant Esophagus epithelium (++) Kupfer cells (+/-)
cross reactivity animal studies Smooth muscle cells (+/-)
should follow
LD50 in mice (µg/g) ~14 µg/g mouse 25-45 µg/g mouse for the IT-combination
Toxicity for No severe irreversible Reversible toxicity to skeletal muscles after
cynomolgus monkey toxicities 0.1-0.25 mg/kg IT-combination
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attention was the presence of genomic DNA. The IT-combination contains <10 pg
DNA/mg protein, being the detection limit of the assay. The relevant FDA’s ‘Points to
Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human
Use’ suggests that, whenever possible, the final product contains no more than 100 pg
cellular DNA per dose. This implies that total human doses of 10 mg and higher (equal-
izing ~5-7 mg/m2) acquire additional testing (e.g. with concentrated immunotoxin to
lower the detection limit). 
So far, the repeated testing for composition, MoAb-binding and dgA-activity demon-
strated stability of both SPV-T3a-dgA and WT1-dgA at -20°C for a minimum period of
three years.
Cross reactivity with human tissues
MoAb SPV-T3a showed two unexpected cross-reactivities: against (1) smooth muscle
cells, and (2) basal epithelial cells of the esophagus. The staining of smooth muscle
cells was weak (+/-) but consistently found throughout various tissues. The diffuse
staining pattern suggested a cytoplasmatic binding of physically disrupted cells. This is
supported by the observation that SPV-T3a-dgA (10-8M for 24 hours) appeared to be
non-toxic to cultured intact human leptomeningial smooth muscle cells (data not
shown). The staining intensity of SPV-T3a with the esophagus-basal epithelium was as
strong (++) as observed with positive lymphocytes, and appeared to be characteristic
for SPV-T3a since it was not observed with any of the other CD3 MoAbs tested (OKT3,
UCHT and WT32). The in vivo consequence of this cross reactivity will depend on the
local concentration SPV-T3a-dgA, and whether SPV-T3a-dgA will be internalized (a pre-
requisite for toxicity). To gain more insight in these parameters, it was decided to
administer the immuntoxin-combination to cynomolgus monkeys, demonstrating in
vitro cross-reactivity of comparable intensity and localization. 
The screening with MoAb WT1 revealed a weak staining (+/-) of some Kupffer cells
located in the liver sinus wall. This staining pattern was not observed during previous
preclinical tissue screenings performed with WT1.23 No further unexpected cross-reac-
tivities were observed.
LD50 mice
The LD50 in mice was determined for comparison with reference immunotoxin RFB4-
dgA, a comparable immunotoxin already tested in FDA-approved phase I/II trials (hav-
ing a LD50 of 14 mg/kg).24 Three of the four mice treated with the highest dose
immunotoxin-combination (770 µg/mouse) died within the follow-up period of two
weeks. One mouse already died during injection, probably due to an administration-
related toxicity (dgA-related deaths are normally first seen after 1-2 days). All mice treat-
ed with 385 µg immunotoxin-combination or less survived. Based on the average initial
weight, this implies an LD50 of 25 - 45 mg/kg mouse.
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Apart from the survival score, mice were daily weighed and observed for behavior.
Administration of IT combination caused weight loss in all groups, which was most
pronounced after 9 days (Figure 3). The extent and duration correlated well with the
dosage. Besides weight-loss, mice treated with 770 or 385 µg IT-combination demon-
strated lethargy, lack of appetite and a neglected fur. The mice treated with the two
lower doses could not be distinguished visually from the control group.
Administration of the immunotoxin-combination to cynomolgus monkeys
The imunotoxin-combination was administered to two male cynomolgus monkeys. As
the administration was performed under general anesthesia, the animals had to be
deprived of nutrition before each infusion. Since this may negatively impact their phys-
ical condition, the administration was restricted to two doses at a 48-hour interval (the
patients in the pilot-study were supposed to receive four doses at the same interval).
This decision was justified by observations of Amlot et al. who demonstrated that the
toxicity of a dgA-based immunotoxin mainly depends on the height of the individual
doses and not on the number of doses administered.24 Both monkeys received two of
the higher individual doses of the proposed human dose escalation scheme (ranging
from 2 to 10 mg/m2), translated to mg/kg. One monkey (about 12 years and 7.6 kg)
received 0.1 and 0.2 mg/kg, the other monkey (4 years and 4.1 kg), received 0.2 and
0.25 mg/kg (equalizing human doses of 4, 8 and 10 mg/m2). In human, the immuno-
toxin-combination will be given as a 100 ml infusion over 4 hours. For the monkeys,
this was changed to 20 ml administered in 1 hour because of their smaller blood volume.
L A B O R A T O R Y  P R O D U C T I O N  O F  C L I N I C A L  G R A D E  I T s
1 2 0
Figure 3 Average weight-changes of immunotoxin treated mice
Mice were treated with formulation buffer (❍) or with 96 µg (), 193 µg (), 385 µg () or 770 (g immuno-
toxine-combination/mouse (). Upon administration, mice were weighed daily for two weeks.
Figure 4 shows the plasma concentrations of the immunotoxin-combination. The clear-
ance curves best fitted a two-compartment model for both SPV-T3a-dgA and WT1-dgA
individually and given in combination. The pharmacokinetic parameters are listed in
Table 2. The T1/2 of the immunotoxin-combination was 9.3 and 5.7 hours in monkeys A
en B, respectively. Notably the T1/2 of SPV-T3a and WT1 in ‘monkey B’ differed consid-
erably, being approximately 9 and 2 hours, respectively. This may be explained by the
capture of WT1-dgA by the CD7-antigen expressed on T and NK cells (virtually all these
cells being CD7+ in ‘monkey B’). ‘Monkey A’ with only ~30% of its T/NK cells being
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Figure 4 Immunotoxin-combination plasma concentrations in cynomolgus monkeys
Two male cynomolgus monkeys were each given two doses immunotoxin-combination with an interval of 48
hours (arrows beneath the x-axis). One monkey received 0.1 and 0.2 mg/kg (❑), the other 0.2 and 0.25 mg/kg
().
Table 2 Pharmacokinetic parameters (± SD)a
Monkey Immunotoxin T1/2β(h) AUC Cl (ml/h) Vd (ml) Cmax
(dose, mg/kg) (µg·h/ml) (ng/ml)
A SPV-T3a-dgA 9.1 ± 0.6 9.4 ± 1.6 26.5 ± 4.5 347.3 ± 29.1 1,830
(0.1 and 0.2) WT1-dgA 9.4 ± 1.6 12.8 ± 1.7 19.6 ± 2.6 265.8 ± 17.5 2,090
Combination 9.3 ± 1.7 22. 3 ± 3.1 4.5 ± 0.6 60.3 ± 4.2 3,920
B SPV-T3a-dgA 9.3 ± 2.0 23.5 ± 3.8 8.5 ± 1.4 113.6 ± 9.2 2,280
(0.2 and 0.25) WT1-dgA 2.2 ± 0.2 4.7 ± 0.3 42.9 ± 3.1 133.7 ± 7.4 1,450
Combination 5.7 ± 1.0 24.8 ± 3.3 8.1 ± 1.1 65.8 ± 4.6 3,840
aAbbreviations: T1/2β, plasma half-life; AUC, area under the concentration versus time curve; Cl, clearance; Vd,
volume of distribution; and Cmax, maximum plasma concentration.
CD7+, demonstrated equal half lives for SPV-T3a-dgA and WT1-dgA (~9 hours). It
should be noted that SPV-T3a-dgA is not influenced by expression of the CD3-antigen
as SPV-T3a does not bind ‘monkey-CD3’. Peak plasma levels were attained directly fol-
lowing each infusion and decreased (nearly) to baseline level in about 48 hours. The
Cmax of the immunotoxin-combination ranged from 1.8 to 3.9 µg/ml and strongly cor-
related with the dose administered. In general, plasma levels of ~1.8 µg/ml (10-8 M) are
considered therapeutic concentrations.25 In both monkeys, these plasma concentra-
tions were maintained for 8-10 hours following the second infusion.
Regarding the cross-reactivity of SPV-T3a, neither macroscopic nor microscopic exam-
inations revealed any evidence of toxicity towards the esophagus. Moreover, immunos-
taining of biopsy derived tissue could not demonstrate any in vivo binding of SPV-T3a-
dgA to the esophagus epithelium. Blood chemistry analyses revealed a transient
drug-related toxicity. Each administration was followed by a sharp increase in serum
creatine kinase (CK), reaching a maximum at 7 hours after infusion and normalizing to
baseline within 2-7 days (Figure 5). Following the second peak, both monkeys demon-
strated a third, more modest, rise of CK-levels that might be explained by a secondary
release of dgA. The increase in CK levels is indicative for destruction of striated mus-
cles and/or heart muscle. Damage of the heart muscle could be excluded by measure-
ment of heart-muscle isomer CKMB. In accordance with the destruction of striated
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Figure 5 Serum CK-levels in cynomolgus monkeys
Following administration of the immunotoxin-combination, both cynomolgus monkeys demonstrated a tran-
sient rise of serum CK-levels. One monkey received 0.1 and 0.2 mg/kg (❑), the other 0.2 and 0.25 mg/kg ()
immuntoxin-combination, separated by a 48-hour interval.
muscle cells, a concomitant (modest) increase in LD, ASAT and ALAT serum levels
could be noted. Four weeks after completion of the study all biochemical parameters
had returned to baseline levels. Complete blood counts and leukocyte differentials dis-
played a normal distribution. Immediately after the infusions, both monkeys seemed a
bit weakened. Aside from the general anesthesia, this may have resulted from the
destruction of striated muscle tissue. One day after the second dose, both monkeys ate
almost as normal again. Within a week, both monkeys functioned as before treatment.
D I S C U S S I O N
This report describes the laboratory preparation and control of two dgA-based
immunotoxins that are currently under evaluation in a clinical pilot-study. The design of
this study was strongly inspired by earlier reports on RFB4-dgA, a comparable immuno-
toxin for the treatment of Non-Hodgkin’s lymphoma.24,26 The murine LD50 of the
immunotoxin-combination compared favorably with that of RFB4-dgA (25-45 mg and 14
mg per kg mouse, respectively).19 Moreover, the monkey experiment demonstrated
pharmacokinetics resembling those previously observed with RFB4-dgA and compara-
ble immunotoxins in man. Importantly, clinically significant plasma concentrations
were reached for several hours without being accompanied by acute irreversible toxici-
ties. With respect to the potential cross-reactivity of SPV-T3a-dgA, it was particularly of
interest that no binding or toxicity to the esophagus was observed. The main toxicity
observed was a clear but transient rise in CK-levels. This is in accordance with myalgias,
sometimes associated with rhabdomyolysis, being the second dose limiting toxicity
associated with dgA-immunotoxins in man (after vascular leak syndrome, VLS).25 Con-
sistent with the human studies, this toxicity resolved upon ending the administration
of immunotoxin. It should be noted, though, that the animal studies do not eliminate
all uncertainties with regard to clinical administration of the immunotoxin-combina-
tion. The esophagus of patients with severe graft-versus-host disease may be more
accessible for SPV-T3a-dgA (e.g. due to disease-associated lesions) than those of
healthy cynomolgus monkeys. Another concern is that monkeys are hardly vulnerable
for dgA-induced VLS, the main toxicity reported in man. However, as these issues can
not be clarified by animal studies, the current data were considered maximally sup-
portive for performing the clinical pilot-study.
So far, the preliminary results of the clinical pilot-study are very encouraging and do
warrant the set up of multi-center Phase I/II  studies. Consequently, in addition to a fur-
ther scaling-up of production, product-specifications will probably have to meet stricter
criteria. A point for improvement forms the reduction of the relatively high amount of
unconjugated WT1. Moreover, stricter guidelines might ask for future MoAb produc-
tions to be performed in serum-free medium. This inevitably will result in repeated
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hybridoma cell banking and subsequent virus testing, as changes in growing conditions
might provoke the expression of different latent viruses. As an additional requirement,
the actual viral removing capacity of the production process will need to be demon-
strated by virus spiking using a scale-down model. Though the FDA foresees in the
human testing of (modified) MoAb combinations, it is anticipated that the required ani-
mal toxicity studies (e.g. acute/subchronic toxicity and reproduction toxicity studies)
will have to be performed with both immunotoxins separately.
Notwithstanding the foreseen adaptations, the current batch is very well suited for its
intended use: the evaluation in a clinical pilot study for the treatment of a life-threaten-
ing disease. As such, the described production forms a stepping stone towards the
future productions as required for the actual registration process. It provided sufficient
quantities of proper quality to enable the clinical evaluation in an academic setting.
Especially for niche indications like severe graft-versus-host disease, some clinical proof
of concept appears a prerequisite for further development by the pharmaceutical indus-
try. The in house production and clinical evaluation of biological therapeutics by acad-
emic centers might therefore contribute increasingly to the development of new drugs
within this area.
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A B S T R A C T
This study evaluated the anti-graft versus host disease (GVHD) potential of a combi-
nation of immunotoxins (ITs), consisting of a murine CD3 (SPV-T3a) and CD7 (WT1)
monoclonal antibody both conjugated to deglycosylated ricin A. In vitro efficacy data
demonstrated that these IT act synergistically, resulting in an approximately 99% elim-
ination of activated T cells at 10-8M (about 1.8 µg/ml). Because most natural killer (NK)
cells are CD7+, NK activity was inhibited as well. Apart from the killing mediated by ricin
A, binding of SPV-T3a by itself impaired in vitro cytotoxic T-cell cytototoxicity. Flow cyto-
metric analysis revealed that this was due to both modulation of the CD3/T-cell recep-
tor complex, and activation-induced cell death. These results warranted evaluation of
the IT-combination in patients with refractory acute GVHD in an ongoing pilot study.
So far, 4 patients have been treated with 3 to 4 infusions of 2 or 4 mg/m2 IT-combina-
tion, administered intravenously at 48-hour intervals. The T1/2 was 6.7 hours, and peak
serum levels ranged from 258 to 3,210 ng/ml. Drug-associated side effects were restrict-
ed to limited edema, fever, and a modest rise of creatine kinase levels. One patient
developed low-titer antibodies against ricin A. Infusions were associated with an imme-
diate drop of circulating T cells, followed by a more gradual but continuing elimination
of T/NK cells. One patient mounted an extensive CD8 T-cell response directly following
treatment, not accompanied with aggravating GVHD. Two patients showed nearly com-
plete remission of GVHD, despite unresponsiveness to the extensive pretreatment.
These findings justify further investigation of the IT-combination for treatment of dis-
eases mediated by T cells.
I N T R O D U C T I O N
Stem cell transplantation forms a widely accepted method for restoration of normal
hematopoiesis of patients treated for a hematological malignancy or otherwise suffer-
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ing from a defective hematopoietic or immunologic system. For a successful engraft-
ment, a minimal number of donor T cells in the graft appears to be a prerequisite. The
underlying mechanism by which these cells promote engraftment is not fully under-
stood, but probably includes the creation of an immunologically tolerogenic environ-
ment by eliminating the remainder of the patient’s immune system.
In treatment of a malignancy, the cotransplantation of donor T cells confers additional
benefit because they contribute to the so-called graft-versus-leukemia (GVL) effect,
which involves the elimination of residual malignant cells.1 The basis of GVL forms the
recognition by donor T cells of (minor or major) histocompatibility antigens expressed
by the malignant recipient cells. Unfortunately, this antigenic disparity may also lead to
graft versus host disease (GVHD), a major cause of morbidity and mortality after allo-
geneic stem cell transplantation.2 GVHD is thought to be initiated by alloactivation of
donor T cells resulting in the production of cytokines (interleukin [IL]-2 and interferon
[INF]-γ) which in turn activate additional effector cells, like monocytes, macrophages,
and natural killer (NK) cells, to produce inflammatory proteins (IL-1, tumor necrosis
factor [TNF]-α, and IL-6).3 This may result in serious direct and indirect cytotoxicity to
epithelial cells of skin, liver, and gut.
When prophylaxis has failed (typically cyclosporine, often combined with methothrex-
ate), severe GVHD is usually treated with low-dose corticosteroids. If the reaction pro-
gresses, the dose may be increased (up to levels of 10-20 mg/kg/day) or, alternatively,
polyclonal antithymocyte/antilymphocyte globulin (ATG/ALG) or experimental
immunosupressive drugs may be applied. An example of such an experimental reagent
is Xomazyme-CD5 Plus, a murine CD5 monoclonal antibody (MoAb) conjugated to the
A-chain of the phytolectin ricin. Especially in the initial reports, Xomazyme-CD5 Plus
demonstrated substantial efficacy in treating steroid-resistant acute GVHD.4,5 In more
recent comparative trails, Xomazyme-CD5 Plus was not more effective than high dose
corticosteroids or ATG.6,7 Encouraged by its initial success, we developed a therapy
based on the use of a combination of 2 anti-T-cell immunotoxins (IT): murine MoAb
SPV-T3a (CD3) and WT1 (CD7), both conjugated to deglycosylated ricin A (dgA). In this
article, we present the preclinical efficacy data and preliminary clinical results, both of
wich suggest that this IT-combination has the potential for helping to control severe
acute GVHD .
M A T E R I A L S  A N D  M E T H O D S
Immunotoxins
The “IT-combination” as referred to in this article, consists of a 1:1 mixture (w/w) of
murine MoAb SPV-T3a (CD3)8 and WT1 (CD7)9,10 both conjugated to deglycosylated
ricin A (dgA) (Inland, Austin, TX) using the SMPT-cross-linker (Pierce, Rockford, IL),
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according to Ghetie et al.11 The preparation and validation were supervised by the insti-
tutional Department of Clinical Pharmacy. The major characteristics of the IT are sum-
marized in Table 1; details will be reported elsewhere (manuscript in preparation).
Murine MoAb UPC-10 (IgG2a) and MOPC-141 (IgG2b) (both Sigma, St. Louis, MO)
conjugated to dgA served as isotype-matched irrelevant controls for the in vitro experi-
ments. Noteworthy, in vitro tissue screening unveiled a cross-reactivity of MoAb SPV-
T3a with the basal epithelium of the human esophagus. To investigate potential in vivo
consequences, the IT-combination was administered to two cynomolgus monkeys
sharing the same cross reactivity. Subsequent esophagus biopsies revealed no toxicity
towards the esophagus epithelium, nor could any localization of SPV-T3a-dgA be
detected. Both monkeys demonstrated a transient rise of creatine kinase (CK)-levels
upon administration of the IT-combination.
Peripheral blood mononuclear cells (PBMC)
PBMC were isolated from peripheral blood by Ficoll-Hypaque density centrifugation
(Pharmacia, Uppsala, Sweden), and cultured in Iscove’s medium (Flow, Irvine, Scot-
land) supplemented with 10% heat-inactivated Pooled Human Serum (PHS), penicillin
(100 U/ml) and streptomycin (100 µg/ml). For generation of PHA-activated T cells,
PBMC were preincubated with 40 µg/ml phytohaemagglutinin (PHA-HA15) (Murex,
Dartford, UK) for 48 hours.
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Table 1 IT characteristics
SPV-T3a-dgA (CD3) WT1-dgA (CD7)
MoAb murine IgG2bκ murine IgG2aλ
Composition (SDS-PAGE) MoAb(dgA)≥3 6% MoAb(dgA)≥3 0%
MoAb(dgA)1-2 88% MoAb(dgA)1-2 78%
MoAb 6% MoAb 23%
dgA 0% dgA 0%
Sterility Sterile Sterile
Endotoxins (EU/mg protein) < 0.8 < 0.7
DNA content (pg/mg protein) < 11 < 9
Protein A (ng/mg protein) 1.1 ± 0.3 2.7 ± 0.8
Cybacron Blue (nM) < 10 < 10
A-chain activity (% native dgA) 84 91
Binding activity (% native MoAb) 70 90
Dissociation in human plasma
at 37°C (% in 24h) 10 10
In vitro cross reactivity Esophagus epithelium (++) Kupfer cells (+/-)
Smooth muscle cells (+/-)
LD50 25-45 µg/g mouse for the IT-combination
Toxicity cynomolgus monkey Reversable increase of CK-levels upon administration of
human doses IT-combination (0.1-0.25 mg/kg)
Flow cytometric quantification of in vitro cell kill
Nonactivated as well as PHA-activated PBMC (106/ml) were incubated in triplicate with
varying concentrations of IT (10-13-10-8 M) at 37°C for 24 hours. Following treatment,
cells were washed and cultured in the presence of PHA (40 µg/ml) for an additional
four days to enable full exposure of IT toxicity. Subsequently, cells were labeled with pro-
pidium iodine (PI) (Molecular Probes, Junction City, OR) and calcein AM (Calc) (Mole-
cular Probes) (both: 2 µg/ml for 30 minutes at room temperature), and analyzed on a
flow cytometer (Coulter Epics Elite, Hialeah, FL). Cells being PI- and Calc+ were referred
to as viable cells. Prior to FCM analysis, a fixed amount of inert beads (Flow-Count flu-
orospheres, Coulter) was added to each sample (1x104/ml) to enable the quantification
of surviving cells.
Reduction of CTL toxicity by SPV-T3a
Cytotoxic T cell (CTL) toxicity was assayed in vitro using an EBNA3C12-reactive CTL
clone. The CTL clone was incubated with MoAb SPV-T3a (10-8 M), or isotype matched
control MoAb MOPC-141, at 37°C for 24 hours. Subsequently, cells were washed and
cultured in culture medium for another 72 hours. Remaining cytolytic activity was
assayed with an autologous Epstein-Barr virus (EBV)-transformed lymphoblastoid cell
line (EBV-LCL), labeled with 100 µCi 51Cr (Amersham, Bucks, UK) at 37°C for 2 hours.
Labeled EBV-LCL were plated in triplicate (103/well) in V-bottom microtiter plates
(Greiner, Fickenhausen, Germany) and saturated with endogenous EBNA3C (5 µM for
1 hour at 37°C) to enhance T-cell receptor (TCR)-mediated lysis. Subsequently, varying
numbers of MoAb-treated CTL cells were added to each well in a final volume of 150 µl
culture medium. Plates were centrifuged (50g, 1 minute) and further incubated at 37°C.
After 4 hours, 100 µl supernatant was collected from each well and counted in a
gamma counter. Specific lysis was expressed as percentage maximal lysis by detergent,
both corrected for spontaneous 51Cr-release.
Modulation of the CD3-antigen by SPV-T3a
Surface CD3 expression of SPV-T3a-treated CTL was determined by indirect fluores-
cence staining with a saturating amount of SPV-T3a (10 µg/ml, 4°C 30 minutes), fol-
lowed by a fluorescein isothiocyanate (FITC)-conjugated F(ab’)2 goat-anti-mouse IgG
(American Qualex International, La Mirada, CA). CD3-antigen still bound by SPV-T3a
used for treatment was identified by staining with the FITC-conjugated antibody only.
Expression was indicated as percentage relative to untreated control cells.
In vitro reduction of NK-activity.
The PBMC (106/ml) were incubated with 10-8M MoAb or IT for 24 hours. Subsequent-
ly, cells were washed and cultured for 3 additional days without MoAb/IT (to enable full
exposure of toxicity). PBMC were serially diluted in 96-well U-bottomed plates, and a
fixed concentration of 51Cr-labeled K562 cells was added (104/well) to yield effector/tar-
get ratios of 10:1 to 0.37:1 in a final volume of 150 µl culture medium. Plates were cen-
C H A P T E R  7
1 3 1
trifuged (50g, 1 minute) and further incubated at 37°C. After 4 hours, 100 µl supernatant
was collected from each well and counted in a gamma counter. NK-activity was
expressed as percentage maximum lysis by detergent, both corrected for spontaneous
51Cr-release. Recombinant IL-2 (500 U/ml) (Cetus, Emeryville, CA) was present during
the entire assay to increase NK-activity.
Clinical pilot study
The first patients were treated in a single center, non-randomized, open-labeled, dose-
escalating study (ongoing) with the aim of obtaining estimates of the safety and effica-
cy of the IT-combination administered to patients with life-threatening GVHD. Patients
with acute GVHD were eligible if they had received second-line high-dose corticosteroid
therapy (methylprednisolone 1000 mg/d) for at least 3 days without decrease in the
severity of clinical symptoms. Patients were not eligible if they had evidence of intra-
pulmonary disease (which might aggravate the clinical severity of vascular leak syn-
drome [VLS]13), or had allergy or antibodies to mouse Ig or dgA. Before entering the
trial, all patients gave informed consent in accordance with the institutional review
board and ethics committee. For assessment of safety and responses, patients were
evaluated daily during hospitalization, and weekly thereafter, with a physical examina-
tion and by obtaining serum chemistries, complete blood counts and leukocyte differ-
ential. In addition, blood samples were collected for determination of the pharmacoki-
netics and immunogenicity of the IT-combination. Toxicities were graded according to
the National Cancer Institute Common Toxicity Criteria (NCI-CTC; version 2.0).
IT-combination administration
Patients were supposed to receive 4 doses of the IT-combination administered intra-
venously in 4-hour infusions at 48-hour intervals. Prior to therapy, an intravenous test
dose of 200 µg IT-combination was administered to rule out anaphylactoid reactions.
Immunosuppressive agents used for prophylaxis and initial treatment of GVHD were
allowed to remain unchanged.
Pharmacokinetics
Plasma levels of intact IT were measured with an enzyme immunoassay. Affinity-puri-
fied rabbit antiricin antibody (Sigma) in carbonate buffer (pH 9.6) was adsorbed to 96-
wells maxisorp plates (Nunc, Roskilde, Denmark), and residual binding sites were
blocked with 4% bovine serum albumin (BSA). Patient plasma samples were serially
diluted in 50% PHS in the absorbed microtiter plates and incubated at 37°C for 1 hour.
Subsequently, plates were washed and alkaline-phosphatase conjugated goat anti-
mouse IgG2b or IgG2a (SBA, Birmingham, MI) was added at 37°C for 1 hour to bind
captured SPV-T3a-dgA or WT1-dgA, respectively. Plates were washed, and the reaction
was developed using p-nitrophenylphosphate. Optical densities were read at 450 nm,
and levels of circulating IT were calculated from standard curves obtained with a known
concentration of IT-combination diluted in pretreatment plasma. The detection limit
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was 0.02 µg/ml for both SPV-T3a-dgA and WT1-dgA. Plasma concentration versus time
data were analyzed using the nonlinear least square regression program WinNonlin
version 1.1 (Scientific Consulting, Apex, NC).
Measurement of HAMA and HARA
An enzyme immunoassay was used for detection of antibody responses to components
of the IT-combination. Patient plasma samples were serially diluted (undiluted to
1:2,048) in phosphate-buffered saline with 1% human serum albumin in 96-wells maxi-
sorp plates (Nunc) containing either adsorbed SPV-T3a, WT1, or dgA. Bound human
antibodies were probed using alkaline phosphatase-conjugated goat antihuman
IgG/IgM (H+L) antibodies (Jackson, West Grove, PA), and the reaction was developed
with p-nitrophenylphosphate. Optical densities were read at 450 nm, and the serum
titer was expressed as the end-point dilution. Positive titers were considered to be at
least 3 times background.
Flow Cytometry
Lymphocyte phenotyping was performed by multicolor flow cytometry using directly flu-
orescent-labeled MoAb according to a whole blood lysis method (FACS lysing, Becton
Dickinson, San Jose, CA). T cells and NK cells were identified simultaneously with a
mixture of fluorescence-labelled CD2 and CD5 MoAb (MT910-PE and DK23-PE, respec-
tively) (DAKO, Copenhagen, Denmark). The percentage T/NK cells relative to all leuko-
cytes was determined by costaining with a CD45-FITC MoAb (J33-FITC) (Immunotech,
Marseille, France), and converted to absolute numbers based on the leukocyte count.
B cells were quantified accordingly, using a PE-conjugated CD19 MoAb (HD37-PE)
(DAKO).
Staging of GVHD and Definitions of Clinical Responses
Each organ system was staged grade 1 through 4 acute GVHD according to established
criteria.14 Patients were also given an overall grade of acute GVHD (I through IV) based
on severity of organ involvement.14 Responses to therapy were defined as follows. A
complete response (CR) as the disappearance of symptoms in all organ systems. A par-
tial response (PR) as the improvement of 1 organ or more, with no worsening in other
organs. A mixed response (MR) as the improvement of 1 organ or more, with worsen-
ing in 1 other organ or more. Stable disease (SD) as no significant change in any organ
system. Progressive disease (PD) as progression in 1 organ system or more without
improvement in other organs.
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In vitro elimination of T cells
T cells may become more susceptible to dgA-IT on activation.15 This would be benefi-
cial for the treatment of immunological disorders. Ideally, such treatment inhibits ongo-
ing or beginning immune responses without affecting the resting T cell pool with its
ability to counter future hazardous infections. To address this issue, nonactivated and
PHA-activated PBMC were treated with IT for 24 hours and analyzed by flow cytometry
for the number of surviving cells (Figure 1). Without prior PHA activation, treatment
with SPV-T3a-dgA and WT1-dgA, either alone or in combination, resulted in a 2.0- to
2.7-fold reduction of viable cells at 10-8M (about 1.8 µg/ml, the highest nontoxic con-
centration in vitro). After 48 hours PHA-activation, SPV-T3a-dgA, WT1-dgA, and the
combination demonstrated an approximate 3-, 11-, and 34-fold increase in maximal
killing capacity, respectively. The combination appeared very effective at concentrations
above 10-9M, resulting in the elimination of 99% of activated T cells at 10-8 M. Costain-
ing with lineage-specific markers revealed no difference in vulnerability between CD4+
and CD8+ T-cell subsets (data not shown). Neither incubation with isotype-matched
control IT, nor with MoAb SPV-T3a or WT1, significantly reduced the number of viable
cells (< 1.15-fold reduction at 10-8 M; n = 3, data not shown).
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Figure 1 Surviving T cells after treatment with IT
Nonactivated (A) and PHA-activated (B) T cells were eliminated by SPV-T3a-dgA (❏) and WT1-dgA (❍),
applied individually and in combination ()(half a dose each). Nonactivated and PHA-activated PBMC were
incubated with various concentrations IT for 24 hours at 37°C. Following treatment, cells were washed and cul-
tured for an additional four days in the presence of PHA to enable full exposure of IT toxicity. Subsequently,
cells were stained with viability markers and analyzed by flow cytometry for the number of viable T cells rela-
tive to the untreated control. Data represent the mean ± SD as obtained with the PBMC of 3 healthy individ-
uals.
Immunosuppressive activity of native MoAb SPV-T3a
SPV-T3a may deliver an immunosuppressive effect, irrespective of its conjugation to
dgA, by modulation of the T-cell-receptor/CD3-complex (TCR/CD3-complex) or by
induction of Fas-mediated apoptosis according to the process described as activation-
induced cell death (AICD).16 To mimic the alloactivation induced in a transplantation
setting, a CTL clone reactive with minor histocompatibility antigen ‘EBV-peptide
EBNA3C’ was stimulated with an autologous EBV-LCL. Incubation of this CTL with
MoAb SPV-T3a for 24 hours, abrogated almost completely its cytolytic activity as mea-
sured in a 51Cr-release assay (Figure 2). Flow cytometric analysis (Figure 3) revealed that
this may be attributed to both (1) AICD of the CTL-clone (to 16% of the untreated con-
trol) and (2) modulation of the CD3 antigen (to 20% of the untreated control). In addi-
tion, about half of the non-modulated CD3 antigens was still occupied by SPV-T3a.
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Figure 2
Reduction of CTL cytotoxicity
by native MoAb SPV-T3a
An EBNA3C-reactive CTL clone was incubated
with 10-8M MoAb SPV-T3a (), isotype-
matched irrelevant MoAb MOPC-141 () or
culture medium () for 24 hours at 37°C. Sub-
sequently, cells were washed and cultured for
another 72 hours in culture medium. CTL cyto-
toxicity was then assayed by specific lysis of a
51Cr-loaded autologous EBV-LCL, and
expressed as percentage relative to maximum
lysis by detergent. Data represent the mean ±
SD of 3 experiments performed in triplicate.
Figure 3
AICD and CD3-modulation
by native SPV-T3a
The EBNA3C-reactive CTL clone was
incubated with 10-8M MoAb SPV-
T3a, or isotype-matched control MoAb
MOPC-141, for 24 hours at 37°C.
Subsequently, cells were washed and
cultured for another 72 hours in cul-
ture medium. The number of surviv-
ing cells was then determined by via-
bility staining and flow cytometric
analysis, and expressed as percentage
relative to the untreated control (A).
Membrane expression of free and
SPV-T3a-bound CD3-antigen was
determined as described in “Material
and Methods” and indicated as per-
centage relative to control cells ( B).
Data represent the mean ± SD of 3
experiments performed in triplicate.
NK activity after IT treatment
Although initiated by CTL, GVHD is thought to be aggravated by less specific cytokine-
stimulated “bystander cells” like NK cells.3,17,18 The capacity of the described MoAb or
IT to reduce NK activity was assayed by inhibition of lysis of 51Cr-loaded K562 cells.
Figure 4 shows the NK activity of PBMC incubated with IT for 24 hours. As expected,
treatment with SPV-T3a-dgA did not effect the NK-activity (NK cells being CD3-). In con-
trast, NK activity was almost completely abolished following 3 days after incubation
with WT1-dgA. Similar results were obtained with cell line Daudi, which is predomi-
nantly vulnerable for lymphokine-activated killer cells (LAK cells; data not shown). Nei-
ther nonconjugated MoAb WT1, nor isotype-matched control IT UPC-10-dgA, impaired
the lysis of K562 or Daudi cells (data not shown, n = 3).
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Figure 4
Effect of IT treatment on NK activity
PBMC were treated with 10-8M WT1-dgA (),
SPV-T3a-dgA () or without IT (❑), for 24
hours at 37°C. After treatment, cells were
washed and cultured for an additional 3 days in
culture medium without IT. Subsequently,
remaining NK activity was determined by spe-
cific lysis of 51Cr-labeled K562 blasts and
expressed as percentage relative to untreated
cells. During the experiment, 50 U/ml recombi-
nant IL-2 was added to the culture medium to
increase NK activity. Data represent the mean ±
SD of 3 experiments performed in triplicate.
Table 2 Patient characteristics
Patient No.
1 2 3 4
Age /Sex 65/M 34/M 47/M 49/M
Primary diseasea MM CML MDS MM
Primary treatmentb - M, P - H, a-I - none - V, A, D
Transplant procedurec - I, C, TBI, PSCT - ATG, C, TBI, BMT - I, C, TBI, BMT - C, TBI, BMT,DLI
Staging of GVHDd Liver: 3 Liver: 0 Liver: 0 Liver: 4
Gut: 1 Gut: 0 Gut: 2 Gut: 0
Skin: 4 Skin: 4 Skin: 0 Skin: 0
Overall: IV Overall: III Overall: II Overall: IV
Previous GVHD C, Pl, S C, Pl, S C, Pl, S C, Pl, S
Medicatione
IT-combination 2, 2, 4 mg/m2 2, 2, 4, 4 mg/m2 4, 4, 4, 4, mg/m2 4, 4, 4 mg/m2
a MM indicates multiple myeloma; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome.
b M indicates melphalan; P: prednisone; H: Hydrea, a-I: α-interferon; V: vincristine; A: Adriamycine;
D: dexamethason.
c I: indicates idarubicine; C: cyclophosphamide; TBI: total body irradiation; PSCT: allogeneic peripheral 
stem cell transplantation; ATG: antithymocyte globuline; BMT: allogeneic bone marrow transplan-
tation; DLI: donor lymphocyte infusion.
d Each organ system was staged grade 1 through 4 aGVHD according to Glucksberg et al.14 Patients were 
also given an overall grade of aGVHD (I through IV) based on severity of organ involvement.14
e C indicates cyclosporine A; Pl: prednisolone; S: Solu-medrol (up to 1g daily for at least 3 days). 
Pilot-study Participants
So far, 4 patients, all white men, have been enrolled in the study. The clinical features
of these patients are summarized in Table 2. Patients 1 and 2 have been treated at the
lowest dose level (2 x 2 mg/m2 followed by 2 x 4 mg/m2) and patient 3 and 4 at the sec-
ond dose level (4 x 4 mg/m2). Due to their early deaths, patient 1 and 4 received only 3
of the 4 planned infusions.
Pharmacokinetics
The plasma clearance curves best fitted a 1-compartment model with a constant rate
infusion and a first-order elimination rate for both SPV-T3a-dgA and WT1-dgA individu-
ally and given in combination. The pharmacokinetic parameters determined over the
entire courses are listed in Table 3. The mean T1/2 was 6.5 ± 2.4 hours for SPV-T3a-dgA,
7.5 ± 1.7 hours for WT1-dgA, and 6.7 ± 2.1 hours for the IT-combination. Peak plasma
levels were attained directly following each infusion and decreased (nearly) to baseline
level in about 48 hours (Figure 5). The maximum plasma concentration (Cmax) for the
IT-combination ranged from 258 ng/ml following the first dose of patient 2 (2 mg/m2)
to 3,210 ng/ml following the third dose of patient 1 (4 mg/m2). The latter seemed to be
an exception as the maximum peak plasma level of the other patients fell within the rel-
ative narrow range of 1,220 to 1,650 ng/ml (all attained after a 4 mg/m2 dose). The 2-
fold higher level of patient 1 may be explained by his aggravating multi-organ failure
interfering with the IT plasma clearance. When comparing the separate infusions, the
mean T1/2 of the IT-combination almost doubled over the complete treatment course
(Table 4). This may be explained by a reduction of available target antigens, which act
as an antigen sink especially during the first infusion(s).
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Table 3 Pharmacokinetic parameters determined over the complete treatment course
Patient No. IT T1/2 (h) AUC Cl (L/h) Vd (L) Cmax
(dose, mg/m2) (µg·h/ml) (ng/ml)
1 SPV-T3a-dgA 3.4 ± 0.6 5.6 ± 0.6 0.36 ± 0.04 1.8 ± 0.2 1,830
(2, 2, 4) WT1-dgA 5.5 ± 1.2 5.3 ± 0.8 0.37 ± 0.06 3.0 ± 0.3 1,380
IT-Combination 4.0 ± 0.7 10. 5 ± 1.3 0.19 ± 0.02 1.1 ± 0.1 3,210
2 SPV-T3a-dgA 6.5 ± 1.0 3.4 ± 0.3 0.59 ± 0.06 5.6 ± 0.5 720
(2, 2, 4, 4) WT1-dgA 6.7 ± 1.4 3.9 ± 0.5 0.5 ± 0.07 5.0 ± 0.6 930
IT-Combination 6.6 ± 1.2 7.3 ± 0.8 0.28 ± 0.03 2.6 ± 0.3 1,650
3 SPV-T3a-dgA 6.9 ± 0.8 9.5 ± 0.7 0.64 ± 0.05 6.4 ± 0.4 675
(4, 4, 4, 4) WT1-dgA 9.1 ± 1.4 3.4 ± 0.3 0.58 ± 0.06 7.6 ± 0.6 545
IT-Combination 6.9 ± 0.8 12.4 ± 0.9 0.32 ± 0.02 3.2 ± 0.2 1,220
4 SPV-T3a-dgA 9.2 ± 1.5 12.2 ± 1.1 0.32 ± 0.03 4.4 ± 0.4 910
(4, 4, 4) WT1-dgA 8.8 ± 2.7 7.5 ± 1.3 0.54 ± 0.09 6.8 ± 1.2 668
IT-Combination 9.1 ± 1.9 19.7 ± 2.3 0.20 ± 0.02 2.7 ± 0.3 1,560
T1/2, plasma half-life; AUC, area under the concentration versus time curve; Cl, clearance; Vd, volume of dis-
tribution; and Cmax, maximum plasma concentration. 
Safety
The adverse events noted during the first 6 weeks following initiation of therapy are list-
ed in Table 5. Because of the advanced disease of the patients, the etiology of the
observed clinical events was obscured by multiple medical complications and con-
comitant medications. Patient 1 and 4 died during therapy due to worsening of com-
plications already existing before start of the treatment, patient 1 from progressive mul-
tiorgan failure, patient 4 to generalized aspergillosis in combination with a
cytomegalovirus (CMV) infection. Those symptoms thought to be related to the IT-
combination were mild and transient. Patient 1 demonstrated edema in his shoulder
not associated with weight gain, potentially due to limited capillary leakage. Patient 3
experienced episodes of fever during and between the IT-combination infusions. This
fever may have been caused by a viral infection as well (see biological responses).
Patient 4 demonstrated a rise of plasma CK-levels (not accompanied by myalgia) to 280
U/l on day 9 of therapy, being 1.45 times the upper limit of the normal range for men. 
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Figure 5 Plasma clearance curves
IT-combination plasma clearance curves are shown from patient 1 (treated with 2, 2, and 4 mg/m2) (❍);
patient 2 (2, 2, 4, and 4 mg/m2) (❑); patient 3 (4, 4, 4, and 4 mg/m2) (s); and patient 4 (4, 4, and 4 mg/m2)
(✕). IT-combination plasma concentrations were deduced by summation of the individual values as deter-
mined for SPV-T3a-dgA and WT1-dgA.
Table 4 The T1/2 (mean ± SD) determined over the separate infusions
Infusion No.
1 2 3 4 
(n=4) (n=4) (n=4) (n=2)
SPV-T3a-dgA 4.5 ± 0.8 5.4 ± 0.7 6.5 ± 2.8 6.2 ± 1.4
WT1-dgA 3.2 ± 1.5 8.3 ± 4.8 7.9 ± 2.0 9.0 ± 3.3
IT-Combination 3.8 ± 1.3 5.7 ± 1.5 7.1 ± 2.2 7.1 ± 0.4
The increase was not accompanied by a rise in the heart muscle isomer creatine kinase
MB (CK-MB). Patient 4 had aphasia of short duration (<1 hour) 1 day after the first infu-
sion of the IT-combination. At that time he was taking cyclosporine and had hemolysis
with high reticulocyte counts, progressive thrombocytopenia, and fragmented red cells
in the blood smear. It was concluded that aphasia was associated with cyclosporin-
induced thrombotic thrombocytopenic purpura (TTP) and was not caused by the IT-
combination (aphasia has been reported as a side-effect of other immunotoxins19-21).
Cyclosporine was withdrawn and aphasia did not recur despite the further administra-
tion of the IT-combination. 
Immunogenicity
Patient plasma samples were measured frequently before, during and after the trial for
human-anti-mouse and human-anti-ricin antibodies (HAMA and HARA, respectively).
No antibodies against SPV-T3a nor WT1 were detected in any of the cases. Patient 4
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Total no. Grades 3/4 All adverse events likely
adverse events related to IT-combination
Allergy/Immunology 0 1b
Audiotory/Hearing 0 0
Blood/bone marrow 0 0
Cardiovascular 0 1c
Coagulation 1d 0
Constitutional symptoms 2e 1b
Dermatology/skin 0 0
Endocrine 0 0
Gastrointestinal 0 0
Hemorrhage 0 0
Hepatic 1f 0
Infection/febrile neutropenia   2g 0
Lymphatics 0 0
Metabolic/Laboratory 0 0
Musculoskeletal 0 1h
Neurology 1i 0
Ocular/visual 0 0
Pain 0 0
Pulmonary 0 0
Renal/Genitorurinary 0 0
Sexual/reproductive 0 0
Syndromes 0 0
Table 5 Adverse Events observed during the first 6 weeks of therapya
a CTC-NCI criteria (version 2.0), using the bone marrow transplantation-specific scaling when applicable.
b Episodes of fever during and between infusions
c Limited capillary leakage
d TTP
e 40% decrease Karnofsky (n=2)
f Transient rise of SGOT & SGPT (after day 24)
g Aspergillosis, CMV-infection
h Rise in CK-levels to 1.45 times upper normal value
i Transient aphasia (<1 hour), probably related to TTP
demonstrated a weakly positive HARA titer, 8 times the pretreatment value, on day 8
(one day before his death).
Biological Responses
Biological responses were monitored by flow cytometric evaluation of circulating T cells
and/or NK cells. The concentrations of NK cells were too low to enable a reliable quan-
tification with NK-specific markers. Therefore, NK cells and T cells were identified
simultaneously using a mixture of a fluorescent-labeled CD2 (binding T cells and NK
cells) and a CD5 MoAb (binding T cells). Figure 6 shows the amount of circulating
T/NK cells expressed as percentage relative to the concentration at start of therapy.
Patient 2 could not be adequately monitored due to the low initial number of circulat-
ing T/NK cells (about 6x107/l). All 3 evaluable patients already demonstrated a remark-
able reduction of T/NK cells during the first administration of IT-combination. Imme-
diately after the 4 hours of infusion, the number of circulating T/NK cells of patient 1,
3, and 4 had dropped to 17%, 8% and 24% of the pretreatment level, respectively. For
patient 1 and 4, this number gradually declined to 1 to 3 % after the third infusion.
Patient 3, in contrast, showed signs of a rebound of NK/T cells between the infusions.
After the last infusion, a progressive expansion of T/NK cells was observed resulting in
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Figure 6 Number of T/NK cells after IT-combination treatment
Patient 1 () and 4 (❍) received 3, and patient 3 () received all of the 4 planned IT-combination doses, given
as 4-hour infusions at 48-hour intervals. The arrow beneath the x axis indicates the start of the first infusion.
T/NK cells were identified by being CD2+ and/or CD5+. Their number was expressed as percentage relative to
the concentration at start of therapy (being 0.7, 1.0, and 0.2 x109 cells/l for patient 1, 3, and 4, respectively).
The inlay figure represents the amount of T/NK cells of patient 3 as determined over a longer period.
a peak concentration of about 45 times the pretreatment value at day 14. Flow cyto-
metric analysis with CD4/CD8 MoAb and a T-cell receptor Vβ-panel pointed out that
these cells were virtually all CD8+ and oligoclonal of origin. At day 18, the number of T
cells had decreased again to about 5 times the pretreatment level (probably by apopto-
sis as suggested by annexin staining, data not shown). These observations, combined
with the episodes of fever patient 3 experienced during the first week, are suggestive for
a T-cell response after a viral infection.
The slow B-cell repopulation following stem cell transplantation prevented a reliable
quantification of circulating B cells in patients 1, 2, and 3. The concentration of periph-
eral blood B cells of patient 4 showed a normal biological fluctuation (0.1- 0.2 x 109/l),
which was not affected by the IT-combination. Moreover, the complete blood counts
and leukocyte differential of all patients revealed no toxicity towards any of the other
hematopoetic lineages (data not shown), thereby illustrating the selectivity of treatment
for T/NK cells.
Skin biopsy specimens from patient 2 clearly demonstrated the biological efficacy of the
IT-combination treatment (Figure 7). The microscopic appearance before treatment is
typical for severe acute GVHD, with scattered infiltration of lymphocytes and a severe-
ly affected epidermal basal layer. After treatment, no remaining signs of lymphocyte
infiltration could be detected, and the basal epidermis had regained its natural well-
organized configuration. The intestinal GVHD of patient 3 was confirmed by a biopsy
from the colon performed at day -5 (grade 3). When repeated at day 31, biopsy demon-
strated a marked reduction of lymphocyte infiltrates without further signs of active
GVHD. In patient 4 only a post mortem liver sample could be taken. Microscopic analy-
sis revealed extensive cholestasis. Notably, no infiltrating lymphocytes could be detect-
ed.
Clinical Responses
Patient 1 showed a slight but clear improvement of his skin, from grade 4 to 3, starting
at day 4. His (abnormal) liver functions remained stable; his gastrointestinal tract could
not be objectively monitored due to administration of morphine. After 7 days of thera-
py, he died as a consequence of multiorgan failure. Patient 2 showed a dramatic reduc-
tion of his grade 4 GVHD of the skin to grade 0/1, starting 4 days after the first infu-
sion and lasting for about 1.5 month. He then developed a modest relapse, GVHD
grade 2 of the skin, which responded well to standard therapy of relatively low-dose cor-
ticosteroids supplemented with UV-B radiation. Patient 2 died 8 months after the IT-
combination administration due to generalized aspergillosis and toxoplasmic
encephalitis. Patient 3 showed strong improvement of his intestinal GVHD, grade 2 to
grade 0, within 7 days after initiation of therapy. Apart from a mild and controllable
GVHD reaction of his skin, grade 1 to 2 responding on low-dose corticosteroids, he
showed no further signs of active GVHD. Two months after initiation of therapy, patient
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Figure 7 Skin biopsies specimens
Skin biopsies were obtained form patient 2 taken just before (A), and two weeks after (B) treatment with the
IT-combination. The appearance of the skin before treatment is typical for severe GVHD. A scattered infiltra-
tion of lymphocytes can be observed, localized primarily around the blood vessels and the junctional region of
dermis (lower side) and epidermis (upper side). The epidermal basal layer is destroyed and the epidermis is dis-
rupted from the basal lamina. Following treatment, no remaining signs of lymphocyte infiltrations were
detectable. The basal layer had regained its natural well-organized configuration (original magnification x100,
hematoxylin-eosin)
A
B
3 died of a bacterial infection. Patient 4 showed a more or less stable GVHD of his liver
during the 7 days of treatment. He died due to a generalized aspergillosis in combina-
tion with a CMV infection on day 8.
D I S C U S S I O N
The in vitro efficacy data demonstrate that simultaneous application of SPV-T3a-dgA
and WT1-dgA results in a synergistic cytotoxicity, leading to an approximately 99% elim-
ination of activated T cells. A comparable synergism has been described for other IT
combinations as well.15,22-28 The most obvious advantage above single IT-treatment is
that fewer target cells will be negative for multiple antigens than for a single antigen. In
addition, the cells that express substantial levels of multiple target antigens may be
loaded with more IT molecules. When the respective IT follow a different intracellular
routing, the chance to escape the cytotoxic activity of the IT may be further reduced.
With respect to anti-T-cell IT, reports addressing the combination approach are thus far
focused on in vitro applications, including the purging of bone marrow grafts.15,22-24 In
this report, we state that the combination of SPV-T3a-dgA and WT1-dgA appears appro-
priate for the in vivo elimination of unwanted T cells as well. This particular combina-
tion affords important benefits that surpass the “common synergism” as observed with
the combinations of anti-T cell IT described so far.
SPV-T3a was selected as CD3 MoAb based on its IgG2b-isotype which strongly reduces
the risk of cytokine release syndrome.29,30 The presence of a CD3-IT provides instant
immunosuppression independent of dgA-based cytotoxicity (Figures 2 and 3). This may
be of vital importance in vivo during treatment of acute life-threatening situations such
as refractory GVHD. The limited (AICD) as well as temporal nature (blocking and mod-
ulation of CD3/TCR) of the underlying mechanisms provide arguments for making a
“real killer” of SPV-T3a by conjugating it to dgA. The inclusion of the CD7-IT is essen-
tial, apart from the above-mentioned synergism, because it makes NK cells a target for
the IT-combination as well (Figure 4). Accumulating evidence points at a distinctive
role of NK cells in the pathophysiology of GVHD.17,18
The pioneer work of Vitetta and colleagues was of great value in designing the clinical
pilot-study. They thoroughly studied the in vivo efficacy of RFB4-dgA (CD22) and HD37-
dgA (CD19) in treating patients with non-Hodgkin Lymphoma in relation to different
dose regimens.13,20,21,31-33 In the present study, four patients with refractory acute
GVHD have been treated with individual doses of 2 or 4 mg/m2 IT-combination,
according to their intermittent bolus infusion protocol. The mean T1/2 of SPV-T3a-dgA
and WT1-dgA resembled those of RFB4-dgA and RFB5-dgA (6.1-7.8 hours), the latter
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being a CD25-IT for the treatment of Hodgkin lymphoma.34 The blood clearance of
these IT is more than twice as fast than reported for HD37-dgA (T1/2 of 18.2 hours). As
with RFB4-dgA and RFB5-dgA, the clearance appeared to be influenced by circulating
target cells. In contrast to RFB4-dgA and RFB5-dgA, this did not result in large inter-
patient variations. Instead, the T1/2 of the IT-combination increased about 2-fold during
the entire treatment course, probably due to (1) the rapid elimination of “MoAb-cap-
turing” target cells (Figure 6), and/or (2) by a reduction of available binding sites per
cell (modulation/occupation). The latter possibility especially holds true for CD3 (see
also Figure 3b). The CD7-antigen, in contrast, demonstrates a rapid re-expression of
free antigen, resulting in the restoration of pre-treatment expression levels within 48
hours (in vitro and in vivo observations, data not shown). Three patients suffered from
severe GVHD that was more or less restricted to the skin, gastrointestinal tract, and
liver, respectively. Their relative narrow-ranged T1/2 and Cmax demonstrates that the type
of organ involved has no major impact on the pharmacokinetics. The single exception
was the patient suffering from a generalized GVHD (affecting skin, liver and gastro-
intestinal tract) in combination with a severe kidney failure. His about 2-fold higher
Cmax may reflect a different IT handling due to his worsening multiorgan failure.
In three patients, Cmax exceeded 1.2 to 1.6 times and in 1 patient Cmax exceeded 3.5
times the “clinically save threshold level” as defined for RFB4-dgA and HD37-dgA (1
µg/ml).13,20,32 Drug-related toxicities appeared to be restricted to limited capillary leak-
age and a modest rise of CK-levels (both n = 1). This may be the result of the IT-com-
bination encompassing two distinct IT, each having a different spectrum of side effects
(resulting in a distribution and, thereby, reduction in severity of drug-related toxicities).
This is in agreement with observations of Vallera et al.35 and Onda et al.36, who both
reported on comparable IT (directed against the same target cell/antigen and contain-
ing the same toxin), that displayed different toxicity profiles when tested in the same
mouse model. None of the 4 patients treated with the IT-combination developed
detectable HAMA. Only 1 patient showed a positive HARA titer (8 times baseline level).
Apart from the small population size, this may be attributed to the huge dosages of cor-
ticosteroids administered, and to incomplete reconstitution of the B cell compartment
early after transplantation.
The design of the pilot study does not allow an estimation of long-term toxicities (e.g.
increase in opportunistic infections or secondary malignancies). Three of the 4 patients
treated so far eventually died of an infection. The IT-combination can not be excluded
as a contributing factor to the underlying immunosuppression. However, a realistic
long-term safety profile can only be obtained when the IT-combination is applied with-
out extensive preceding and concomitant second-line medication. At least theoretical-
ly, based on its short T1/2 and narrow specificity range, the IT-combination is expected
to accomplish a relatively limited immunosuppression by only temporarily affecting the
T/NK cell compartment. Moreover, the composition of the IT-combination is better
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defined and expected to vary less than that of ATG/ALG37-39, which use is often associ-
ated with sustained T cell depletion.40,41 From this viewpoint, it appears encouraging
that the third patient showed a strong oligoclonal T-cell expansion directly after treat-
ment with the IT-combination. The presumed antiviral T-cell response was not associ-
ated with a relapse of GVHD. This suggests a strong immunogenicity of the respective
antigen and/or some form of treatment selectivity towards activated cells. The latter is
in agreement with the in vitro observations and might be explained by the fact that on
activation T cells show an increased expression of the CD7 target-antigen9,10 and
become vulnerable for CD3-triggered AICD.42,43
All patients showed a response, ranging from the elimination of the majority of circu-
lating T/NK cells, to the dramatic clinical responses as observed in the patients 2 and
3. The biphasic pattern of T/NK cell removal indicates that multiple mechanisms are
involved, some of which have not been observed in vitro. As for the in vitro efficacy data,
the IT-combination needs several days before it displays its full killing capacity. This is
in accordance with observations of Beyers et al.5, who reported that it took 5 daily infu-
sions of H65-ricin A (CD5) to achieve a more or less gradual reduction of T cells to 20%
of the initial number. In contrast, the IT-combination induced in vivo a massive and
rapid reduction of T/NK cells already during the first four hours of infusion. Compara-
ble biological responses have been described for native murine MoAb44-46, including
anti-CD3/TCR MoAb of IgG2b isotype.47,48 The underlying mechanism is not fully clear
yet. Some indirect evidence is provided that MoAb SPV-T3a is responsible for this ini-
tial rapid T-cell reduction. Tax and colleagues (unpublished observation, W.J.M.T.)
demonstrated that nonconjugated MoAb WT1 did not influence the number of circu-
lating T cells when administered in vivo to renal patients for the treatment of graft rejec-
tion. In addition, flow cytometric analysis of blood samples of the first patient demon-
strated that the minor population of CD3-CD7+ cells (mostly NK cells) was reduced at a
much slower rate (up to 2 days) than the CD3+CD7+ T cells (data not shown). In gen-
eral, reduction of lymphocytes by native murine MoAb is often transient, a few days or
less. In the present study, the initial rapid elimination was followed by a more gradual
but sustained reduction of T/NK cells. This suggests a dgA-based elimination of target
cells, which is supported by the in vitro killing capacity of the IT-combination observed
at concentrations obtained in vivo.
It is impossible from the clinical data to determine the exact contribution of SPV-T3a-
dgA and WT1-dgA (or their MoAb-moieties) to the observed biological and clinical
responses. Unfortunately, no animal models are available that allow an efficacy evalua-
tion of the individual components (SPV-T3a does not bind monkey-CD3). The high tol-
erability of the IT-combination argues against the clinical testing of theoretically less
effective individual components (being single IT or MoAb). Instead, further studies
should be focussed on elucidating the full potency of the IT-combination in its present
form. Apart from dose optimization and application in an earlier phase of GVHD, this
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may include the treatment of alternative indications that potentially benefit from the in
vivo elimination of T cells.
The authors are aware of the limited nature of the clinical data obtained so far. Howev-
er, the major finding that emerged from these data is that the IT-combination concept
might work. Substantial biological as well as clinical responses have been observed in
the absence of acute severe toxicities. This is especially meaningful considering the
extensive pretreatment of the enrolled patients. Ideally, further studies will point out
that the IT-combination forms a safe and effective tool for helping control certain dis-
eases mediated by T cels.
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SUMMARY AND DISCUSSION
S U M M A R Y  A N D  D I S C U S S I O N
This thesis addresses the use of ITs in relation to hematological disorders. Chapter 1
provides a general overview of the mechanisms of action and current status of ITs,
whereas Chapter 2 focuses on the potential applications in the field of hematology. The
subsequent Chapters 3 to 5 describe part of the institutional fundamental research per-
formed to improve this form of therapy. In Chapters 6 and 7, the rationale as well as
the ‘in house’ preparation and first clinical results of an IT-combination for GVHD are
addressed. Hereinafter, Chapters 3 to 7 are discussed in more detail followed by a gen-
eral perspective regarding the current and future status of ITs.
Chapter 3 describes a comparison of the internalization and cytotoxicity of an anti-CD3
ricin A chain IT (WT32-RTA). The study is based on an improved method to determine
the cellular uptake of radiolabeled MoAb/IT. Initially, internalization studies were solely
relying on cell-associated radioactivity. The activity removable by acid or protease treat-
ment formed a measure for membrane bound MoAb/IT, whereas non-removable activ-
ity represented the amount of internalized molecules. Though very useful in studying
several IT-related phenomena, this method had a major shortcoming. Intracellularly
processed (read: degraded) and subsequently exocytosed MoAb/IT was not taken into
account. With regard to IT, however, these molecules could very well have contributed
to the intoxication of the cell by delivering the toxin before being processed. When
studying internalization, it is therefore important to measure the amount of processed
and shed MoAb/IT-fragments in the culture supernatant as well. This was hampered,
initially, by the presence of other low weight radioactive material in the starting materi-
al. Removal of this material was cumbersome, involving dialysis or repetitive dilu-
tion/concentration steps of the radioactive starting material. Some investigators cir-
cumvented this problem by preloading target cells with radiolabeled MoAb/IT at 4°C,
and subsequently washing out small radioactive particles and unbound MoAb/IT. The
actual internalization studies could then be performed at 37°C, with intracellularly
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processed and shed MoAb/IT now being readily detectable as the low weight radioac-
tive material emerging in the supernatant. A limitation of this strategy, however, was the
absence of unbound MoAb/IT surrounding the target cells. Normally, this excess of
MoAb/IT influences the MoAb-antigen binding equilibrium, and forms a ‘sink’ for the
binding of re-expressed antigen. With the introduction of dispensable concentrators,
the extensive removal of low weight radioactive material came within practical reach (to
<0.3% of the total radioactivity). Consequently, internalization studies could be per-
formed in the continuous presence of unbound MoAb/IT and more accurately reflect-
ed the therapeutic situation. 
When thus applied to study the internalization of the CD3 MoAb/IT with leukemia T-
cell line Jurkat, an ongoing biphasic cellular uptake of MoAb/IT could be demonstrat-
ed. This internalization was characterized by a rapid initial uptake, followed by slower
but progressive internalization driven by the constant re-expression of CD3-antigen.
Addition of cytotoxicity enhancers NH4Cl or monensin retarded intercellular degrada-
tion, resulting in an increased number of intracellularly present IT/MoAb. This should
increase the possibility of cytoplasmatic deliverance of the toxin-moiety and, thereby,
lower the amount of internalized IT necessary for intoxication of the cell. These obser-
vations closely matched the kinetics of cytotoxicity as determined in a protein synthe-
sis inhibition assay. Both prolongation of the incubation time and addition of NH4Cl or
monensin clearly increased the efficacy of the CD3-IT towards Jurkat cells. An interest-
ing observation was that the IT-induced cytotoxicity was characterized by a lag period
due to a delay in either the internalization or the subsequent processing of membrane
bound IT. Translated to the ex vivo purging of bone marrow, the above results argue for
a 24 h IT-incubation in the presence of either NH4Cl or monensin to ensure an optimal
purging efficacy, also to cells with low antigen density, without causing harm to normal
progenitor cells.
Looking at a future role of internalization studies, they may be of help in determining
optimal dose schedules for in vivo treatment. They could provide a rationale for select-
ing either a continuous or bolus infusion protocol, depending on their effect on inter-
nalization. When considering multiple bolus infusions, internalization studies may help
to identify the optimal interval. Increasing the time between infusions, for instance, may
render target cells more vulnerable for the subsequent dose by allowing a more com-
plete re-expression of antigen.
Another example of the relevance of internalization studies is described in Chapter 4.
This study addresses the striking discrepancy in cytotoxicity of two anti-CD19 ricin A-ITs
differing in isotype only (IgG1 and IgG2a). Internalization experiments with both anti-
CD19 MoAb, as well as with their F(ab’)2 fragments, revealed that the presence of the
IgG1 Fc-part enhanced the cellular uptake. The involvement of FcγRII (CD32) in this
process was demonstrated by a decreased cytotoxicity of the IgG1-IT (and not IgG2a-
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IT) in the presence of FcγRII-blocking MoAb. These results suggest that the IgG1 Fc-
part of membrane bound anti-CD19 IT interacts with FcγRII, which supports the cellu-
lar uptake of the antigen-IT complex analogous to the mechanism described by Kur-
lander. Additional experiments identified functional FcγRIIa as the responsible
FcγR-isoform. The tremendous increase in potency as compared to the relative modest
rise in internalization (~100-fold and 3-fold, respectively), suggests that the enhanced
uptake is accompanied by a different intracellular routing which favors ricin A toxicity.
Alternatively, the increased number of intracellular molecules may exceed a critical
threshold above which the cell is no longer capable of efficiently inactivating the IT. The
relevance of this phenomenon for other ITs has to be determined yet. Additional exper-
iments with an IgG1 anti-CD22 IT revealed no effect of FcγRII-blocking on cytotoxicity.
It should be noted, though, that the intracellular routing of anti-CD22 ITs is more effec-
tive than that of anti-CD19 ITs (as indicated by a superior toxicity despite similar or
lower internalization rates). Any favorable effect of the IgG1-isotype might therefore
only marginally influence the already high efficacy of anti-CD22 ITs. Nevertheless, the
above study forms a clear example of the potential importance of the MoAb isotype on
IT efficacy. This will be even more apparent regarding in vivo applications, considering
the potential interactions with the patient’s immune system. As such, these data pro-
vide an argument against the routine exclusion of MoAb Fc-fragments from recombi-
nant fusion toxins. Though being technically more convenient, Fv-based ITs lack the
(potential) benefit of Fc-mediated effector mechanisms contributing to, or even syner-
gizing, the toxin-based elimination of target cells.
Prior to clinical use, ITs have to be extensively screened for activity against target and
non-target cells. Chapter 5 describes a sensitive flow cytometric (FCM) method capa-
ble of determining IT-induced cell kill in freshly derived patient-samples. This method
is based on the FCM determination of surviving target-cells following staining with via-
bility markers propidium iodine (PI) and calceine (Calc). The exact quantification of sur-
viving cells was enabled by admixture of a known concentration of inert beads prior to
FCM-analysis. An important finding using this method was that IT-based inhibition of
protein synthesis is not directly accompanied by the physical disruption of the cell
membrane. A post-treatment period of several days was necessary to enable full expo-
sure of the IT-induced cell kill, comparable to that as determined with clonogenic
assays. 
As demonstrated in Chapter 5, the described method enables the evaluation of target
cell depletion in a heterogeneous population as blood or BM. The use of a cell-specif-
ic, fluorescence-labeled, MoAb is most straightforward, enabling live/death discrimina-
tion and target-cell identification in one analysis. For this approach to be useful, the tar-
get-cell needs to express a specific antigen besides the target-antigen already used for
therapy. The latter is inappropriate as this antigen might be modulated or covered by
the therapeutic MoAb/IT. Moreover, residual malignant cells may be enriched for cells
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with low levels of target-antigen expression. When no appropriate ‘identification-anti-
gen’ is present, target cells may be identified by PCR-amplification of a cell specific
DNA-sequence. This requires the pre-sorting of the viable fraction to prevent the DNA
of IT-eliminated cells from contributing to the PCR-signal. In practice, triple-sorted
viable cells should contain less than one in 106 erroneously sorted non-viable cells,
matching the detection limit of a sensitive PCR-assay. 
The flowcytometric analysis of cell kill has now been applied in various studies evaluat-
ing the efficacy of varying IT towards different cell types, including freshly derived het-
erogeneous samples.1,2 These studies confirmed the relevance of directly measuring
the number of surviving cells, and suggest this assay may prove a helpful tool in opti-
mizing IT-therapy. As such, it forms a valuable addition to the conventional clonogenic
and protein synthesis inhibition assays.
The first part of Chapter 7 describes the experiments that provided the rationale for the
development of an IT-based therapy for aGVHD. These experiments pointed out that
anti-CD3 and anti-CD7 ricin A-IT (SPV-T3a-dgA and WT1-dgA, respectively), act syner-
gistically in killing T cells. The most obvious advantage of using a combination of ITs is
that fewer target cells will be negative for multiple antigens than for a single antigen.
Moreover, cells expressing both target-antigens may be loaded with more IT molecules.
Apart from this ‘common synergism’, the particular combination of SPV-T3a-dgA and
WT1-dgA affords important additional benefits. The presence of a CD3-IT provides
instant immunosuppression, which relies on the binding of the CD3/T-cell-receptor
complex (CD3/TCR) and is independent of dgA-based toxicity. The underlying mecha-
nisms, modulation of the CD3/TCR complex and activation induced cell death (AICD),
may be of vital importance in vivo during treatment of acute life-threatening situations
such as refractory GVHD. The anti-CD3 MoAb SPV-T3a was selected based on its ‘non-
T-cell-activating’ IgG2b-isotype which strongly reduces the risk of cytokine release syn-
drome (associated with the use of ‘activating’ CD3 MoAb). Inclusion of the CD7-IT is
essential, apart from the above mentioned ‘common synergism’, since it makes NK
cells (largely CD3-/CD7+) a target for the IT-combination as well. Accumulating evidence
points to a distinctive role of NK cells in the pathophysiology of aGVHD. Altogether,
these results formed the base for the clinical evaluation of the IT-combination in
patients with refractory aGVHD.
The conversion of laboratory experiments to the early clinical studies asks for a revolu-
tionary change of the production process. Apart from the scale up of equipment and
materials, the handling, purity and activity of the final product have to meet stricter
requirements. It would be most straightforward to outsource such productions to
authorized contract manufacturers with relevant experience. Unfortunately, the required
financing often forms a major obstacle. Even early clinical studies are generally consid-
ered ‘too less fundamental’ to qualify entirely for regular scientific granting. Potential
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pharmaceutical partners, on the other hand, often prefer clear signs of clinical efficacy
before taking the obvious risk of investing in experimental drugs. To overcome this
impasse, and supported by a grant of the government (technology foundation STW), it
was decided to perform most of the production and validation ‘in house’. Chapter 6
describes this production of clinical grade material as performed at the Central Hema-
tology Laboratory under supervision of the department of Clinical Pharmacy, and with
the assistance, amongst others, of the departments of Pathology, Virology and the Cen-
tral Animal Laboratory. To ensure the highest possible safety and functionality of the
final product, previously a draft quality was formulated based on the FDA-document
‘Points to consider in the manufacture and testing of monoclonal antibody products for
human use’. Reports of the production of comparable ITs already tested in FDA-
approved trials formed an additional guideline. The actual production provided suffi-
cient material for the planned clinical pilot study. Yields were comparable to those pre-
viously reported in literature (>25% MoAb-recovery). The specifications of the final
products mostly matched those as prescribed in the draft-quality. The few minor devi-
ations, regarding the percentage unconjugated WT1 and the DNA-content of both WT1-
dgA and SPV-T3a-dgA, were, retrospectively, considered to be within an acceptable
range. Animal experiments revealed a murine LD50 (lethal dose for half of the animals)
equal, or higher, than that of similar ITs already in clinical use. The major concern
formed the cross-reactivity of SPV-T3a with the human esophagus, observed during the
in vitro screening of a human tissue panel. To evaluate the potential clinical relevance
of this observation, human doses IT-combination were administered to two cynomol-
gus monkeys (sharing the in vitro cross-reactivity). Neither toxicity nor binding of SPV-
T3a-dgA to the monkey esophagus could be detected. Notably, therapeutic serum con-
centrations (>1.8 µg/ml) were obtained for several hours in both monkeys without
acute irreversible toxicities occurring. The main side effect was a transient rise of CK-
levels, indicative for dgA-associated muscle injury. Altogether, the above data justified
the evaluation of the produced material in a clinical pilot-study for the treatment of life-
threatening aGVHD. As such, the ‘in house’ production can be considered an essential
stepping stone towards the future large-scale productions required for the actual regis-
tration studies.
So far five patients have been treated with three to four infusions of 2 or 4 mg/m2 IT-
combination, administered intravenously at 48-hour intervals. The second part of
Chapter 7 describes the results obtained with the first four patients. The T1/2 was ~7
hours, with peak serum levels ranging from 258 to 3,210 ng/ml. The infusions were well
tolerated. Drug-associated side effects were restricted to limited edema, fever, and a
modest rise of creatine kinase levels, suggesting the maximal tolerated individual dose
lies well above 4 mg/m2. Remarkably, the IT-combination did not provoke vascular leak-
age, or other serious toxicities, while the peak serum concentrations in all patients
either reached (n = 1) or exceeded (n = 4) the ‘clinically save threshold’ as defined for
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comparable IT (being 1 µg/ml). An explanation for this may be that administration of
two distinct ITs may result in a distribution and, thereby, dilution of individual side
effects. This is in accordance with observations of others who reported on almost iden-
tical ITs (directed against the same target cell/antigen and containing the same toxin),
which displayed different toxicity profiles when tested in the same mouse model. More-
over, the concomitant administration of high dose corticosteroids may have positively
affected the maximal tolerable dose. Notably, only one of the patients treated so far
developed low titer antibodies against ricin A. This may again be attributed to the high
dose corticosteroids. Alternative explanations are the incomplete reconstitution of the
B cell compartment early post-transplantation, and the successful depletion of acces-
sory T cells. Biological responses could be noted in all five patients, as characterized by
a rapid and extensive drop of circulating T/NK cells. The biphasic pattern of this deple-
tion suggests the involvement of multiple mechanisms. The rapid depletion of T cells,
already observed directly after infusion, appears to be MoAb-related. While the subse-
quent more gradual but sustained elimination of T/NK cells points to a ricin A-based
mechanism. Noteworthy, one patient mounted an extensive CD8 T-cell response direct-
ly following treatment (indicative for an anti-viral immune response), not accompanied
with aggravating GVHD. The other patient whose peripheral T cells could be reliably
monitored for a longer period, demonstrated a gradual reconstitution of circulating T
cells starting two weeks after initiation of therapy. The accompanying shift in the TCR-
Vβ repertoire, suggested these were newly generated T cells. (patient No. 5, unpub-
lished observations). Two of the five patients already died during the first treatment
week, due to underlying diseases and pre-existing organ impairment. The three other
patients demonstrated extensive clinical responses, despite unresponsiveness to the
intensive pretreatment.
Though limited in nature, these preliminary data are suggestive for a clear therapeutic
window where, in contrast, hardly one existed for the other dgA-based IT tested so far.
This may be explained by the combination approach, which, on one hand, decreases
the overall toxicity, and, on the other hand, increases effectiveness by appealing on mul-
tiple, synergistic, effector mechanisms. Notwithstanding the clear biological and clini-
cal responses, all five patients eventually died due to transplantation related complica-
tions (mostly infections). These results are inherent to the type of study, only permitting
the enrollment of patients with very advanced and therapy-resistant disease (not
responding to cyclosporin plus 1g corticosteroids daily). The absence of severe side
effects, now justifies the treatment of a limited number of patients with less advanced
aGVHD. This enables the evaluation of the IT-combination in a more appropriate clin-
ical setting. Moreover, it should predict the suitability of the IT-cocktail for alternative
indications that may benefit from the temporary removal of T/NK cells. Most obvious
is the treatment of graft-rejection (either stem cells or solid organs). In addition, ani-
mal studies clearly demonstrated that anti-T cell IT may have a role in creating the prop-
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er immunologic environment for non-myeloablative stem cell transplantation, achiev-
ing tolerance induction, or even treating certain T-cell mediated auto-immune disor-
ders.
General perspective
The introduction of a new therapeutic strategy often creates high expectations regard-
ing its use for treating life-threatening diseases. These do not always reflect the
inevitable hurdles generally accompanying the development cycle of new drugs. As
such, ITs form no exception. Based on the initial reports, describing complete cures of
lethally tumor-xenografted mice, they seemed the ultimate representation of Paul
Ehrlich’s magic bullet concept. The subsequent translation of ITs to the clinic, howev-
er, revealed major obstacles preventing instant therapeutic success in man. Several of
the problems encountered resembled those previously seen in MoAb trials. Obvious
examples form the occurrence of humoral responses, in this case also directed against
the toxin-moiety, and the heterogeneous expression of target-antigens. Moreover, as
with MoAbs, the Phase I/II testing in patients with advanced bulky disease is not con-
sidered optimal to expose the full potential of this form of treatment. Most important-
ly, though, the clinical studies revealed serious toxicities, not previously detected to the
same extent in the test animals. Especially for ricin-based ITs, the occurrence of severe
vascular leakage dramatically narrowed the therapeutic window. As a consequence,
safely attainable serum concentrations appeared to be several-fold lower than those
previously determined to be effective in mice.3 Altogether, these early clinical results
tempered the initial hype, leaving only a limited number of old-time believers still trying
to make the concept work. Basically, their approach was to transfer ITs back to appro-
priate animal models, and to solve the individual obstacles with the help of new excit-
ing (recombinant-DNA) techniques coming available.4-6 As it looks now, there are
some serious indications that their persistence will be rewarded.
With respect to reduction of the immunogenicity, various strategies are currently being
explored. One is based on the conjugation of non-immunogenic human toxin equiva-
lents to either human antibodies, growth factors or cytokines. This approach already
resulted in the construction of several ‘fully human’ ITs with proven in vitro activity7-12.
Another strategy focuses on making the highly potent conventional toxins less
immunogenic by genetically altering the most immunogenic determinants, or by pegy-
lation of the molecule.13,14 Combined with routinely produced human MoAbs, these
may render ‘Stealth’ ITs being (almost) invisible for the patient’s immune system. A
third approach is based on transient repressing immune reactions by the co-adminis-
tration of immunomodulating agents.15,16 In order to anticipate on heterogeneous anti-
gen expression, the simultaneous use of multiple ITs have been addressed. Several ani-
mal studies convincingly demonstrated the synergistic efficacy of a cocktail of ITs.17-19
Additionally, the first clinical results obtained with such combinations are now being
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reported.2,20 Noteworthy, the IT-combination described in Chapters four and five
underscored the potential significance of MoAb-based effector mechanisms contribut-
ing to the overall IT efficacy.2 The superiority of the concomitant use of ITs with con-
ventional chemo/radiation therapy has been clearly demonstrated in several animal
experiments.21-23 These encouraging results should facilitate the clinical evaluation of
ITs in the more appropriate adjuvant setting. With regard to the dose limiting toxicities,
the most important finding is probably the unraveling of the cause of vascular leakage.
Baluna et al. of the group of Vitetta identified a sequence motif in the ricin A chain, pre-
sent in other toxins and the VLS-inducing cytokine IL-2 as well, which is responsible for
VLS by binding to and damaging endothelial cells.6,24-27 Future studies should point
whether deletions or mutations in this sequence, or the use of nondamaging blocking
peptides, may increase the therapeutic index of ITs prepared with the conventional
plant or bacterial toxins.
Altogether, these recent developments will undoubtedly result in the production of next
generation ITs with strongly improved in vivo characteristics. It appears that ITs are still
very much alive and ready to fulfill at least some of their clinical promises in the fore-
seeable future. As such, the recent FDA-approval of a recombinant IT for the treatment
of a refractory hematological malignancy (Ontak, DAB389IL-2), might be regarded as
an important and indicative turning point.
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S A M E N V A T T I N G
Immunotoxines (ITs) zijn hybride moleculen bestaande uit een zogenaamde monoclo-
nale antistof (MoAb) gekoppeld aan een effectieve gifstof (toxine). De gebruikte MoAbs
hebben de eigenschap dat ze zeer sterk, en met een hoge mate van specificeit, binden
aan een eiwit (antigeen) dat voorkomt op de buitenkant van de te vernietigen cel. Een-
maal in de bloedbaan ingespoten, zullen de ITs zich aan deze cellen kunnen binden.
Het IT-antigeen complex wordt vervolgens door de cel opgenomen (geïnternaliseerd),
waarna het toxine zijn werk kan doen en de cel zal uitschakelen (zie Figuur 1, Hoofd-
stuk 1). Daar de gebruikte toxines op eigen kracht de cel niet binnenkomen, treffen ITs
in principe alleen die cellen waartegen het MoAb gericht is.
Het UMC St Radboud introduceerde 15 jaar geleden als een van de eerste research cen-
tra het IT onderzoek in Nederland. De eerste klinische toepassing betrof de zuivering
van autologe beenmergtransplantaten van patiënten met een kwaadaardige bloedziek-
te. Doel van deze behandeling was de eventueel aanwezige kankercellen in het been-
mergtransplantaat op te ruimen om daarmee de kans op terugkeer van de kwaadaardi-
ge ziekte te verkleinen. De min of meer routinematige toepassing van deze behandeling
kan beschouwd worden als het startpunt van dit proefschrift. Deze toepassing leidde
op zichzelf tot additioneel onderzoek om de mate van opzuivering van het beenmerg
te verbeteren, alsook om deze op een betrouwbare mannier te monitoren. Internatio-
naal leidde het enthousiasme over de mogelijke therapeutische toepassingen onder-
tussen tot diverse (meest Amerikaanse) studies waarbij ITs aan patiënten werden toe-
gediend voor de bestrijding van diffuse en solide tumoren en uiteenlopende
immuunziekten. Aangemoedigd door de behaalde resultaten, speciaal op het gebied
van beenmerg- en lymfeklieraandoeningen, en ingegeven door de klinische behoefte,
besloot de afdeling Hematologie een op IT gebaseerde therapie te ontwikkelen voor
omgekeerde afstoting na beenmergtransplantatie (graft-versus-host disease: GVHD).
Dit proefschrift beschrijft een deel van het IT onderzoek zoals dat gedurende de laatste
tien jaar in het UMC St Radboud is uitgevoerd. Na een algemene inleiding (Hoofdstuk
1) en de positionering binnen de hematologie (Hoofdstuk 2) volgt een beschrijving van
het fundamentele laboratorium onderzoek (Hoofdstukken 3 en 5) en de opzet en eer-
ste klinische resultaten van een pilot-studie voor de behandeling van GVHD
(Hoofdstukken 6 en 7). In het hierop volgende worden Hoofstukken 3 tot en met 7 in
meer detail besproken, gevolgd door een algemene beschouwing over de huidige en
toekomstige rol van ITs.
Hoofdstuk 3 beschrijft een verbeterde methode om de cellulaire opname te bepalen
van radioactief gelabelde MoAbs of daarvan afgeleide ITs. Het bijzondere aan deze
methode is dat ze bij de bepaling van de totale internalisatie rekening houdt met mole-
culen die intracellulair zijn afgebroken en vervolgens door de cel zijn uitgescheiden. Dit
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is met name van belang voor ITs, waarbij dergelijke moleculen kunnen bijdragen aan de
intoxicatie van een cel door het toxine af te leveren alvorens te worden afgebroken.
Bovenstaande methode werd gebruikt om de relatie tussen internalisatie en effectiviteit
van een anti-CD3 IT (WT32-RTA) te bestuderen. Met behulp van leukemische T-cellijn
Jurkat, kon een voortdurende cellulaire opname van het anti-CD3 MoAb/IT worden
gedemonstreerd. Deze werd gekenmerkt door een snelle initiële opname gedurende de
eerste 12 uur, gevolgd door een langzamere maar voortdurende internalisatie gedreven
door constante reëxpressie van het CD3-antigeen. Toevoeging van NH4Cl of monensi-
ne vertraagde de intracellulaire afbraak, wat resulteerde in een toegenomen hoeveelheid
intracellulair aanwezig IT/MoAb. Theoretisch leidt dit tot een verhoogde kans op afgif-
te van het toxine, en daarmee een verlaging van het aantal geïnternaliseerde moleculen
benodigd voor de intoxicatie van de cel. Deze observaties kwamen sterk overeen met
de daadwerkelijke effectiviteit van het anti-CD3 IT zoals bepaald in een eiwitsynthese
inhibitie assay. Zowel een verlenging van de incubatietijd, alsook de toevoeging van
NH4Cl of monensine, leidde tot een verhoogde cytotoxiciteit ten aanzien van Jurkat cel-
len. Een interessante observatie hierbij was dat de maximale eiwitsynthese remming
iets leek na te lopen, ten gevolge van een vertraging in de internalisatie ofwel daarop-
volgende verwerking van membraangebonden IT. Vertaald naar de zuivering van been-
merg, pleiten bovenstaande resultaten voor een 24-uurs incubatie met IT in de aanwe-
zigheid van NH4Cl of monensine. Dit zou resulteren in een optimale effectiviteit, ook
ten aanzien van cellen met lage antigene dichtheid, zonder schade te berokkenen aan
normale hematopoietische progenitorcellen.
Voor wat betreft de toekomst, kunnen internalisatiestudies van pas komen bij de bepa-
ling van het optimale doseringsschema voor klinische studies. Zij zouden een onder-
bouwing kunnen leveren voor protocollen met een continue dan wel meerdere kortdu-
rende infusies, afhankelijk van het effect op de internalisatie. In het geval van
kortdurende infusies kunnen zij bovendien van nut zijn voor de bepaling van het opti-
male interval tussen twee opeenvolgende infusies. Verlenging van dit interval, bijvoor-
beeld, kan leiden tot een meer volledige reëxpressie van het doelwit-antigeen, en daar-
mee, een verhoging van de gevoeligheid voor een volgende dosis.
De relevantie van internalisatie studies wordt onderstreept in Hoofdstuk 4. Deze stu-
die behandelt het opmerkelijke verschil in effectiviteit tussen twee anti-CD19 ITs die
alleen verschillen in MoAb-isotype (IgG1 en IgG2a). Internalisatie studies met zowel
intact IgG als F(ab’)2 fragmenten, brachten aan het licht dat de aanwezigheid van het
anti-CD19 IgG1-Fc gedeelte resulteert in een verhoogde cellulaire opname. De rol van
Fcγ-receptor II (FcγRII: CD32) in deze kon worden aangetoond door een verlaagde effec-
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tiviteit van het anti-CD19 IgG1-IT in aanwezigheid van FcγRII-blokkerende MoAb. Deze
resultaten wijzen op een interactie van membraangebonden anti-CD19 IgG1-MoAb met
FcγRII, resulterende in een verhoogde internalisatie van het antigeen-IT complex, naar
analogie van het zogenaamde Kurlander-effect. Met behulp van additionele experimen-
ten kon (functioneel) FcγRIIa vervolgens geïdentificeerd worden als het verantwoorde-
lijke receptor-isotype. De relatief bescheiden toename in internalisatie gaat gepaard met
een onevenredige verhoging van de cytotoxiciteit (ongeveer 3-voudig en 100-voudig,
respectievelijk). Dit wijst erop dat de toename in internalisatie gepaard gaat met een
afwijkende intracellulaire route gunstig voor de effectiviteit van het toxine, ofwel dat de
hoeveelheid intracellulair IT een kritische grens overschrijdt waarboven ze niet meer
effectief geïnactiveerd kan worden. De relevantie van dit fenomeen voor andere ITs is
nog niet duidelijk. Additionele experimenten met een anti-CD22 IgG1-IT lieten geen
positief effect zien van de blokkade van FcγRII op de cytotoxiciteit. Echter, de intracel-
lulaire routing van anti-CD22 IT is veel effectiever dan die van anti-CD19 IT (gegeven de
superieure toxiciteit bij gelijke of lagere internalisatie). Enige positieve effecten van het
IgG1-isotype hebben daarom waarschijnlijk slechts een marginaal effect op de reeds
hoge effectiviteit van het CD22-IT.
Bovenstaande in vitro studie geeft een duidelijk voorbeeld van het potentiële belang van
het MoAb Fc-gedeelte op de uiteindelijke IT effectiviteit. Bij de daadwerkelijke klinische
toepassing zal dit nog duidelijker naar voren komen, denkend aan de mogelijke inter-
acties met het humane immuun systeem. Als zodanig vormen bovenstaande data een
argument tegen het routinematig uitsluiten van Fc-fragmenten bij zogenaamde ‘recom-
binante fusietoxines’. Deze missen de eventuele bijdrage van Fc-gebaseerde effector
mechanismen aan de toxine-gebaseerde opruiming van ongewenste cellen.
Voor de ontwikkeling van een optimale IT therapie is het van belang het aantal onge-
wenste cellen te bepalen dat ontsnapt aan verschillende behandelingschema’s. In
Hoofdstuk 5 wordt een gevoelige flowcytometrische methode beschreven om de IT-
geïnduceerde celdood in verse patïentenmonsters op een adequate wijze te kunnen
monitoren. Deze methode is gebaseerd op de flowcytometrische identificatie van dode
en levende cellen na kleuring met viabiliteitsmerkers. De exacte kwantificering van over-
levende cellen wordt mogelijk gemaakt door bijmenging van een bekende hoeveelheid
inerte bolletjes voorafgaande aan de analyse. Een belangrijke bevinding bij het gebruik
van deze methode was de totale omvang van de IT-geïnduceerde celdood pas na enke-
le dagen aangetoond kan worden. 
Zoals gedemonstreerd in Hoofdstuk 5, kan met de beschreven methode de opruiming
van ongewenste cellen in een heterogene populatie als bloed of beenmerg worden
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bestudeerd. Het meest eenvoudige is het om voor de identificatie van deze cellen
gebruik te maken van een fluorescerend celspecifiek MoAb. Dit vereist echter de expres-
sie van een ‘identificatie antigeen’ anders dan het therapeutisch gebruikte ‘doelwit anti-
geen’. Deze laatste kan gemoduleerd zijn of bezet met het therapeutische MoAb/IT.
Daarnaast kunnen de overblijvende cellen verrijkt zijn voor cellen met een lage expres-
sie van het doelwit antigeen. Als alternatief kan gekozen worden voor de PCR-amplifi-
catie van een celspecifieke DNA-sequentie. Pre-sorting van levende cellen moet in dit
geval voorkomen dat het DNA van dode maar nog aanwezige cellen ten onrechte bij-
draagt aan het PCR signaal. In de praktijk leidt een ‘triple-sort’ tot minder dan één op
de miljoen foutief gesorteerde dode cellen, wat overeenkomt met de detectielimiet van
een gevoelige PCR assay.
De flowcytometrische bepaling van IT-geïnduceerde celdood is inmiddels toegepast in
uiteenlopende studies, ondermeer voor de monitoring van IT-effectiviteit in heteroge-
ne, vers geïsoleerde, bloed- of beenmergmonsters van patiënten. Deze studies sugge-
reren dat deze methode zeer bruikbaar is voor de optimalisering van IT-therapie, en een
waardevolle aanvulling vormt op de conventionele assays. 
Het eerste deel van Hoofdstuk 7 beschrijft de experimenten die de onderbouwing
leverden voor de ontwikkeling van een IT-gebaseerde therapie voor aGVHD. Deze expe-
rimenten wezen uit dat een anti-CD3 en anti-CD7 IT (SPV-T3a-dgA en WT1-dgA, res-
pectievelijk), een synergistische werking vertonen ten aanzien van de eliminatie van T
cellen. Een algemeen voordeel van het gebruik van een combinatie van ITs is dat min-
der cellen negatief zullen zijn voor twee dan voor één antigeen. Bovendien kunnen cel-
len die beide antigenen tot expressie brengen beladen worden met meer IT moleculen.
Afgezien van dit ‘gewone’ synergisme, kent de combinatie SPV-T3a-dgA en WT1-dgA
nog een aantal extra voordelen. Het CD3-IT levert additionele immunosuppressie door
de binding van het CD3/T-cell-receptor (CD3/TCR) complex. De onderliggende oorza-
ken, modulatie van het CD3/TCR complex en activatie geïnduceerde celdood (AICD),
kunnen van vitaal belang zijn tijdens de behandeling van acute levensbedreigende situ-
aties zoals therapieresistente aGVHD. Het anti-CD3 MoAb (SPV-T3a) is geselecteerd
op basis van zijn ‘niet-activerende’ IgG2b-isotype, welke het risico op ‘cytokine release
syndrome’ sterk vermindert. De toevoeging van het CD7-IT is essentieel, afgezien van
het bovengenoemde ‘gewone’ synergisme, omdat het ook NK cellen (grotendeels CD3-
CD7+) elimineert. Er zijn steeds meer aanwijzingen voor de rol van NK cellen in de pat-
hofysiologie van aGVHD. Bovenstaande bevindingen vormden de wetenschappelijke
basis voor de klinische evaluatie van de IT-combinatie in patiënten met therapiere-
sistente GVHD.
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De vertaling van laboratoriumexperimenten naar (vroege) klinische studies vraagt een
grondige aanpassing van het productieproces. Afgezien van de opschaling van materi-
alen en grondstoffen, moeten de bewerking, zuiverheid en activiteit van het eindpro-
duct aan veel strengere eisen voldoen. Hoofdstuk 6 beschrijft de productie zoals uit-
gevoerd op het Centraal Hematologisch Laboratorium onder supervisie van de afdeling
Klinische Farmacie, en met de ondersteuning van, onder andere, de afdelingen Patho-
logie, Virologie en het Centraal Dierenlaboratorium. Om een zo hoog mogelijke veilig-
heid en functionaliteit van het eindproduct te garanderen, werd van te voren een ont-
werpkwaliteit geformuleerd gebaseerd op het FDA-document ‘Aandachtspunten in de
vervaardiging en het testen van monoclonale antilichaam producten voor humaan
gebruik’. Beschrijvingen van de productie en validatie van vergelijkbare IT die reeds
getest waren in FDA-goedgekeurde trials vormden een additionele richtlijn. De ‘in huis’
productie leverde voldoende materiaal op voor de voorgenomen pilot-studie. De speci-
ficaties van het eindproduct kwamen grotendeels overeen met de ontwerpkwaliteit. De
enkele uitzonderingen, aangaande het percentage ongebonden WT1 en de DNA-hoe-
veelheden van WT1-dgA en SPV-T3a-dgA, vielen, retrospectief, binnen aanvaardbare
grenzen. De LD50 (lethale dosis voor 50% van de dieren) voor muizen, kwam overeen,
of was zelfs hoger, dan die van vergelijkbare IT die reeds in de kliniek werden toegepast.
De voornaamste zorg betrof de kruisreactiviteit van SPV-T3a met humaan oesophagus
epitheel, waargenomen tijdens de in vitro screening van een humaan weefselpanel. Ter
bestudering van de klinische relevantie van deze bevinding, werden humane doses IT-
combinatie toegediend aan een tweetal cynomolgus apen. In deze studies kon geen
toxiciteit noch binding van het SPV-T3a-dgA aan de oesophagus worden aangetoond.
Therapeutische serumconcentraties (>1.8 µg/ml) werden in beide apen bereikt gedu-
rende meerdere uren, zonder dat er onomkeerbare acute toxiciteiten optraden. De
belangrijkste bijwerking was een tijdelijke verhoging van kreatine kinase (CK)-waarden,
wijzend op spierafbraak door het toxine.
Bovenstaande data rechtvaardigden de evaluatie van het geproduceerde materiaal in
een klinische pilot-studie voor de bestrijding van levensbedreigende aGVHD. De onder-
liggende ‘in huis’ productie kan wat dat betreft gezien worden als een essentiële stap
richting de toekomstige grootschalige productie voor de daadwerkelijke registratie-
studies.
Tot nog toe zijn vijf patiënten behandeld met drie of vier infusies van 2 of 4 mg/m2 IT-
combinatie, toegediend middels een vier uur durend intraveneus infuus met tussen-
pozen van 48 uur. De resultaten zoals behaald met de eerst vier patiënten staan
beschreven in het tweede deel van Hoofdstuk 7. De gemiddelde serum halfwaardetijd
was ongeveer 7 uur, met piek serumwaarden variërend tussen 258 tot 3.210 ng/ml.
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Ondanks dat piek serumconcentraties werden behaald die gelijk (n = 1) of boven (n =
4) de klinisch veilige grens lagen zoals gedefinieerd voor vergelijkbare IT (1 µg/ml), wer-
den geen ernstige toxiciteiten waargenomen. De bijeffecten waren beperkt tot een
geringe vochtretentie (n = 1), koorts (n = 2) en een lichte stijging van CK waarden (n =
1), wijzend op een maximaal tolereerbare doses van 4 mg/m2 of meer. Dit opmerkelijk
gunstige toxiciteitsprofiel is waarschijnlijk terug te voeren op de toediening van twee
verschillende ITs, welke mogelijk resulteert in een distributie en daarmee verdunning
van individuele bijeffecten. Daarnaast kan de gelijktijdige toediening van hoge doses
corticosteroïden de maximaal tolereerbare dosis positief beïnvloed hebben. Slechts één
van de tot nog toe behandelde patiënten ontwikkelde een geringe antilichaamrespons
tegen ricine A. Afgezien van de hoge dosering corticosteroïden, kan dit verklaard wor-
den door een onvolledige reconstitutie van het B-cel compartiment en/of de succes-
volle eliminatie van accessoire T-cellen door de IT-combinatie.
Alle vijf patiënten vertoonden een duidelijke biologische respons, gekenmerkt door een
gefaseerde daling van circulerende T/NK cellen. De initiële snelle depletie van T-cellen,
reeds gedurende de infusies, lijkt MoAb-gerelateerd, terwijl de daaropvolgende meer
geleidelijke daling van T/NK cellen wijst op een ricine A gebaseerd mechanisme. Een
patiënt ontwikkelde direct na de laatste infusie een sterke oligoclonale expansie van
CD8-positieve T-cellen, niet gepaard gaande met een terugkeer van de GVHD (indica-
tief voor een anti-virale immuun reactie). De andere patiënt wiens perifere T-cellen voor
een langere tijd gevolgd konden worden, liet twee weken na start van de behandeling
een geleidelijke terugkeer van circulerende (waarschijnlijk naïeve) T-cellen zien. Twee
van de vijf patiënten overleden voor toediening van het laatste infusie ten gevolge van
reeds bestaande complicaties. De drie overige patiënten vertoonden een duidelijke kli-
nische respons, ondanks dat hun ziekte niet gereageerd had op de voorafgaande
behandeling.
Bovenstaande gegevens wijzen op een duidelijke ‘therapeutische window’. Dit kan ver-
klaard worden door de combinatie-benadering die gelijktijdig de toxiciteit vermindert en
de effectiviteit verhoogt door een beroep te doen op meerdere, synergistische, effector
mechanismen. Niettegenstaande de duidelijke biologische en klinische responsen, zijn
alle vijf patiënten uiteindelijk overleden aan transplantatie gerelateerde complicaties
(meest infecties). Dit is inherent aan het type studie, welke alleen de behandeling van
patiënten met vergevorderde, therapieresistente, ziekte toestaat. De bemoedigende eer-
ste klinische resultaten rechtvaardigen nu de evaluatie bij patiënten met minder ver-
gevorderde GVHD. Daarnaast kunnen andere indicaties overwogen worden die baat
zouden hebben bij de tijdelijke opruiming van T- en NK-cellen. Meest voor de hand lig-
gend is de behandeling van afstoting na transplantatie (van stamcellen of solide orga-
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nen). Afgezien hiervan hebben dierstudies overtuigend aangetoond dat anti-T-cel ITs de
juiste immunologische omgeving kunnen creëren voor niet-myeloablatieve stamcel-
transplantatie, het realiseren van tolerantie-inductie, of zelfs de behandeling van bepa-
lde T-cel gemedieerde autoimmuun-ziekten.
Algemene beschouwing
De introductie van nieuwe therapeutische strategieën roept dikwijls hooggespannen
verwachtingen op ten aanzien van de behandeling van levensbedreigende ziekten. Deze
worden vaak gevolgd door de onvermijdelijke tegenslagen die veelal gepaard gaan met
de ontwikkeling van nieuwe medicijnen. ITs vormen hierop geen uitzondering. Volgend
op de eerste publicaties, die de genezing beschreven van muizen getransplanteerd met
levensbedreigende humane tumoren, werden ITs beschouwd als immunologische
‘magic bullets’. Gedurende de daaropvolgende vertaalslag naar de kliniek, stuitte men
echter op belangrijke obstakels die onmiddellijke therapeutisch successen in de weg
stonden. Een aantal van deze obstakels was reeds waargenomen bij de vroege MoAb-
studies. Duidelijke voorbeelden vormen het optreden van antilichaam-reacties, in dit
geval tevens gericht tegen het toxine, en de heterogene expressie van doelwit-antige-
nen. Afgezien hiervan, lijkt de opzet van Fase I/II studies, met de inclusie van patiën-
ten met therapie-resistente uitgebreide ziekte, niet optimaal voor de evaluatie van de
potentie van MoAbs of ITs. De belangrijkste tegenvaller was echter het optreden van
ernstige bijweringen welke voorheen niet in die mate bij proefdieren waren waargeno-
men. In het geval van ricine-gebaseerde ITs betrof dit met name ernstige ‘vaatlekkage
syndroom’. De hieruit volgende, relatief lage, maximaal tolereerbare doses resulteerden
in maximale serumconcentraties die beduidend lager lagen dan de therapeutische con-
centraties waargenomen in de oorspronkelijke muizenmodellen. Alles bij elkaar tem-
perden deze resultaten de oorspronkelijke hype, wat als gevolg had dat slechts een rela-
tief klein groep van onderzoekers van het eerste uur overbleef om het concept nieuw
leven in te blazen. De ITs werden hiertoe teruggebracht in het diermodel om daar de
verschillende obstakels één voor één aan te pakken met de beschikbaar gekomen nieu-
we revolutionaire technieken (o.a. recombinant DNA-technieken). Zoals het zich nu laat
aanzien, lijkt dit doorzettingsvermogen beloond te worden. 
Wat betreft de immunogeniciteit, worden momenteel verschillende strategieën toege-
past. Een van deze is gebaseerd op de identificatie van humane toxine-equivalenten
(b.v. humane RNases). Koppeling van dergelijke stoffen aan antilichamen, groeifacto-
ren of cytokines van humane origine, resulteert in principe in hybride moleculen met
lage of afwezige immunogeniciteit. Deze benadering heeft reeds geresulteert in de con-
structie van verscheidene ‘volledig humane’ ITs met bewezen in vitro activiteit. Een
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andere strategie is gericht op de verlaging van de immunogeniciteit van de uiterst
potente conventionele toxines. Dit kan ofwel door de genetische modificatie van de
meest immunogene determinanten, ofwel door deze chemisch af te schermen met
polyethyleen glycol (‘PEGylation’). In combinatie met humane MoAb, zou het gebruik
van dergelijke gemodificeerde toxines resulteren in zogenaamde ‘Stealth ITs’ welke
nagenoeg onzichtbaar zijn voor het immuunsysteem van de patiënt. Als alternatief voor
bovenstaande strategieën, bestaat er ook nog de mogelijkheid van een tijdelijke onder-
drukking van immuunreacties door een gedoseerd gebruik van immuun-onderdruk-
kende medicijnen.
De aanpak van heterogene antigene expressie wordt gezocht in de gelijktijdige toedie-
ning van meerdere ITs gericht tegen verschillende antigenen. Het synergistische effect
van dergelijke combinaties is inmiddels in verscheidene dierstudies op overtuigende
wijze aangetoond. Op dit moment verschijnen publicaties van de eerste klinische resul-
taten verkregen met dergelijke combinaties. De IT-combinatie beschreven in Hoofd-
stukken 5 en 6 onderschrijft bovendien het belang van MoAb-gebaseerde effector
mechanismen op de algehele effectiviteit van IT.
Verscheidene dierexperimenten hebben inmiddels overduidelijk het nut aangetoond
van het gebruik van ITs als aanvulling op de conventionele chemotherapie of bestraling.
Deze bemoedigende resultaten brengen de klinische evaluatie van ITs in de meer geëi-
gende adjuvant setting dichterbij.
Wat betreft de dosis limiterende bijwerkingen, is de meest in het oog springende ont-
wikkeling waarschijnlijk de opheldering van de oorzaak van vaatlekkage syndrome
(VLS). In de A-keten van ricine is een aminozuurketen volgorde (motief )
geïdentificeeerd die ook aanwezig is in de andere conventionele plantaardige en bacte-
riële toxines alsook in het eveneens vaatlekkage inducerende Interleukine-2 (IL-2). Dit
motief blijkt verantwoordelijk voor VLS door de binding en destructie van endothiale
cellen. Naar verwachting zal de verwijdering of mutatie van dit motief, ofwel het gebruik
van niet-destructieve blokkerende peptides, de therapeutische index van conventionele
ITs sterk verhogen.
Het leidt geen twijfel dat de bovenstaande ontwikkelingen zullen resulteren in de pro-
ductie van nieuwe ITs met sterk verbeterde in vivo karakteristieken. Alles wijst er dan
ook op dat ITs levensvatbaarder zijn dan ooit, en binnen afzienbare tijd tenminste een
deel van hun oorspronkelijke beloften in zullen lossen. De FDA-goedkeuring van een
recombinant IT (Ontak, DAB389IL-2) voor de behandeling van een therapieresistente
hematologische maligniteit, kan dan ook beschouwd worden als een belangrijke mijl-
paal.
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L I S T  O F  A B B R E V I A T I O N S
AICD activation-induced cell death
ATG antihymocyte globuline
AUC area under the concentration versus time curve
BMT bone marrow transplantation
BSA bovine serum albumin
Calc calcein AM
CD cluster of differentiation
CK creatine kinase
Cmax maximum plasma concentration
CsA cyclosporin A
CTL cytotoxic T lymphocyte
dgA deglycosylated ricin A-chain
DLI donor lymphocyte infusion
DLT dose limiting toxicity
DT diphtheria toxin
DTT dithiothreitol
ELISA enzym-linked immunosorbent assay
ER endoplasmatic reticulum
Fab antigen binding fragment of monoclonal antibody
Fv variable fragment of Fab
FCM flow cytometry
FCS fetal calf serum
FITC fluorescein isothiocyanate
FS forward scatter
aGVHD acute graft-versus-host disease
HAMA human-anti-mouse antibodies
HARA human-anti-ricin antibodies
HLA human leucocyte-associated antigen
HRP horseradish peroxidase
ID50 50% inhibiting dose
IFN interferon
IL interleukin
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Ig Immunoglobulin
IT immunotoxin
kDa kilo Dalton
LD50 50% lethal dose
MHC major histocompatibility complex
MoAb monoclonal antibody
MTD maximal tolerable dose
NHL non-Hodgkin’s lymphoma
NK cell natural killer cell
NO nitric oxide
PBL peripheral blood lymphocytes
PBS phosphate buffered saline
PE Pseudomonas exotoxin
pH hydrogen ion strength
PHA phytohaemagglutinin
PI propidium iodide
RAS right angle scatter
RIP ribosome inhibitory protein
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SMPT 4-succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene
SPDP N-succinimidyl-3-(2-pyridyldithio)propionate
SD standard deviation
STC stem cell transplantation
TCR T cell receptor
TNF tumor necrosis factor
T1/2 plasma half-life
TTP thrombotic thrombocytopenic purpura
VH heavy chain variable domain
VL light chain variable domain
VLS vascular leak syndrome
WBC white blood cell count
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De verschijningsdata van de in dit proefschrift opgenomen artikelen geven al aan dat
de promotie geen vluggertje geweest is. Het aantal mensen dat ik dank verschuldigd
ben is met de jaren meegegroeid. Zonder anderen daarbij tekort te willen doen, wil ik
enkele van hen graag met name noemen.
Theo, jij hebt als promotor een cruciale rol gespeeld. Ook toen bij andere het geloof in
de ‘magic bullets’ tanende was, bleef jij enthousiast over de mogelijke toepassingen
van immuntoxines. Ik ben je dan ook zeer dankbaar voor je beslissing om, min of meer
tegen de stroom in, het IT-combinatie concept in de praktijk te brengen. Je
enthousiasme en doelgerichte aanpak heeft het project door menig moeilijk moment
gesleept. Frank, jij hebt mij wegwijs gemaakt in de wereld van immunotoxines. Het in
dit proefschrift beschreven onderzoek steunt op de stevige grondvesten die jij als een
van de internationale pioniers op dit gebied hebt gelegd. Bedankt ook voor je nauw-
gezette correcties van de manuscripten die je onder ogen kreeg. Ondanks, of misschien
wel dankzij, dat we niet altijd op een lijn zaten bleven onze discussies zeer levendig en
vormden vaak een drijfveer om ons (heel vaak ook on-)gelijk te halen op het lab. Ton, jij
vormde als ‘chef de clinique’ de cruciale schakel naar de patiënten. Het door jouw uit-
gestraalde vertrouwen en onuitputtelijke enthousiasme werkte als een katalysator op
het onderzoek. Ik wil je ook bedanken voor je altijd snelle en adequate correcties. Hans,
jou ben ik dankbaar voor de reeds in een vroeg stadium toegezegde ondersteuning
vanuit het laboratorium. Zonder deze hadden we de risicovolle pilot-studie niet van de
grond gekregen.
Liesbeth, jij stond mee aan de basis van het IT-combinatie idee en hebt het leeuwendeel
van de laboratoriumwerkzaamheden voor je rekening genomen. Je handigheid en accu-
ratesse bij de uitvoering van experimenten deden me al snel beseffen dat ik praktisch
op het lab eigenlijk nog maar weinig te zoeken had. Afgezien van de gezelligheid en
onze vruchtbare ‘hak op de tak’ besprekingen, wil ik je bedanken voor je inzet, door-
zettingsvermogen en inventiviteit waarmee je het onderzoek mee hebt vormgegeven.
Nooit klopte ik vergeefs bij je aan. Sabine, jij maakte indruk door de voortvarende wijze
waarop je nieuwe testen introduceerde en door je inzet bij de evaluatie van patiënten
monsters. Ook jij heel erg bedankt voor de fijne samenwerking. Op het lab waren er
verder natuurlijk Arie Pennings, Peter Linssen, Elly Geestman en de andere collega’s die
ik wil bedanken voor hun praktische ondersteuning en gezellige momenten. Ook de
studenten Sonja, Zeban, Carolien, en Arnold ben ik zeer dankbaar voor hun inbreng bij
het beschreven onderzoek. Peter Donnelley wil ik noemen voor zijn (vaak spoed)
correcties van Engelse teksten.
Peter van Horssen, als mede immuntoxine-promovendus heb je de ‘ups en downs’ van
dichtbij meegemaakt. Ik denk met plezier terug aan onze fijne samenwerking en wil je
bijzonder bedanken voor de steun en adviezen gedurende het onderzoek. PeWe, Toon,
Jules, niet te geloven dat wij met z’n vieren dat kleine kamertje gedeeld hebben. Jullie
naambordjes hangen vandaag de dag nog steeds aan de deur, als een soort van
eerbetoon aan de (enige echte) mannen die ‘de Barak’ gekend heeft. Jullie heel erg
bedankt voor de gezelligheid en onderlinge support. Ook de latere bewoners Maria en
Isabelle wil ik bedanken voor de gezelligheid.
Een van de leuke ervaringen bij de uitvoering van het beschreven onderzoek was de
enthousiaste en actieve ondersteuning door andere afdelingen. In eerste instantie was
daar Klinische Farmacie. Met op twee A-4tjes samengevat de karakteristieken van de IT-
combinatie, verschenen we bij Hans Bakker en Chiel Hekster met het verzoek om zo
snel mogelijk met de klinische studie te kunnen beginnen. Een goed jaar later kwamen
we weer bij ze vandaan. De A4-tjes waren aangezwollen tot twee 5 cm-dikke ordners vol
met beschrijvingen van de op het medicijn uitgevoerde testen. Deze omvangrijke
evaluatie en vastlegging was het resultaat van een nauwe en prettige samenwerking
tussen de afdelingen Hematologie en Klinische Farmacie. Hans, Chiel en collega’s
bedankt voor jullie inspanningen en buitengewoon constructieve houding in deze. Een
ander treffend voorbeeld wordt gevormd door Dirk Ruiter, Cathy Maass en collega’s van
de afdeling Pathologie. Professor Ruiter besteedde menig uur in de namiddag aan het
nauwgezet screenen van humane weefsels op ongewenste kruisreactiviteit. Heel veel
dank hiervoor. Daarnaast wil ik bedanken Jos van der Logt en Frans Heessen voor de uit-
voering van de biosafety testen, Albert Peters en collega’s voor de prettige en professio-
nele ondersteuning bij de dierexperimenten, Fokke Nagengast voor de endoscopie bij
de apen en niet te vergeten Roos Masereeuw voor de farmacokinitiek analyses. De Ver-
pleging, Toine, Lucia en collega’s, wil ik bedanken voor het mee opzetten en de uitvoe-
ring van de monitoring van patiënten. Door jullie toedoen is deze zeer accuraat en zo
min mogelijk belastend verlopen. Ik heb heel veel respect voor de professionele wijze
waarop jullie de meestal zeer zieke patiënten begeleiden en verzorgen. Quirine wil ik
bedanken voor de snelle en accurate verwerking van de patiënten gegevens. Wil Tax en
Hergen Spits, jullie bedankt voor het ter beschikking stellen van de hybridoma’s en de
wetenschappelijke adviezen gedurende het onderzoek. Ook de inbreng van Jan van de
Winkel mag niet onvermeld blijven. Jan, afgezien van de samenwerking voor de CD19
studie, wil ik je bedanken voor je luisterend oor en je waardevolle adviezen. Ik heb
bewondering voor de ongekende wijze waarop je mensen weet te motiveren.
Los van de (klinisch-)wetenschappelijke kant was er ook de kant van octrooien, -
subsidies, adviseurs en contracten. Op dit gebied ben ik dank verschuldigd aan Wilma
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Derksen (Farma Research),  Emile Douma en Gerrit den Hartog (Ernst en Young),
Theone Kon (Amersham Pharmacia Biotech), Jan de Koning, Tosca en Lotte (CSC), Hein
van de Pasch (Stichting Gelderkennis), Jan Prins (Stork), Johan Renes en collega’s (Ver-
eenigde) en Eljo Schuite (Sigma-Tau Ethifarma). Jullie allen bedankt voor de prettige
samenwerking en praktische ondersteuning. Ook de bondgenoten bij het ‘Immunotoko
avontuur’, Joost Ballemans, Hans Bolluijt, Gerard Hoskens, Frits Smedts en Rolph Wou-
ters wil ik bedanken voor hun belangeloze inzet. Vanzelfsprekend ben ik ook veel dank
verschuldigd aan de subsidiegever NWO. De direct betrokkenen, Nico Boots en Werner
Most, wil ik complimenteren voor de constructieve en prettige wijze waarop ze hun
projecten begeleiden.
Ik wil eindigen met het bedanken van familie, vrienden en kennissen voor hun belang-
stelling en steun. Geert-Jan en Marcel, jullie bedankt voor de ontelbare adviezen en
morele support. Ansel, Twan en Timo ook jullie heel erg bedankt voor jullie meeleven
en meedenken. Pa en Ma, jullie ben ik heel veel dank verschuldigd voor alle onder-
steuning door de jaren heen. Zonder jullie hand en spandiensten was er van promo-
veren weinig terechtgekomen (ik hoop met dit proefschrift het ‘middagje Pietje Huis-
man’ eindelijk weggepoetst te hebben). Ik ben jullie en Hermien ook heel dankbaar voor
die ontelbare keren dat jullie bij ons hebben opgepast en het werk gewoon door kon
gaan. En bovenal was er natuurlijk Joyce. Ik ben heel blij dat je er altijd voor mij was,
zonder jou was dit nooit gelukt. Ik heb je jaren voor (de gek) gehouden dat de promo-
tie er bijna aan zat te komen, dat we alleen ‘even die klinische studie moesten doen’.
Bedankt voor je begrip en de ruimte die je me gaf om mijn droom na te jagen in pla-
ts van ‘snel’ te promoveren en een ‘normale’ baan te zoeken. Ik moet niet zelden als
een Don Quichote zijn overgekomen. Jelle, Youp en Merel, jullie bedankt voor jullie
opgewekte en stimulerende aanwezigheid.
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De schrijver van dit proefschrift werd geboren op 30 mei 1964 te Nijmegen. In 1984
behaalde hij het Atheneum-B diploma aan het Elshof College te Nijmegen, waarna hij
begon met de studie Biologie aan de Katholieke Universiteit Nijmegen. In het kader van
deze studie werden stages gelopen bij de afdeling Parasitologie van het bedrijf Intervet
te Boxmeer (Dr. A. Vermeulen), de afdeling Moleculaire Biologie van de Katholieke Uni-
versiteit Nijmegen (Prof. Dr. R.N.H. Konings†) en de afdeling Hematologie (Prof. Dr.
C. Haanen, later Prof. Dr. T. de Witte) van het UMC St Radboud te Nijmegen. In sep-
tember 1989 behaalde hij het doctoraal examen Biologie met als specialisatie ‘Toege-
paste Richting’. Vanaf die tijd is hij werkzaam op het Centraal Hematologisch Labora-
torium (Dr. J. Wessels, later Dr. E. Mensink) van het UMC St Radboud, als
wetenschappelijk onderzoeker op het door Dr. F. Preijers geïnitieerde Immunotoxine
onderzoek. Gedurende dit onderzoek is het plan opgevat om de veelbelovende labora-
torium resultaten te vertalen in een experimenteel medicijn, de zogenaamde immuno-
toxine-combinatie (IT-combinatie), voor patiënten met levensbedreigende omgekeerde
afstotingsziekte (graft-versus-host disease: GVHD). Middels een subsidie van de Stich-
ting Technische Wetenschappen (Technologiestichting STW) van de Nederlandse Orga-
nisatie voor Wetenschappelijk Onderzoek (NWO), en met een actieve ondersteuning
door diverse afdelingen binnen het UMC St Radboud, heeft de schrijver een pilot-studie
opgezet om de IT-combinatie op beperkte schaal in de kliniek te testen. De ‘in huis’
productie en daaropvolgende klinische toepassing vormen als zodanig de bekroning
van het in dit proefschrift beschreven onderzoek. Op basis van de eerste hoopgevende
resultaten is besloten de IT-combinatie verder bedrijfsmatig te ontwikkelen, waartoe in
1998 het aan het UMC St Radboud gelieerde ‘Immunotoko B.V.’ is opgericht. Dit
initiatief is ondersteund door de NWO die de schrijver een subsidie heeft toegekend in
het kader van het Stimuleringsprogramma voor Innovatief Geneesmiddelenonderzoek
en Ondernemerschap in Nederland (STIGON). Met deze support gaat hij, als
bestuurder van Immunotoko B.V., de komende periode trachten de IT-combinatie
verder te ontwikkelen richting registratie als een ‘Orphan Drug’ tegen GVHD en
afstoting van transplantaten.
De schrijver is getrouwd met Joyce Burgers en de trotse vader van Jelle, Youp en Merel.



